Device Incident Report : Medical Devices Branch - Device Vigilance and Monitoring

24/09/2010

SIGNED

DIR: 2 - ID: 140419

Released by Theta Technologies on 26/06/1985 21:02:22

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
22028	2010/015587		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22		
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
23/09/2010	24/09/2010		27/10/2010	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
03/11/2010			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Sponsor		For IRIS Meeting		
Clinical Event Information:				
Implant removed including planned. Report sourced from specialist. Contact:		me silicone granulomatous deposits rema Alternative Person First Name:	Alternative Person Surname:	
Alternative Person Phone:	Alternative Person Fax:			
h Patient Information				
Sex:	Weight:	Age:		
Patient Focused Corrective Actio	n Taken:			
Patient History:				
Patient Outcome/Consequences				
Other Devices Involved:				

Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
s22				
Reporter Title:	First Name:	Surname:		
Dr	s22	s22		
Position:		Company/Institution:		
Surgeon		s22		
Address 1:	Address 2:	Town/Suburb:	State:	
s22		s22	s22	
Country:	Postcode:	Phone:	Fax:	
Australia	s22	s22	s22	
Mobile:	Email:			
	s22			

Initial Reporter Section - in the final release this will connect to the existing list of reporters in IRIS

As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
Postcode:	Phone:	Fax:	Mobile:	
Email:				

Device Information Section Product Exempt: Search Device ARTG: Device ARTG #: If No, fill out ARTG No: No 128767 128767 Therapeutic Licence Type: Product Licence Category: Device Class: GMDN Code: Included 36197 Medical Device Class III GMDN Text: Brand Name: Prosthesis, internal, mammary, gel filled

Form Details

,01/2021,00.10			In Botano	Document 1
Initial Device Description:				Document
Silicone Gel Breast Implant				
Usage of Device:	Software Version:			
Model #:	Serial #:	Batch #:	Lot #:	
MLPX350	12920542	1473870		
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Access Contact Phone:	Access Contact Fax:			
Manufacturer Information Section				
Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Inamed Pty Ltd T/A Inamed Aes		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	
Postcode:	Phone:	Fax:		
Email:		Manufacturer Informed: Yes	Date Aware of Adverse Event:	
Contact Title:	Contact First Name:	Contact Surname:		
Supplier Information Section				
Supplier Name:		Address 1:	Address 2:	
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

Statistics Checklist Section

Sample Received:

Potential Effect:

Serious Injury

Risk Frequency:

Date:

No

Assessed By:		Form Details		Document 1
issessed by.				
terile:	Reusable:	Single Use:		
No	No			
ctual Effect:	Injured Party:			
Serious Injury	Patient			
isk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:	
		Routine		

Sponsor Information Section				
Search Sponsors:	Name:		Client #:	
Al	Allergan Australia Pty Limited		17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073	s22	02 9498 0299	
Email:				
eallergan.com				
Investigation Information Section				
Device Analysis Results:				
Corrective/Preventative Actions:				
Details of Similar Events:				
Number of Similar Events:		Rate of Similar Events:		
Countries Similar Events Also Occurr	ed:			
Additional Comments:				

Note: As in other places, on the production system the ARTG # text box will be replaced with a link to the register				
Other Devices				
Search Device ARTG	Device ARTG No	Product Name	Serial #	

Related DIR Information - Click **New** to begin entering information.

Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Click New to begin entering information.

Samples Record - Ch	to begin entern	ig information.				
Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Details					
Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes
Letter		19/10/2010			Overdue Sponsor Response - > 10 Days
Receipt Acknowledgement	01/10/2010				S:\DATA\IRS\PRD\POSTMAKT\INVESTIG\DIR\RN22028.DOC
Sponsor Notification	01/10/2010				S:\DATA\IRS\PRD\POSTMAKT\INVESTIG\DIR\SN22028.DOC
Completion Notification	03/11/2010				S:\DATA\IRS\PRD\POSTMAKT\INVESTIG\DIR\RC22028.DOC
Completion Notification	03/11/2010				S:\DATA\IRS\PRD\POSTMAKT\INVESTIG\DIR\SC22028.DOC

List of Problem Type Codes - Click **New** to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Mechanical			
Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Mechanical problem			
Outcome Details			
Outcome Details Outcome of Investigation		If Additional Outcome Detail Requested	

Investigation Summary:		Document 1
current worldwide silicone migration/extravasations rate for this m	ne current worldwide rupture rate for this model is 0.338% and the rupture rate in Australia is 0.776%. The nodel is 0.048% and 0.155% in Australia. Gel rupture is a known possible complication with this type of device. ctions for use. No further investigation will occur at this time, however the TGA will continue to monitor the rate e.	

Flow Details : DIR-REQ - Device Incident Request : 30400

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach
30400	DIR-REQ		Closed	theta	IRIS Coordinator	03/11/2010	Normal	0

Signature Details

Role	IRIS Investigator
User	theta - Theta Technologies
Signed At	03/11/2010 00:00:00
Comment	Automatically signed off closed DIR forms as part of data migration

DIR: 2 - ID: 141675

Form Details

Document 2

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

03/05/2011 SIGNED

Released by Theta Technologies on 26/06/1985 21:02:22

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
23328	2011/007043		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22	03/05/2011	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
03/05/2011	03/05/2011		30/05/2011	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
09/06/2011			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Specialist		For IRIS Meeting		
Clinical Event Information:				
Removal and replacement seem Report sourced from Specialist. Contact:	s to have solved the problem of burning pa Alternative Person Title:	ain. Alternative Person First Name:	Alternative Person Surname:	
Alternative Person Phone:	Alternative Person Fax:			
Patient Information				
Sex:	Weight:	Age:		
Patient Focused Corrective Action	n Taken:			
Patient History:				
Patient Outcome/Consequences:				
Other Devices Involved:				

12/07/2024,	09:25
-------------	-------

Submitting	Doportor	Contion
Submitting	Reputer	Section

Submitting Reporter Section					
Search Reporter By Surname:	Reporter #:				
Reporter Title:	First Name:	Surname:			
Dr	s22	s22			
Position:		Company/Institution:			
Plastic Surgeon					
Address 1:	Address 2:	Town/Suburb:	State:		
s22	s22	s22	s22		
Country:	Postcode:	Phone:	Fax:		
Australia		s22	s22		
Mobile:	Email:				
	s22				

Initial Reporter Section - in the final release this will connect to the existing list of reporters in IRIS

As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
Search Reporter By Surname:	Initial Reporter #:			
Title:	Title: First Name:		Surname:	
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
Postcode:	Phone:	Fax:	Mobile:	
Email:				

Device Information Section

Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:
No		171475	171475
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:
Medical Device	Included	Class III	36197
GMDN Text:		Brand Name:	

Form Details

	CH 1			Document 2
Prosthesis, internal, mammary, gel	filled			
Initial Device Description:				
Breast Implant - Silicone				
Usage of Device:	Software Version:			
Model #:	Serial #:	Batch #:	Lot #:	
5T-410mm	11535879			
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Access Contact Phone:	Access Contact Fax:			

Manufacturer Information Section

Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	
Postcode:	Phone:	Fax:		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
		No		
Contact Title:	Contact First Name:	Contact Surname:		

Supplier Information Section

Supplier Name:		Address 1:	Address 2:	
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

Form Details

Statistics Checklist Section					
Date:	Assessed By:				
Sample Received:	Sterile:	Reusable:	Single Use:		
No	No	No			
Potential Effect:	Actual Effect:	Injured Party:			
Serious Injury	Serious Injury	Patient			
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:	
			Routine		

Sponsor Information Section					
Search Sponsors:	Name:		Client #:		
Al	Allergan Australia Pty Limited		17		
Attention To:	Address 1:	Address 2:	Town/Suburb:		
s22	Locked Bag 1514		PYMBLE		
State:	Postcode:	Phone:	Fax:		
NSW	2073	s22	02 9498 0292		
Email:					
s22 @allergan.com					
Investigation Information Section					
Device Analysis Results:					
Corrective/Preventative Actions:					
Details of Similar Events:					
Number of Similar Events:		Rate of Similar Events:			
Countries Similar Events Also Occurred					
Additional Comments:					

Note: As in other places, on the production system the ARTG # text box will be replaced with a link to the register

Other Devices

Form Details

Search Device ARTG	Device ARTG No	Product Name	Serial # Document 2	

Related DIR Information - Click **New** to begin entering information.

Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Click **New** to begin entering information.

Sample Details Sample Requested Sample Received # Samples from Reporter Outcome of TGA's Testing Sample # Sample Requested Sample Received # Samples from Reporter Outcome of TGA's Testing

Correspondence Details

Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Receipt Acknowledgement	16/05/2011				D:\TEMP\DIR\RN23328.DOC	
Sponsor Notification	31/05/2011				D:\TEMP\DIR\SN23328.DOC	
Completion Notification	09/06/2011				D:\TEMP\DIR\RC23328.DOC	
Completion Notification	09/06/2011				D:\TEMP\DIR\SC23328.DOC	

List of Problem Type Codes - Click **New** to begin entering information.

Type Details				
Type of Problem (Level 1) Type of Problem (Level 2) If 'Other' Type Selected				
Mechanical				

Cause Details				
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected		
Mechanical problem				

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
No further action		

Recall Number:

Investigation Summary: Requested Pain and Rupture rates from sponsor. Pain rate is 0.142% (Worldwide) and Rupture Rate is 0.071% (Worldwide). No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern of occurence and may re-open the file as appropriate

Flow Details : DIR-REQ - Device Incident Request : 31656

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 🕜	Priority	Attach
31656	DIR-REQ		Closed	s22	OPR Administration User	05/08/2015	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	05/08/2015 12:05:53	
Comment		

Form Details

Document 3

Device Incident Report : Medical Devices Branch - Device Vigilance and Monitoring

24/02/2011

SIGNED

DIR : 2 - ID : 141267

Released by Theta Technologies on 26/06/1985 21:02:22

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
22910	2011/002643		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22	04/01/2011	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
04/01/2011	24/02/2011			
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
03/03/2011			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Nurse		For IRIS Meeting		
Clinical Event Information:				
He initially implanted an 'Access s22 Report sourced from Private Nur Contact:		Alternative Person First Name:	Alternative Person Surname:	
Alternative Person Phone:	Alternative Person Fax:			
Patient Information				
Sex:	Weight:	Age:		
Patient Focused Corrective Action	n Taken:			
Patient History:				
Patient Outcome/Consequences:				
Other Devices Involved:				

Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
s22				
Reporter Title:	First Name:	Surname:		
	s22	s22		
Position:		Company/Institution:	Company/Institution:	
Perioperative Services Manager	r	s22		
Address 1:	Address 2:	Town/Suburb:	State:	
s22		s22	s22	
Country:	Postcode:	Phone:	Fax:	
Australia	s22	s22	s22	
Mobile:	Email:			
	s22			

Initial Reporter Section - in the final release this will connect to the existing list of reporters in IRIS

As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
Postcode:	Phone:	Fax:	Mobile:	
Email:				
Device Information Section				
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
No		169956	169956	

Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:	
Medical Device	Included	Class III	45417	
GMDN Text:		Brand Name:		
Prosthesis, mammary, internal,	gel/saline-filled, inflatable			

12

2/07/2024, 09:22		For	m Details	
Initial Device Description:				Document 3
Breast Implant				
Usage of Device:	Software Version:			
Model #:	Serial #:	Batch #:	Lot #:	
Access 410	71340007	Lot.#: 09MSM0032		
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Access Contact Phone:	Access Contact Fax:			
Manufacturer Information Section	1			
Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	
Postcode:	Phone:	Fax:		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
		No		
Contact Title:	Contact First Name:	Contact Surname:		
Supplier Information Section				
Supplier Name:		Address 1:	Address 2:	
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

Form Details

Date:	Assessed By:				Document 3
Sample Received:	Sterile:	Reusable:	Single Use:		
No	No	No			
Potential Effect:	Actual Effect:	Injured Party:			
Temporary Injury	Temporary Injury	Patient			
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:	
			Routine		
Sponsor Information Section					
Search Sponsors:	Name:		Client #:		
Al	Allergan Australia Pty Limi	ted	17		
Attention To:	Address 1:	Address 2:	Town/Suburb:		
s22	Locked Bag 1514		PYMBLE		
State:	Postcode:	Phone:	Fax:		
NSW	2073	s22	02 9498 0292		
Email:					
@allergan.com	n				
Investigation Information Se	ction				
Device Analysis Results:					
Corrective/Preventative Acti	ons:				
Details of Similar Events:					
Number of Similar Events:		Rate of Similar Events:			
Countries Similar Events Als	o Occurred:				
Additional Comments:					

Note: As in other places, on the produc	lote: As in other places, on the production system the ARTG # text box will be replaced with a link to the register				
ther Devices					
Search Device ARTG	Device ARTG No	Product Name	Serial #		

Form Details

 Related DIR Information - Click New to begin entering information.

 Incident Details
 DIR #
 Brand Name
 Reporter First Name
 Reporter Surname
 Company/Institution

Samples Record - Click **New** to begin entering information.

Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Details						
Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Completion Notification	03/03/2011				S:\DATA\IRS\PRD\POSTMAKT\INVESTIG\DIR\RC22910.DOC	
Completion Notification	03/03/2011				S:\DATA\IRS\PRD\POSTMAKT\INVESTIG\DIR\SC22910.DOC	

List of Problem Type Codes - Click New to begin entering information.				
Type Details				
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected		
Labelling/Instructions for Use Packaging Markings Issue				

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Not product related			

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
Not investigated		

Recall Number:	
Investigation Summary:	
No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern of occurrence and may re-open the file as appropriate.	

Form Details

Flow Details : DIR-REQ - Device Incident Request : 31248

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 😿	Priority	Attach
31248	DIR-REQ		Closed	theta	IRIS Coordinator	03/03/2011	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	22/09/2015 14:01:33	
Comment	Automatically signed off closed DIR forms as part of data migration	

Form Details

Document 4

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

24/08/2011 SIGNED

DIR: 2 - ID: 142672

Released by Theta Technologies on 26/06/1985 21:02:22

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
24356	2011/012923	0035757/AZ	Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22	25/07/2011	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
25/07/2011	24/08/2011		16/09/2011	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
20/09/2011			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Sponsor		For IRIS Meeting		
Clinical Event Information:				
Full capsulectomy and implant re Pathology review: <u>\$22</u> \$22 Reported event description to Alle \$22 Breast reconstruction. \$22 Lump in right br Diagnosis: Anaplastic T Cell Lymp Device not returned to company. Similar events: Yes Report sourced from Sponsor. Contact:	ergan as follows: east - found in capsule - Implant rem <u>ovec</u>		Alternative Person Surname:	
Alternative Person Phone:	Alternative Person Fax:			
Patient Information				
Sex:	Weight:	Age:		

Form Details

012024, 03.30				Document 4
Patient Focused Corrective Action	Taken:			
Patient History:				
Patient Outcome/Consequences:				
Other Devices Involved:				
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
Reporter Title:	First Name:	Surname:	Surname:	
Ms	s22	s22		
Position:		Company/Institution:		
Regulatory Affairs Officer		Allergan Australia		
Address 1:	Address 2:	Town/Suburb:	State:	
Allergan Australia	Level 4/810 Pacific Hwy	Gordon	NSW	
Country:	Postcode:	Phone:	Fax:	
Australia	2072	s22	9498 0299	
Mobile:	Email:			
	s22 allergan.com			
Initial Reporter Section - in the fina	I release this will connect to the existi	ng list of reporters in IRIS		
As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
Search Reporter By Surname:	Initial Reporter #:			

Search Reporter by Sumame.					
Title:	First Name:	Surname:			
Position:		Company/Institution:			
Address 1:	Address 2:	Town/Suburb:	State:		
Postcode:	Phone:	Fax:	Mobile:		

Email:

12/07/2024,	09:30
-------------	-------

Device Information Section				
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
No		128764	128764	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:	
Medical Device	Included	Class III	36197	
GMDN Text:		Brand Name:		
Prosthesis, internal, mammary, g	gel filled			
Initial Device Description:				
Breast Implant (mfr# 0035757//	AZ)			
Usage of Device:	Software Version:	Software Version:		
Model #:	Serial #:	Batch #:	Lot #:	
Style 410FF				
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Access Contact Phone:	Access Contact Fax:			

Manufacturer Information Section

Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Inamed Pty Ltd T/A Inamed Aesthetics Pty Ltd		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	
Postcode:	Phone:	Fax:		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
		No		
Contact Title:	Contact First Name:	Contact Surname:		
Supplier Information Section				
Supplier Name:		Address 1:	Address 2:	
Town/Suburb:	State:	Postcode:	Phone:	

Form Details

				Document 4
Fax:	Email:		Supplier Informed:	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

Statistics Checklist Section

Date:	Assessed By:			
Sample Received:	Sterile:	Reusable:	Single Use:	
No	No	No		
Potential Effect:	Actual Effect:	Injured Party:		
Serious Injury	Serious Injury	Patient		
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:
			Routine	

Sponsor Information Section	
-----------------------------	--

Search Sponsors:	Name:		Client #:
Al	Allergan Australia Pty Limited		17
Attention To:	Address 1:	Address 2:	Town/Suburb:
s22	Locked Bag 1514		PYMBLE
State:	Postcode:	Phone:	Fax:
NSW	2073	s22	02 9498 0292
Email:			

@allergan.com

Investigation Information Section

Device Analysis Results:		
Corrective/Preventative Actions:		
Details of Similar Events:		
Number of Similar Events:	Rate of Similar Events:	

Form Details

	Document 4
Countries Similar Events Also Occurred:	
Additional Comments:	
7.5.12: This is a duplicate report of one of the cases presented in DIR 21041	

Note: As in other places, on the production system the ARTG # text box will be replaced with a link to the register

Other Devices Device ARTG No Product Name Serial # Search Device ARTG Device ARTG No Product Name Serial

Related DIR Information - Click	New to begin entering information.				
Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Clic	Samples Record - Click New to begin entering information.							
Sample Details								
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing			

Correspondence Details						
Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Sponsor Notification	02/09/2011				D:\TEMP\DIR\SN24356.DOC	
Completion Notification	20/09/2011				D:\TEMP\DIR\RC24356.DOC	
Completion Notification	20/09/2011				D:\TEMP\DIR\SC24356.DOC	

 List of Problem Type Codes - Click New to begin entering information.

 Type Details

 Type of Problem (Level 1)
 Type of Problem (Level 2)

 Mechanical

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	

Form Details

		December 14
Unable to confirm complaint		Document 4
Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
No further action		
Recall Number:		

Investigation Summary:
The sponsor was requested to provide the rates of occurrence for similar events.
There has been one other confirmed similar incident of ALCL between 01/01/2004 to 13/09/2011 out of a distribution of 1842 devices in Australia (0.1%) and 22 727 devices worldwide.
The sponsor is currently undertaking ongoing collaboration with expert pathologists with experience in diagnosis of lymphomas to facilitate evaluation of any available tissue or cytology samples and has a strategy and communication plan in place to share all ongoing developments with the physician community and regulatory bodies.
No further investigation will occur at this time; however the TGA will continue to monitor the rate and pattern of occurrence and may re-open the file as appropriate.

Flow Details : DIR-REQ - Device Incident Request : 32653

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 🛷	Priority	Attach
32653	DIR-REQ		Closed	s22	OPR Administration User	08/10/2015	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	08/10/2015 11:38:04	
Comment		

DIR: 6 - ID: 151781

Form Details

Document 5

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

13/03/2012 SIGNED

Released by Theta Technologies on 01/03/2012 12:04:11

Report #:	Records Management #:	Reporter's Reference #:	Report Type:			
25941	2012/007830	0049481/AZ	Final			
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:			
Closed			11/03/2012			
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:			
11/03/2012	13/03/2012	20/03/2012				
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:			
10/11/2014			Yes			
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:				
Patient	For IRIS Meeting					
Clinical Event Information:						
Manufacturer contacted by Dr on valued at \$22	breast ruptured (MRI). removal of implant and examination of in	nplant they have offered to pay replacer	nent depending on result of examination			
Manufacturer contacted by Dr on valued at \$22 \$22 Please advice me on this as I am Follow-up: Allergan Australia is in results. Please find with attachem Allergan has attempted to obtain \$22 by D	removal of implant and examination of in very concerned as to what the leakage is receipt of follow up information received then to this report. follow-up information with Dr 522 evice was returned to company and is pre	doing to my body. d to company on <mark>\$22</mark> from patient (on the 28MAY12, 8JUN12, 21JUN12. sently undergoing Laboratory Analysis T	(Initials <mark>522)</mark> with diagnositc Imaging Right side device was explanted on th			
Manufacturer contacted by Dr on valued at \$22 \$22 Please advice me on this as I am Follow-up: Allergan Australia is in results. Please find with attachem Allergan has attempted to obtain \$22 by D	removal of implant and examination of in very concerned as to what the leakage is receipt of follow up information received to this report. follow-up information with Dr	doing to my body. d to company on <mark>\$22</mark> from patient (on the 28MAY12, 8JUN12, 21JUN12. sently undergoing Laboratory Analysis T	(Initials <mark>522)</mark> with diagnositc Imaging Right side device was explanted on th			
Manufacturer contacted by Dr on valued at \$22 \$22 Please advice me on this as I am Follow-up: Allergan Australia is in results. Please find with attachem Allergan has attempted to obtain \$22 by DI\$22 . De A DIR report was submitted to the	removal of implant and examination of in very concerned as to what the leakage is receipt of follow up information received to this report. follow-up information with Dr <mark>\$22</mark> evice was returned to company and is pre e TGA on 20JUN12 relating to this case (2	doing to my body. d to company on <mark>\$22</mark> from patient (on the 28MAY12, 8JUN12, 21JUN12. sently undergoing Laboratory Analysis T 25941).	(Initials <mark>922)</mark> with diagnositc Imaging Right side device was explanted on the esting.			
Manufacturer contacted by Dr on valued at \$22 \$22 Please advice me on this as I am Follow-up: Allergan Australia is in results. Please find with attachem Allergan has attempted to obtain \$22 by DI\$22 . De A DIR report was submitted to the Number of Incidents in Report:	removal of implant and examination of in very concerned as to what the leakage is receipt of follow up information received to this report. follow-up information with Dr <mark>\$22</mark> evice was returned to company and is pre e TGA on 20JUN12 relating to this case (2	doing to my body. d to company on <mark>\$22</mark> from patient (on the 28MAY12, 8JUN12, 21JUN12. sently undergoing Laboratory Analysis T 25941).	(Initials <mark>922)</mark> with diagnositc Imaging Right side device was explanted on the esting.			
Manufacturer contacted by Dr on valued at \$22 \$22 Please advice me on this as I am Follow-up: Allergan Australia is in results. Please find with attachem Allergan has attempted to obtain \$22 by Dt \$22 by Dt \$20 by Dt \$22 by Dt \$20 by Dt	removal of implant and examination of in very concerned as to what the leakage is receipt of follow up information received to this report. follow-up information with Dr S22 evice was returned to company and is pre e TGA on 20JUN12 relating to this case (2 Contact:	doing to my body. d to company on <u>\$22</u> from patient (on the 28MAY12, 8JUN12, 21JUN12. sently undergoing Laboratory Analysis T 25941). Alternative Person Title:	(Initials <mark>922)</mark> with diagnositc Imaging Right side device was explanted on the esting.			
Manufacturer contacted by Dr on valued at \$22. \$22. Please advice me on this as I am Follow-up: Allergan Australia is in results. Please find with attachem Allergan has attempted to obtain \$22. by D \$22. De A DIR report was submitted to the Number of Incidents in Report: 1 Alternative Person Surname:	removal of implant and examination of in very concerned as to what the leakage is receipt of follow up information received to this report. follow-up information with Dr S22 evice was returned to company and is pre e TGA on 20JUN12 relating to this case (2 Contact:	doing to my body. d to company on <u>\$22</u> from patient (on the 28MAY12, 8JUN12, 21JUN12. sently undergoing Laboratory Analysis T 25941). Alternative Person Title:	(Initials <mark>922)</mark> with diagnositc Imaging Right side device was explanted on the esting.			

Form Details

0112024, 11.00			T OTTI DOIGIIS	
Patient Focused Corrective Action	Taken:			Document 5
Patient History:				
Patient Outcome/Consequences:				
Other Devices Involved:				
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
s22	5166			
Reporter Title:	First Name:	Surname:		
Ms	s22	s22		
Position:		Company/Institution:		
Regulatory Affairs Officer		Allergan Australia		
Address 1:	Address 2:	Town/Suburb:	State:	
Allergan Australia	Level 4/810 Pacific Hwy	Gordon	New South Wales	
Country:	Postcode:	Phone:	Fax:	
Australia	2072	s22	9498 0299	
Mobile:	Email:			
	s22 allergan.com			
	I release this will connect to the existi	ng list of reporters in IRIS		
As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
No			No	
Search Reporter By Surname:	Initial Reporter #:			
s22	5616			
Title:	First Name:	Surname:		
Dr	s22	s22		
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
s22	s22	s22	s22	
Postcode:	Phone:	Fax:	Mobile:	
s22	s22	s22		
Email:				

12/07/2024,	11:36
-------------	-------

	-	-			~	-	4	F
D	n	C		m	е	n	Т	5
_	~	0	v		0		۰.	U

If No fill out APTG No:	Search Device ARTG:	Device ARTG #:	
In No, In out Acto No.	126554	126554	
Product Licence Category:	Device Class:	GMDN Code:	
Included	Class III	36197	
	Brand Name:		
el filled	McGhan Silicone Breast Implant		
Software Version:			
Serial #:	Batch #:	Lot #:	
Expiry Date:	Date of Implant:	Date of Explant:	
	s22	s22	
Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
	Manufacturer Client Id:	Address 1:	
	s22		
Town/Suburb:	State/Province:	Country:	
Phone:	Fax:		
	Manufacturer Informed:	Date Aware of Adverse Event:	
	Yes	20/04/2012	
Contact First Name:	Contact Surname:		
	Address 1:	Address 2:	
State:	Address 1: Postcode:	Address 2: Phone:	
	Included Included Included Included Included Inclu	If No, fill out ARTG No: 126554 Product Licence Category: Device Class: Included Class III Brand Name: Brand Name: el filled McGhan Silicone Breast Implant Software Version:	If No, fill out ARTG No: 126554 126554 Product Licence Category: Device Class: GMDN Code: Included Class III 36197 Brand Name:

Form Details

Email:		Supplier Informed:	Document 5
Contact Title:	Contact First Name:	Contact Surname:	
Contact Fax:			
	Contact Title:	Contact Title: Contact First Name:	Contact Title: Contact First Name: Contact Surname:

Statistics Checklist Section				
Date:	Assessed By:			
13/03/2012	s22			
Sample Received:	Sterile:	Reusable:	Single Use:	
No	Yes	No	Yes	
Potential Effect:	Actual Effect:	Injured Party:		
Serious Injury	Serious Injury	Patient		
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:
Unlikely	Serious	Occasionally	Routine	
DIRE Meeting Notes:				
Discussed at outstanding DIR	R meeting. Agreed to close.			

~	T	-		C
Spons	or Int	forma	TIOD	Section
oponio	21 711	011110	101011	00001011

oponior information occupi				
Search Sponsors:	Name:		Client #:	
Allergan	Allergan Australia Pty Lto	d	17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22			PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073	s22	(02) 9498 0292	
Email:				
eallergan.com				
Investigation Information Section				
Device Analysis Results:				
Corrective/Preventative Actions:				
Details of Similar Events:				

Form Details

Number of Similar Events:	Rate of Similar Events:	Document 5
Countries Similar Events Also Occurred:		
Additional Comments:		

Note: As in other places, on the product	tion system the ARTG # text box will be r	replaced with a link to the register		
Other Devices				
Search Device ARTG	Device ARTG No	Product Name	Serial #	

Related DIR Information - Click	New to begin entering information.				
Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Clic	k New to begin enterin	g information.				
Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Details					
Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes
Questionnaire sent	04/06/2012	18/06/2012	22/06/2012		
Reporter Notification sent	04/06/2012				
Completion Letter	10/11/2014	21/11/2014			See TRIM reference R14/1153458 and email R14/1153482

List of Problem Type Codes - Click **New** to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Mechanical	Leak		

07/2024, 11:36		Form De	tails	Document 5
Cause Details				Doodmento
Cause of Problem (Level 1)	Cause of Problem (Level 2)		f 'Other' Cause Selected	
Known Complication	Known Complication			
Outcome Details				
Outcome of Investigation		If Ad	litional Outcome Detail Requested	
Reviewed, No Further Action Required				
			ent. No further investigation will occur at this time; however	
the TGA will continue to monitor the rat This report has been entered into the M (IRIS) is to improve the standard of me device users, industry and government	e and pattern of occurrence and may re-open the file as a ledical Device Incident Report Investigation Scheme (IRIS edical devices and to reduce the number and severity of in	appropriate.) database. The aim icidents with devices	ent. No further investigation will occur at this time; however of the Medical Device Incident Report Investigation Scheme in Australia, through voluntary cooperation between medical	
the TGA will continue to monitor the rat This report has been entered into the M (IRIS) is to improve the standard of me device users, industry and government I have noted that your report mentions Consumer Commission (ACCC) which m advice. You can contact your suregon o	e and pattern of occurrence and may re-open the file as a ledical Device Incident Report Investigation Scheme (IRIS edical devices and to reduce the number and severity of in	appropriate. b) database. The aim ocidents with devices assist you with refun tThe TGA does not not state for further info	of the Medical Device Incident Report Investigation Scheme in Australia, through voluntary cooperation between medical nds, however you can contact the Australian Competition and egulate clinical practice and is not able to provide clinical rmation about this issue.	

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To
FILE	w	DIR 25941 - Questionnaire Letter	92	Form	
FILE	w	DIR 25941 - Questionnaire Letter_PS_contributi	102	Form	
FILE	7	MCGHAN	3318	Form	
FILE	7	RMR Single s22	993	Form	

Flow Details : DIR-REQ - Device Incident Request : 34739

Request Details

ID

Тур

Туре

Location

Assigned To

Attach

Priority

Status

Assigned By

12	/07/2024, 11:36				Form Details			
	34739	DIR-REQ	Closed	brogac	OPR Administration User	11/11/2014	Documen Normal	t <mark>5</mark> 0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	10/11/2014 15:47:43	
Comment		

Form Details

Document 6

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

26/09/2011

SIGNED

DIR: 2 - ID: 142890

Released by Theta Technologies on 26/06/1985 21:02:22

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
24585	2011/014636	0037204/AZ	Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22	02/09/2011	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
02/09/2011	26/09/2011			
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
26/10/2011			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Sponsor		For IRIS Meeting		
Clinical Event Information:				
Explant Date: TBA. On 08/06/2011 HCP repo9rts to performed a Ultrasound on the side. <u>\$22</u> Patient underwent a repair of a <u>\$22</u> Patient presented with <u>\$22</u> S22 Medication as follows: \$22	. Explant date	underwent '522 ure of left breast". There is no abnormali to be confirmed. Left side Catalog numb has completely recovered from her 522	". HCP y seen in the breast tissue on either er 222 Left side Lot Number	
Rupture complaints received: Australia 2.65%. ANZ 2.89% Worlwide 2022% Report sourced from sponsor.				
Contact:	Alternative Person Title:	Alternative Person First Name:	Alternative Person Surname:	
Alternative Person Phone:	Alternative Person Fax:			

Form Details

20112024, 09.39			Form Details	
Patient Information				Document 6
Sex:	Weight:	Age:		
Patient Focused Corrective Action	Taken:			
Patient History:				
Patient Outcome/Consequences:				
Other Devices Involved:				
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
s22				
Reporter Title:	First Name:	Surname:		
Ms	s22	s22		
Position:		Company/Institution:		
Regulatory Affairs Officer		Allergan Australia		
Address 1:	Address 2:	Town/Suburb:	State:	
Allergan Australia	Level 4/810 Pacific Hwy	Gordon	NSW	
Country:	Postcode:	Phone:	Fax:	
Australia	2072	s22	9498 0299	
Mobile:	Email:			
	s22 allergan.com			
Initial Reporter Section - in the fina	I release this will connect to the existing	ng list of reporters in IRIS		
As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	

Form Details

0112024, 09.59		TOIL	Details	
Postcode:	Phone:	Fax:	Mobile:	Document 6
Email:				
Device Information Section				
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
No		128767	128767	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:	
Medical Device	Included	Class III	36197	
GMDN Text:		Brand Name:		
Prosthesis, internal, mammary,	gel filled			
Initial Device Description:				
McGhan Breast Implant - (mfr r	ef: 0037204/AZ)			
Usage of Device:	Software Version:			
Model #:	Serial #:	Batch #:	Lot #:	
27-110301	YW9566			
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Access Contact Phone:	Access Contact Fax:			
Manufacturer Information Section	1			
Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	
Postcode:	Phone:	Fax:		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
		Yes		
Contact Title:	Contact First Name:	Contact Surname:		
Supplier Information Section				

Form Details

Supplier Name:		Address 1:	Address 2:	Document 6
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

Statistics Checklist Section				
Date:	Assessed By:			
Sample Received:	Sterile:	Reusable:	Single Use:	
No	No	No		
Potential Effect:	Actual Effect:	Injured Party:		
Serious Injury	Serious Injury	Patient		
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:
			Routine	

Sponsor Information Section

Search Sponsors:	Name:	Name:		
Al	Allergan Australia Pty Limite	d	17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073	s22	(02) 9498 0299	
Email:				
eallergan.com	n			
Investigation Information Se	ction			
Device Analysis Results:				
Corrective/Preventative Acti	ons:			

Form Details

Details of Similar Events:	Document 6				
Number of Similar Events:	Rate of Similar Events:				
Countries Similar Events Also Occurred:					
Additional Comments:					
Diary Entry: 01/11 2011 - ARTG number updated as per final report received of					

Note: As in other places, on the production system the ARTG # text box will be replaced with a link to the register

Other Devices					
Search Device ARTG	Device ARTG No	Product Name	Serial #		

Related DIR Information - Click New to begin entering information.							
Incident Details							
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution			

Samples Record - Click **New** to begin entering information.

Sample Details							
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing		

Correspondence Details							
Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes		
Completion Notification	26/10/2011				D:\TEMP\DIR\SC24585.DOC		

List of Problem Type Codes - Click New to begin entering information.							
Type Details							
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected					
Mechanical							

Cause Details

12/07/2024, 09:39

Form Details

Materials and chemistry Outcome Details Outcome of Investigation If Additional Outcome Detail Requested Not investigated Recall Number: Investigation Summary:	Document 6
Outcome of Investigation If Additional Outcome Detail Requested Not investigated Image: Compare the second sec	
ot investigated Recall Number:	
Recall Number:	
investigation Summary:	
No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern of occurrence and may re-open the file as appropriate.	

Flow Details : DIR-REQ - Device Incident Request : 32871

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 😿	Priority	Attach
32871	DIR-REQ		Closed	theta	IRIS Coordinator	01/11/2011	Normal	0

Signature Details

Role	IRIS Investigator
User	s22
Signed At	02/10/2015 14:45:19
Comment	Automatically signed off closed DIR forms as part of data migration

Document 7

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

09/12/2011 SIGNED

DIR : 3 - ID : 145835

Released by Theta Technologies on 30/11/2011 15:13:57

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
25028	2011/018537		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22	07/12/2011	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
07/12/2011	09/12/2011			
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
05/04/2012			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Surgeon		For IRIS Meeting		
Clinical Event Information:				
Ruptured gel filled breast recons	struction implant.			
Replaced with a new device.				
Contact:	Alternative Person Title:	Alternative Person First Name:	Alternative Person Surname:	
Alternative Person Phone:	Alternative Person Fax:			
Patient Information				
Sex:	Weight:	Age:		
Female				
Patient Focused Corrective Action	1 Taken:			
Patient History:				
Patient Outcome/Consequences:				
Other Devices Involved:				
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			

ileader.production.tga.gov.au/InformationLeaderAD/Forms/FormDetailPrint.aspx?sid = -286828871

Form Details

s22	5274			Document 7
Reporter Title:	First Name:	Surname:		
0	s22	s22		
Position:		Company/Institution:		
Surgeon		s22		
Address 1:	Address 2:	Town/Suburb:	State:	
Country:	Postcode:	Phone:	Fax:	
Australia		Unknown		
Mobile:	Email:			
Initial Reporter Section - in the fin	nal release this will connect to the existir	ng list of reporters in IRIS		
As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
Yes	If No, I'll out the following.			
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
Postcode:	Phone:	Fax:	Mobile:	
Email:				
Device Information Section				
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
No		128763	128763	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:	
Medical Device	Included	Class III	36197	
GMDN Text:		Brand Name:		
Prosthesis, internal, mammary, gel filled		McGhan Breast Prosthesis		
Initial Device Description:				
McGhan Breast Prosthesis				
Usage of Device:	Software Version:			

Form Details

Single Use				Document 7
Model #:	Serial #:	Batch #:	Lot #:	
410 FX				
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
01/03/2008		s22	s22.	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
With Reporter				
Access Contact Phone:	Access Contact Fax:			

Manufacturer Information Section

Manufacturer Name: Allergan		Manufacturer Client Id:	Address 1:	
		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	
Postcode:	Phone:	Fax:		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
Contact Title:	Contact First Name:	Contact Surname:		

Supplier Information Section

Supplier Name:		Address 1:	Address 2:	
Allergan Australia				
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
			Yes	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

Statistics Checklist Section						
Date:	Assessed By:					
09/12/2011	s22					
Sample Received:	Sterile:	Reusable:	Single Use:			

ileader.production.tga.gov.au/InformationLeaderAD/Forms/FormDetailPrint.aspx?sid=-286828871

Form Details

No	Yes	No	Yes	D	ocument 7
Potential Effect:	Actual Effect:	Injured Party:			
Serious Injury	Temporary Injury	Patient			
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:	
Unlikely	Minor	Likely	Routine		

Sponsor Information Section

oponsor information occion				
Search Sponsors:	Name:		Client #:	
Allergan	Allergan Australia Pty Ltd		17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073	s22	(02) 9498 0292	
Email:				
@Allergan.com				
Investigation Information Section				
Device Analysis Results:				
Corrective/Preventative Actions:				
Details of Similar Events:				
Number of Similar Events:		Rate of Similar Events:		
Countries Similar Events Also Occurred	1:			

Additional Comments:

Note: As in other places, on the production system the ARTG # text box will be replaced with a link to the register						
Other Devices						
Search Device ARTG	Device ARTG No	Product Name	Serial #			

Related DIR Information - Click **New** to begin entering information.

12	/07/2024, 10:34		Form Details			Desument 7
	Incident Details					Document 7
	DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Click New to begin entering information.							
Sample Details							
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing		

Correspondence Details						
Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Questionnaire Sent	14/12/2011	04/01/2012	30/12/2011			
Reporter notification					Reporter didn't provide mail or phone detials. Letter not sent.	
Sponsor Completion	05/04/2012				R12/655148	
Reporter Completion	05/04/2012				Not sent as no contact details provided - saved on TRIM file	

List of Problem Type Codes - Click **New** to begin entering information.

Type Details						
Type of Problem (Level 1) Type of Problem (Level 2) If 'Other' Type Selected						
Material Material Separation						
Cause Details						
Cause Details						
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected				
Known Complication	Known Complication					

Outcome Details			
Outcome of Investigation	If Additional Outcome Detail Requested		
No further action			

Recall	Number:
--------	---------

Investigation Summary:

The TGA has reviewed this incident. The sponsor confirmed that rupture is a known complication for this device and advised that the current worldwide reported rupture rate for this implant is 0.2%. The product literature was reviewed and specifies rupture as a known risk for this implant. A post market review of breast implants is currently being

12/07/2024, 10:34 undertaken.

Form Details

Document 7

No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern of occurrence and may re-open the file as appropriate.

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To
FILE	w	Attachement 1 (DIR 25028 Questionnaire	15	Form	
FILE	7	completed DIR 25028-ARTG#128763	164	Form	
FILE	7	CUI PID - DIR 25028	3241	Form	
FILE	x≣	DIR 25028, List of Complaints, Style 410FX, Ru	11	Form	
FILE	7	RMF - DIR 25028	327	Form	

Flow Details : DIR-REQ - Device Incident Request : 33496

Request Details

33496	DIR-REQ		Closed	s22	OPR Administration User	05/04/2012	Normal	0
ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 🛷	Priority	Attach

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	05/04/2012 10:25:35	
Comment		

Document 8

06/02/2012

SIGNED

Device Incident Report : Medical Devices Branch - Device Vigilance and Monitoring DIR : 4 - ID : 149385

			Released by <mark>\$22</mark>	on 12/12/2011 12:55:15
Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
25564	2012/005708		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed			02/02/2012	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
02/02/2012	06/02/2012	14/02/2012		
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
27/08/2014			Yes	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Patient		For IRIS Meeting		
Contact:	Alternative Person Title:	Alternative Person First Name:	Alternative Person Surname:	
Alternative Person Phone:	Alternative Person Fax:			
atient Information				
Sex:	Weight:	Age:		
Patient Focused Corrective Action	n Taken:			
Patient History:				
Patient Outcome/Consequences:				

12/07/2024,	11	1:0	6
-------------	----	-----	---

				Document 8
Other Devices Involved:				
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
Reporter Title:	First Name:	Surname:		
Ms	s22	s22		
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
s22		s22	s22	
Country:	Postcode:	Phone:	Fax:	
Australia	<mark>s22</mark>	s22		
Mobile:	Email:			

Initial Reporter Section - in the final release this will connect to the existing list of reporters in IRIS

As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
Postcode:	Phone:	Fax:	Mobile:	
Email:				
Device Information Section				
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
		128767	128767	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:	

Form Details

0//2024, 11.00		FOIII	Details	_
Medical Device	Included	Class III	36197	Document 8
GMDN Text:		Brand Name:		
Prosthesis, internal, mammary,	gel filled	Inamed Breast Implants (allerga	n)	
Initial Device Description:				
Inamed Breast Implants (allerga	an)			
Usage of Device:	Software Version:			
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
27-110361	11658256 & 11711854		1148082 & 1162438	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
20/02/2006		s22	s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Access Contact Phone:	Access Contact Fax:			
Manufacturer Information Section	V - 1 - 1			
Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	
Postcode:	Phone:	Fax:		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
Contact Title:	Contact First Name:	Contact Surname:		
Supplier Information Section				
Supplier Name:		Address 1:	Address 2:	
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

12/07/2024,	11	:06
-------------	----	-----

Date:	Assessed By:			
06/02/2012	s22			
Sample Received:	Sterile:	Reusable:	Single Use:	
No	Yes	No	Yes	
Potential Effect:	Actual Effect:	Injured Party:		
Death	Serious Injury	Patient		
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE
Unlikely	Serious	Rarely	Routine	
Search Sponsors: allergan Attention To:	Name: Allergan Australia Pty Ltd Address 1:	Address 2:	Client #: 17 Town/Suburb:	
Sponsor Information Section				
		Addross 2:		
		Address 2:		
State:	Locked Bag 1514 Postcode:	Phone:	PYMBLE Fax:	
NSW	2073	FIGHE.	14.	
Email:	2075			
GO-Medical-Affairs@allerg	an com			
Investigation Information S				
Device Analysis Results:				
Corrective/Preventative Act	tions:			
Details of Similar Events:				
Number of Similar Events:		Rate of Similar Events:		

Additional Comments:

Form Details

Document 8

Note: As in other places, on the production system the ARTG # text box will be replaced with a link to the register

Other Devices					
Search Device ARTG Device ARTG No Product Name Serial #					

Related DIR Information - Click **New** to begin entering information.

Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Click New to begin entering information.							
Sample Details							
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing		

Correspondence Details

Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes
Reporter Notification Sent	13/03/2012				
Sponsor Questionnaire	19/07/2012	30/07/2012	24/08/2012	 The number of reports for ALCL that Allergan Australia have received; 8. The number of reports for ALCL that Allergan have received (worldwide number) including the reports in Australia; 86. The number of breast implants supplied in Australia; and 92,486 from January 1, 2004 through July31, 2012. The number of breast implants supplied worldwide, including the number supplied in Australia. 4,336,895 from January 1,2004 through July 31,2012 	WW rate: 0.00198% Aust rate: 0.00864%

List of Problem Type Codes - Click **New** to begin entering information.

Type Details					
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected			
Other	Other	patient factors			
Cause Details					
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected			

Form Details

07/2024, 11.00			D
Other	Other		Document 8
Outcome Details			
Outcome of Investigation		If Additional Outcome Detail Requested	
Reviewed, for Trending Purposes Only			
Recall Number:			
Investigation Summary:			
At the time of this report the rate for this event is be re-investigated.	very low. The manufacturer and r	egulators are continuing to monitor this issue and should the rate begin to r	ise the issue will

Flow Details : DIR-REQ - Device Incident Request : 34213

Request Details

34213	DIR-REQ	Location	Closed	s22	OPR Administration User	02/09/2014	Normal	0
ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	02/09/2014 09:11:43	
Comment		

Document 9

on 12/12/2011 12:55:15

Device Incident Report : Medical Devices Branch - Device Vigilance and Monite DIR : 4 - ID : 150275	oring
DIR : 4 - ID : 150275	Released by <mark>\$22</mark>

-			-	-
5	164	N	H	13

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
25704	2012/006412		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed			16/02/2012	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
16/02/2012	17/02/2012			
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
15/05/2012			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Surgeon				
Clinical Event Information:				
Breast reconstruction post 522 hernation of intact gel. Replacement with a new prosth	21 22	the reconstructed breast <mark>\$22</mark>	post op. found superior rupture with	
Contact:	Alternative Person Title:	Alternative Person First Name:	Alternative Person Surname:	
Alternative Person Phone:	Alternative Person Fax:			
Patient Information				
Sex:	Weight:	Age:		
Female	s22	🤓 years		
Patient Focused Corrective Actio	n Taken:			
Patient History:				
Patient Outcome/Consequences:				
Other Devices Involved:				
Submitting Reporter Section				

Form Details

Search Reporter By Surname:	urname: Reporter #:			Document 9
s22	5387			
Reporter Title:	First Name:	Surname:		
Dr	s22	s22		
Position:		Company/Institution:		
Surgeon		s22		
Address 1:	Address 2:	Town/Suburb:	State:	
s22		s22	s22	
Country:	Postcode:	Phone:	Fax:	
Australia	s22	s22		
Mobile:	Email:			
	s22			
Initial Reporter Section - in the fina	al release this will connect to the existir	a list of reporters in IRIS		
As Above?:			Initial Reporter Confidential:	
	If No, fill out the following:			
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
Postcode:	Phone:	Fax:	Mobile:	
Email:				
Device Information Section				
Product Exempt:		Search Device ARTG:	Device ARTG #:	
Floudet Exempt.	If No, fill out ARTG No:			
Therapeutic Licence Type:	Product Licence Category:	171387 Device Class:	171387 GMDN Code:	
Medical Device	Included			
GMDN Text:	Included	Class III 36197 Brand Name:		
Prosthesis, internal, mammary, g	el filled	Allergan Breast Implant		
Initial Device Description:	er mied	Allergan Dicast Implant		
Allergan Breast Implant				
raicigan bicase implane				

Form Details

Usage of Device:	Software Version:			Document 9
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
510FX	13206164	1532586	11	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
19/03/2004		s22	s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Place of use				
Access Contact Phone:	Access Contact Fax:			

Manufacturer Information Section

	Manufacturer Client Id:	Address 1:	
	\$22		
Town/Suburb:	State/Province:	Country:	
Phone:	Fax:		
	Manufacturer Informed:	Date Aware of Adverse Event:	
Contact First Name:	Contact Surname:		
	Phone:	State/Province: Phone: Fax: Manufacturer Informed:	S22 Town/Suburb: State/Province: Country: Phone: Fax: Fax: Manufacturer Informed: Date Aware of Adverse Event:

Supplier Information Section

Supplier Name:		Address 1:	Address 2:	
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
			Yes	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
16/02/2012				
Contact Phone:	Contact Fax:			

Statistics Checklist Section

Date:

Assessed By:

Form Details

D	o	C	u	m	e	n	t	9

17/02/2012	s22			Document 9
Sample Received:	Sterile:	Reusable:	Single Use:	
No	Yes	No	Yes	
Potential Effect:	Actual Effect:	Injured Party:		
Serious Injury	Serious Injury	Patient		
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:
Rarely	Serious	Occasionally	Routine	

Search Sponsors:	Name:		Client #:	
allergan	Allergan Australia Pty Ltd		17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073	s22	(02) 9498 0292	
Email:				

s22 @Allergan.com		
Investigation Information Section		
Device Analysis Results:		
Corrective/Preventative Actions:		
Details of Similar Events:		
Number of Similar Events:	Rate of Similar Events:	
Countries Similar Events Also Occurred:		
Additional Comments:		

Note: As in other places, on the production system the ARTG # text box will be replaced with a link to the register						
Other Devices						
Search Device ARTG	Device ARTG No	Product Name	Serial #			

Form Details

Related DIR Information - Click **New** to begin entering information.

Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Click **New** to begin entering information.

Sample Details						
Sample # Sample Requested Sample Received # Samples from Reporter # Samples from Sponsor Outcome of TGA's Testing						

Correspondence Details					
Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes
asked for ww rates	01/05/2012	12/05/2012	15/05/2012		
RC	15/05/2012				R12/830742
SC	15/05/2012				R12/830737

List of Problem Type Codes - Click **New** to begin entering information.

Type Details				
Type of Problem (Level 1) Type of Problem (Level 2) If 'Other' Type Selected				
Material	Material Separation			
Cause Details				

Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Known Complication	Known Complication		

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
No further action		

Recall Number:	
Investigation Summary:	

The sponsor has provided statistics that indicate the reported rate of rupture for this implant since 2006 is 0.08% in Australia and 0.17% worldwide rate.





Flow Details : DIR-REQ - Device Incident Request : 34406

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 🛷	Priority	Attach
34406	DIR-REQ		Closed	s22	OPR Administration User	15/05/2012	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	15/05/2012 16:21:44	
Comment		

DIR: 6 - ID: 153310

Form Details

Document 10

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

30/03/2012 SIGNED

Released by Theta Technologies on 01/03/2012 12:04:11

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
26189	2012/009113		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22	28/03/2012	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
28/03/2012	30/03/2012	10/04/2012		
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
21/05/2012			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Surgeon		For IRIS Meeting		
Clinical Event Information:				
	ciated infammation of tissue affected. ts replaced with Cereform 360 shaped ge	els.		
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:	
1				
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:		
Patient Information				
Sex:	Weight:	Age:		
Female	s22	🥙 years		
Patient Focused Corrective Action T	laken:			
Patient History:				
Patient Outcome/Consequences:				
Other Devices Involved:				
Submitting Reporter Section				

12

/07/2024, 11:41		Fo		
Search Reporter By Surname:	Reporter #:			Document 10
s22	5440			
Reporter Title:	First Name:	Surname:		
Dr	s22	s22		
Position:		Company/Institution:		
Surgeon		s22		
Address 1:	Address 2:	Town/Suburb:	State:	
s22.	s22	s22	s22	
Country:	Postcode:	Phone:	Fax:	
Australia	s22	s22		
Mobile:	Email:			
	s22			
Initial Reporter Section - in the fina	al release this will connect to the existin	g list of reporters in IRIS		
As Above?:			Initial Reporter Confidential:	
	If No, fill out the following:			
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
Postcode:	Phone:	Fax:	Mobile:	
Email:				
Device Information Section				
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
No	II NO, III OUL AKTO NO.	128767	128767	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:	
Medical Device	Included	Class III	36197	
GMDN Text:		Brand Name:		
Prosthesis, internal, mammary, g	el filled	CUI Round Gel Breast Implant	ts	
Initial Device Description:				

CUI Round Gel Breast Implants

Form Details

Usage of Device:	Software Version:			Document 10
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
340cc				
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
01/01/1998		s22	s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Discarded				
Access Contact Phone:	Access Contact Fax:			

Manufacturer Information Section

Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	
Postcode:	Phone:	Fax:		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
Contact Title:	Contact First Name:	Contact Surname:		

Supplier Information Section

Supplier Name:		Address 1:	Address 2:	
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
			No	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

Statistics Checklist Section

Date:

Assessed By:

Form Details

Docume	ent 10
--------	--------

Exclude report from DIRE:

Sponsor Information Section				
Search Sponsors:	Name:		Client #:	
allerga	Allergan Australia Pty Ltd		17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073	s22		
Email:				
eallergan.com				
Investigation Information Sec	tion			
Device Analysis Results:				
Corrective/Preventative Action	ons:			
Details of Similar Events:				
Number of Similar Events:		Rate of Similar Events:		
Countries Similar Events Also	o Occurred:			
Additional Comments:				
Note: As in other places, on t	the production system the ARTG # text b	ox will be replaced with a link to the	register	

Other Devices

/07/2024, 11:41								Form	Details		Desumer	40
											Document	t 10
Related DIR Infor	mation - Cli	ck New to begi	in entering	information.								
Incident Details												
DIR #		Brand Name	2		Repo	orter First Name	e Reporter	Surname	Company/Institution	n		
Samples Record -	Click New	to begin enteri	ng informa	ation.								
Sample Details												
Sample #	Samp	e Requested	Sample	Received	# Samp Reporte		# Samples f Sponsor	rom	Outcome of TGA's Test	ting		
Correspondence I	Details											
Correspondence	Гуре	Date Sent		Date Respons Expected	se	Date Received	i Sp	onsor's Re	sponse		Investigator's Notes	
Reporter Complet	tion	21/05/2012									R12/837113	
Sponsor Complet	ion	21/05/2012									R12/836924	
List of Problem Ty	/pe Codes -	Click New to b	egin enter	ing information	n.							
Type Details												
Type of Problem ((Level 1)			Type of Pr	roblem (L	_evel 2)			If 'Other' Type Select	ted		
Material				Burst								

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Known Complication	Known Complication		

Outcome Details	
Outcome of Investigation	If Additional Outcome Detail Requested
No further action	

Recall Number:	
Investigation Summary:	
Information received from the current sponsor of this device confirmed the reported rupture rate in Australia as 0.5% (2004 - 2011).	

No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern of occurrence and may re-open the file as appropriate.

Flow Details : DIR-REQ - Device Incident Request : 35082

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 😿	Priority	Attach
35082	DIR-REQ		Closed	s22	OPR Administration User	21/05/2012	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	24/09/2015 11:14:53	
Comment		

Document 11

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

18/04/2012 SIGNED

DIR : 6 - ID : 154614

Released by Theta Technologies on 01/03/2012 12:04:11

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
26395	2012/011251		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22	18/04/2012	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
18/04/2012	18/04/2012	24/04/2012		
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
02/05/2012			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Patient		For IRIS Meeting		
Clinical Event Information:				
On or around \$22 I presen furthest thought, I initially assume The first day the Radiologist was o the Radiologist's findings concluded On being told of this situation by the I visited Dr on \$22 and he refer The MRI concurred with the finding On \$22 I visited Dr again who	nted to my GP with right breast pain and d it was a \$22 pen again after \$22 d that my right implant had ruptured an he Radiologist I immediately phoned Dr erred me for an MRI which I had on \$22 gs of the ultrasound, both reports & films advised that he could perform the breast	d silicone had migrated to my lymph no and I was given an appointment date of s can be provided should the TGA like to	s22	
cover any surgery cost only a repla S22 Allergan state on their Australian b after the 10 year mark, this I was	of the implants and Dr himself told me t acement implant. Dr has asked me to pa preast implant website, in the frequently prepared for, but not the s22, , s	ay him \$22 to explant and replace asked questions section, that their devi see http://www.natrelle.com.au/Faq.asp	ce would not need to be replaced until < .	
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:	
1	Reporter			
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:		

Form Details

				Document 11
Patient Information				
Sex:	Weight:	Age:		
Female	s22	s22 months		
Patient Focused Corrective Action	Faken:			
Patient History:				
Patient Outcome/Consequences:				
I am not sure of the outcome or c	onsequence that the ruptued implant	can or will cause to my health, and	if there is any Dr has not made me aware o	f it.
s22				
Other Devices Involved:				
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
s22	First Names	Cumana		
Reporter Title:	First Name:	Surname:		
Ms Position:	s22	S22 Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
s22	s22	<mark>s22</mark>	s22	
Country:	Postcode:	Phone:	Fax:	
	s22	<mark>s22</mark>		
Mobile:	Email:			
Initial Reporter Section - in the fina	I release this will connect to the exist	ing list of reporters in IRIS		
As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
Yes				
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		

Form Details

Address 1:	Address 2:	Town/Suburb:	State:	Document 11
Postcode:	Phone:	Fax:	Mobile:	
	Thone.			
Email:				
Device Information Section				
Product Exempt:	If No. fill out ADTC No.	Search Device ARTG:	Device ARTG #:	
	If No, fill out ARTG No:	171512	171512	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:	
Medical Device	Included	Class III	36197	
GMDN Text:		Brand Name:		
Prosthesis, internal, mammary, gel fi	lled	Allergan / NATRELLE® 410 Anato	omical breast implant	
Initial Device Description:				
Allergan / NATRELLE® 410 Anatomic	al breast implant			
Usage of Device:	Software Version:			
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
410 MX	13131903		1520810	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
21/01/2008		s22		
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
With Patient	Ms	s22	s22	
Access Contact Phone:	Access Contact Fax:			
s22				
Manufacturer Information Section				
Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22	Level 4 810 Pacific Highway	
Address 2:	Town/Suburb:	State/Province:	Country:	
Gordon	Sydney	NSW	Australia	
Postcode:	Phone:	Fax:		
2072	s22	9498 0290		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
Contact Title:	Contact First Name:	Contact Surname:		

12/07/2024,	11:43
-------------	-------

Supplier Information Section				
Supplier Name:		Address 1:	Address 2:	
Dr <mark>s22</mark>		s22	s22	
Town/Suburb:	State:	Postcode:	Phone:	
s22	s22	s22	s22	
Fax:	Email:		Supplier Informed:	
s22	s22		Yes	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
10/04/2012	Dr	s22	s22	
Contact Phone:	Contact Fax:			
s22	s22			

Statistics Checklist Section

Date:	Assessed By:				
18/04/2012	s22				
Sample Received:	Sterile:	Reusable:	Single Use:		
No	Yes	No	Yes		
Potential Effect:	Actual Effect:	Injured Party:			
Serious Injury	Temporary Injury	Patient			
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:	
Rarely	Serious	Occasionally	Routine		
DIRE Meeting Notes:					
To be reviewed					

Sponsor Information Section				
Search Sponsors:	Name:		Client #:	
allergan	Allergan Australia Pty Ltd		17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073	s22		
Email:				
s22 @Allergan.com				
Investigation Information Section				

Device Analysis Results:		Document
Corrective/Preventative Actions:		
Details of Similar Events:		
Number of Similar Events:	Rate of Similar Events:	
Countries Similar Events Also Occurred:		
Additional Comments:		

Note: As in other places, on the production system the ARTG # text box will be replaced with a link to the register

Other Devices					
Search Device ARTG	Device ARTG No	Product Name	Serial #		

Related DIR Information - Click New to begin entering information.						
Incident Details						
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution		

Samples Record - Click New to begin entering information.							
Sample Details							
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing		

Correspondence Details						
Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Reporter completion	02/05/2012	13/05/2012				
Sponsor completion	02/05/2012	13/05/2012				

List of Problem Type Codes - Click **New** to begin entering information.

07/2024, 11:43		Form Details		
Type Details			Document 1	11
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected		
Material	Material Separation			
Cause Details				
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected		
Known Complication	Known Complication			
Outcome Details Outcome of Investigation		If Additional Outcome Detail Requested		
No further action				
Recall Number:				
Investigation Summary:				
_	ues, the reporter of this event has been advised	n breast implants, no further action will occur at this stag to contact the Australian Competition and Consumer Con d costs for revision surgery.		

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To
FILE		Device and Service Invoice 001	433	Form Item	Report Information Section / Brand Name
FILE		Device Serial Number 001	451	Form Item	Report Information Section / Brand Name
FILE		S22 Medical Imaging Report dated 100412 001	1086	Form Item	Report Information Section / Brand Name
FILE	7	Superscan MRI Report 130412	709	Form Item	Report Information Section / Brand Name

Flow Details : DIR-REQ - Device Incident Request : 35350



ileader.production.tga.gov.au/InformationLeaderAD/Forms/FormDetailPrint.aspx?sid=2008642495

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	02/05/2012 14:51:02	
Comment		

Device Incident I DIR : 6 - ID : 154766

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

19/04/2012 SIGNED

Released by Theta Technologies on 01/03/2012 12:04:11

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
26415	2012/010634		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22	19/04/2012	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
19/04/2012	19/04/2012	01/05/2012		
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
11/05/2012			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Surgeon		For IRIS Meeting		
Clinical Event Information:				
No other details available. Implant removed. New pocket created. New implants inserted left and rigi Implant date: <mark>\$22</mark>	ht.			
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:	
1				
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:		
Patient Information				
Sex:	Weight:	Age:		
Female	s22	s22 Patient initials s22		
Patient Focused Corrective Action T	aken:			
Patient History:				
No other relevant history.				
Patient Outcome/Consequences:				
Other Devices Involved:				

12/07/2024,	11:45
-------------	-------

Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
s22	5440			
Reporter Title:	First Name:	Surname:		
Dr	<mark>s22</mark>	s22		
Position:		Company/Institution:		
Surgeon		s22		
Address 1:	Address 2:	Town/Suburb:	State:	
s22	s22	s22	s22	
Country:	Postcode:	Phone:	Fax:	
Australia	s22	s22		
Mobile:	Email:			
	s22			

Initial Reporter Section - in the final release this will connect to the existing list of reporters in IRIS

As Above?:	If No, fill out the following	:	Initial Reporter Confidential:	
Yes				
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name: Surname:			
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
Postcode:	Phone:	Fax:	Mobile:	
Email:				

Device Information Section

Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:
		126554	126554
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:
Medical Device	Included	Class III	36197
GMDN Text:		Brand Name:	

07/2024, 11:45		Form	Details	Desument 40
Prosthesis, internal, mammary,	gel filled	CUI Breast Implants, 320 Smoot	h Shell, Round, Gel	Document 12
Initial Device Description:				
CUI Breast Implants, 320 Smoo	th Shell, Round, Gel			
Usage of Device:	Software Version:			
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
CUI			68127	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
			s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Access Contact Phone:	Access Contact Fax:			
	3			
Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Manufacturer Name: Allergan		s22		
Manufacturer Name: Allergan Address 2:	Town/Suburb:		Address 1: Country:	
Manufacturer Name: Allergan Address 2:		s22		
Manufacturer Name: Allergan Address 2:	Town/Suburb:	State/Province:		
Manufacturer Name: Allergan	Town/Suburb:	State/Province:		
Manufacturer Name: Allergan Address 2: Postcode: Email:	Town/Suburb: Phone:	S22 State/Province: Fax: Manufacturer Informed:	Country:	
Manufacturer Name: Allergan Address 2: Postcode:	Town/Suburb:	State/Province: Fax:	Country:	
Manufacturer Name: Allergan Address 2: Postcode: Email: Contact Title:	Town/Suburb: Phone:	S22 State/Province: Fax: Manufacturer Informed:	Country:	
Manufacturer Name: Allergan Address 2: Postcode: Email:	Town/Suburb: Phone:	S22 State/Province: Fax: Manufacturer Informed:	Country:	

Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
			No	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

12/07/2024,	11:45
-------------	-------

Statistics Checklist Section				
Date:	Assessed By:			
20/04/2012	s22			
Sample Received:	Sterile:	Reusable:	Single Use:	
No	Yes	No	Yes	
Potential Effect:	Actual Effect:	Injured Party:		
Serious Injury	Temporary Injury	Patient		
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:
Rarely	Serious	Occasionally	Routine	
DIRE Meeting Notes:				
For investigation				
Sponsor Information Section				
Search Sponsors:	Name:	Name:		
allergan	Allergan Australia Pty Ltd	Allergan Australia Pty Ltd		
Attention To:	Address 1:	Address 2:	Town/Suburb:	
	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073			
Email:				
eallergan.com				
Investigation Information Section	1			
Device Analysis Results:				
Corrective/Preventative Actions:				
Details of Similar Events:				

Rate of Similar Events:

Number of Similar Events:

Countries Similar Events Also Occurred:

Additional Comments:

Form Details

Note: As in other places, on the production system the ARTG # text box will be replaced with a link to the register

Other Devices					
Search Device ARTG Device ARTG No Product Name Serial #					

Related DIR Information - Click **New** to begin entering information.

Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Click New to begin entering information.						
Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Details

Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes		
Request for information	07/05/2012	18/05/2012	07/05/2012		See TRIM R12/780609.		
Reporter Notification Sent	07/05/2012						
Reporter Completion	11/05/2012				R12/784142		
Sponsor Completion	11/05/2012						

List of Problem Type Codes - Click **New** to begin entering information.

Type Details				
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected		
Material	Material Separation			

Cause Details				
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected		
Known Complication	Known Complication			

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	

Form Details

					_	4	10
	n	C	III	ne	en	IT I	12
_	-	~	~				

No further action		Boodinone 12
Recall Number:		
Investigation Summary:		
Information received from the current sponsor of this device confirmed the reported rupture rate in Australia a	as 0.5% (2004 - 2011).	
No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern	of occurrence and may re-open the file as appropriate.	

Flow Details : DIR-REQ - Device Incident Request : 35386

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 🛷	Priority	Attach
35386	DIR-REQ		Closed	s22	OPR Administration User	11/05/2012	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	15/07/2014 09:50:48	
Comment		

14/05/2012 SIGNED

Device Incident I DIR : 6 - ID : 156448

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

			Released by Theta Technol	ogies on 01/03/2012 12:04:11
Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
26691	2012/012044		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed			11/05/2012	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
11/05/2012	14/05/2012	22/05/2012		
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
22/05/2012			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Surgeon		For IRIS Meeting		
Clinical Event Information:				
Complete rupture of right implant Implant/gel removed and new imp Implanted: \$22	(retropectoral). Unknown cause. lants inserted.			
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:	
1				
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:		
Patient Information				
Sex:	Weight:	Age:		
Female	\$ 22	s22 Patient initials s22		
Patient Focused Corrective Action T	Taken:			
Patient History:				
Otherwise healthy.				
Patient Outcome/Consequences:				
Other Devices Involved:				
Submitting Reporter Section				

12

/07/2024, 11:47			Form Details	Document 13		
Search Reporter By Surname:	Reporter #:	Reporter #:				
s22	5441	5441				
Reporter Title:	First Name:					
Dr	s22	s22				
Position:		Company/Institution:				
Surgeon		s22				
Address 1:	Address 2:	Town/Suburb:	State:			
s22		s22	s22			
Country:	Postcode:	Phone:	Fax:			
Australia	s22	s22				
Mobile:	Email:					
	s22					
Initial Reporter Section - in the fina	I release this will connect to the	e existing list of reporters in IRIS				
As Above?:	If No, fill out the following	2	Initial Reporter Confidential:			
Yes	In No, nil out the following					
Search Reporter By Surname:	Initial Reporter #:					
Title:	First Name:	Surname:				
Position:		Company/Institution:				
Address 1:	Address 2:	Town/Suburb:	State:			
Postcode:	Phone:	Fax:	Mobile:			
Email:						
Device Information Section						

Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
No		126554	126554	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:	
Medical Device	Included	Class III	36197	
GMDN Text:		Brand Name:		
Prosthesis, internal, mammary,	gel filled	CUI Breast Implant		
Initial Device Description:				
CUI Breast Implant				

Form Details

Usage of Device:	Software Version:			Document 13
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
CUI Round Smooth Gel 290g			119681	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
			s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Access Contact Phone:	Access Contact Fax:			

Manufacturer Information Section

Manufacturer Name:		Manufacturer Client Id:	Address 1:
Allergan		s22	
Address 2:	Town/Suburb:	State/Province:	Country:
Postcode:	Phone:	Fax:	
Email:		Manufacturer Informed:	Date Aware of Adverse Event:
Contact Title:	Contact First Name:	Contact Surname:	

Supplier Information Section

Supplier Name:		Address 1:	Address 2:	
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

Statistics Checklist Section

Date:

Assessed By:

Form Details

Document 13	
-------------	--

14/05/2012	s22			Docume	int io
Sample Received:	Sterile:	Reusable:	Single Use:		
No	Yes	No	Yes		
Potential Effect:	Actual Effect:	Injured Party:			
Serious Injury	Serious Injury	Patient			
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:	
Rarely	Minor	Occasionally	Routine		
DIRE Meeting Notes:					
Invetsigate					

Sponsor Information Section	1			
Search Sponsors:	Name:		Client #:	
allergan	Allergan Australia Pty Lto	1	17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22				
State:	Postcode:	Phone:	Fax:	
		s22		
Email:				
@allergan.com	n			
Investigation Information Se	ection			
Device Analysis Results:				
Corrective/Preventative Act	ions:			
Details of Similar Events:				
Number of Similar Events:		Rate of Similar Events:		
Countries Similar Events Al	so Occurred:			
Additional Comments:				
Note: As in other places, on	the production system the ARTG # te:	xt box will be replaced with a link to the	register	

Other Devices

Search Device ARTG

Device ARTG No

ileader.production.tga.gov.au/InformationLeaderAD/Forms/FormDetailPrint.aspx?sid=2008642495

2/07/2024, 11:47		Form Details			Document 13				
Related DIR Inform	ation - Clic	k New to beg	in entering informatior).					
Incident Details									
DIR #		Brand Name		Rep	orter First Name	Reporter Surname	Company/Institution		
Samples Record - C Sample Details Sample #		o begin enterio	ng information. Sample Received	# Sam	ples from #	# Samples from	Outcome of TGA's Testing	3	
				Report	er S	Sponsor			
Correspondence De	etails								
Correspondence Ty	ре	Date Sent	Date Respo Expected	onse	Date Received	Sponsor's R	esponse	Investigator's Notes	
Reporter Completio	n	22/05/2012	02/06/201	2				R12/845844	
Sponsor Completion	n	22/05/2012						R12/845825	

List of Problem Type Codes - Click **New** to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Material	Burst		
Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Known Complication	Known Complication		
Outcome Details			
Outcome of Investigation		If Additional Outcome Detail Requested	
No further action			

Recall Number:	
Investigation Summary:	
Information received from the current sponsor of this device confirmed the reported rupture rate in Australia as 0.5% (2004 - 2011).	

No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern of occurrence and may re-open the file as appropriate

Flow Details : DIR-REQ - Device Incident Request : 35752

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 😿	Priority	Attach
35752	DIR-REQ		Closed	s22	OPR Administration User	22/05/2012	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	22/05/2012 16:02:43	
Comment		

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

15/05/2012

SIGNED

DIR: 6 - ID: 156612

Released by Thet	a Technologies on	01/03/2012 12:04:11
------------------	-------------------	---------------------

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
26729	2012/012044		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22	15/05/2012	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
15/05/2012	15/05/2012	22/05/2012		
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
22/06/2012			Yes	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Sponsor				
Clinical Event Information:				
On the \$22 , patient had a remove saline rupture.	val & replacement of bilateral breast im	plants. At surgery, both implants remov	ed by Dr were found to have any outer	
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:	
1	Reporter			
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:		
Patient Information				
Sex:	Weight:	Age:		
Female	N/A	s22		
Patient Focused Corrective Action Ta	ken:			
Patient History:				
None specified				
Patient Outcome/Consequences:				
Implants were replaced with Mento	r 350 cc implants, submammary.			
Other Devices Involved:				
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			

Form Details

522				Document 14
Reporter Title:	First Name:	Surname:		
Miss	s22	s22		
Position:		Company/Institution:		
Plastic & Cosmetic Nurse Consult	tant (RN) for Dr <mark>s22</mark>	Dr <mark>s22</mark>		
Address 1:	Address 2:	Town/Suburb:	State:	
s22	s22	s22	s22	
Country:	Postcode:	Phone:	Fax:	
	s22	s22	s22	
Mobile:	Email:	322		
	s22			
Initial Reporter Section - in the fin	al release this will connect to the existin	ig list of reporters in IRIS		
As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		
Address 1:	Address 2:	Town/Suburb:	State:	
Postcode:	Phone:	Fax:	Mobile:	
Email:				
Device Information Section				
Product Exempt:		Search Device ARTG:	Device ARTG #:	
No	If No, fill out ARTG No:	128762	128762	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:	
Medical Device	Included	Class III	36197	
GMDN Text:	Inducu	Brand Name:	50157	
Prosthesis, internal, mammary, g	nel filled	McGhan Breast Implants		
Initial Device Description:		Piconan Dicase implaites		
	Double Lumen (inner silicone/outer sali	ne) smooth		
Usage of Device:	Software Version:	ncj, shout		

Form Details

				Document 14
Model #:	Serial #:	Batch #:	Lot #:	
Unknown	Unknown	Unknown	Unknown	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
			s22.	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Discarded				
Access Contact Phone:	Access Contact Fax:			

Manufacturer Information Section	Manu	ifacture	r Inform	ation	Section
----------------------------------	------	----------	----------	-------	---------

Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22	Unknown	
Address 2:	Town/Suburb:	State/Province:	Country:	
		<>	Australia	
Postcode:	Phone:	Fax:		
	Unknown			
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
Contact Title:	Contact First Name:	Contact Surname:		

Supplier Information Section

	Address 1:	Address 2:	
State:	Postcode:	Phone:	
Email:		Supplier Informed:	
		No	
Contact Title:	Contact First Name:	Contact Surname:	
Contact Fax:			
	Email: Contact Title:	Email: Contact Title: Contact First Name:	Email: Supplier Informed: No Contact Title: Contact First Name: Contact Title: Contact Surname:

Statistics Checklist Section				
Date:	Assessed By:			
16/05/2012	s22			
Sample Received:	Sterile:	Reusable:	Single Use:	

ileader.production.tga.gov.au/InformationLeaderAD/Forms/FormDetailPrint.aspx?sid=2008642495

Form Details

/2024, 11:48			Form Details	Document 14
No	Yes	No	Yes	Document 14
otential Effect:	Actual Effect:	Injured Party:		
Serious Injury	Serious Injury	Patient		
isk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:
Rarely	Serious	Occasionally	Routine	
IRE Meeting Notes:				
More information required				
ponsor Information Section				
Search Sponsors:	Name:		Client #:	
allergan	Allergan Australia Pty Ltd		17	
ttention To:	Address 1:	Address 2:	Town/Suburb:	
22	Locked Bag 1514		PYMBLE	
itate:	Postcode:	Phone:	Fax:	
NSW	2073			
mail:				
allergan.com@	1			
vestigation Information Sec	tion			
Device Analysis Results:				
Corrective/Preventative Actio	ins:			
Details of Similar Events:				
Number of Similar Events:		Rate of Similar Events:		
Terriber of Similar Events.				
Countries Similar Events Also	Occurred:			
dditional Comments:				
eter As is other place	he production system the ADTO # tout h	www.ill he replaced with a link to the sec	inter	
ALC: AS IN OTHER PLACES, ON T	The production system the ARTG # Text b	oox will be replaced with a link to the reg	JISLEI	

Form Details

Related DIR Information - Click **New** to begin entering information.

Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Click **New** to begin entering information.

Sample Details							
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing		

Correspondence Details					
Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes
Request for Information	23/05/2012	05/06/2012	20/06/2012		
Reporter Notification	23/05/2012				
SC / RC	22/06/2012				R12/917306 / R12/917313

List of Problem Type Codes - Click **New** to begin entering information.

Type Details				
Type of Problem (Level 1)	Type of Problem (Level 2)		If 'Other' Type Selected	
Material	Material Separation			
Cause Details				
Cause of Problem (Level 1)	Cause of Problem (Level 2)		If 'Other' Cause Selected	
Known Complication	Known Complication			
Outcome Details				
Outcome of Investigation		If A	dditional Outcome Detail Requested	
No further action				
Recall Number:				

Investigation Summary:

The sponsor advised that the reported rate of rupture for this device in Australia is 0.6%.

Attachment(s) Details



Flow Details : DIR-REQ - Device Incident Request : 35790

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 🛷	Priority	Attach
35790	DIR-REQ		Closed	s22	OPR Administration User	22/06/2012	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	22/06/2012 11:05:20	
Comment		

DIR: 6 - ID: 156618

Form Details

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

15/05/2012 SIGNED

Released by Theta Technologies on 01/03/2012 12:04:11

Report Information Section			
Report #:	Records Management #:	Reporter's Reference #:	Report Type:
26731	2012/012907		Final
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed		s22	15/05/2012
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
16/05/2012	16/05/2012	22/05/2012	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
06/05/2013			Yes
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Surgeon		For IRIS Meeting	
Clinical Event Information:			
On the <mark>\$22, , patient had left had an intracapsular rupture.</mark>	d removal of bilateral breast implants, at Findings also confirmed by breast ultrase	surgery Dr noted that the implant from und.	the right breast was intact, however t
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:
1	Reporter		
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:	
Patient Information			
Sex:	Weight:	Age:	
Female		s22	
Patient Focused Corrective Action T	āken:		
Patient History:			
s22			
Patient Outcome/Consequences:			
Bilateral breast implants were rem	ioved.		

Address 1:

11/2024, 11.30			FUITI Details	
Other Devices Involved:				Document 15
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
s22				
Reporter Title:	First Name:	Surname:		
Miss	s22	s22		
Position:		Company/Institution:		
Plastic & Cosmetic Nurse Consulta	int (RN)	Dr <mark>s22</mark>		
Address 1:	Address 2:	Town/Suburb:	State:	
s22	s22	s22	s22	
Country:	Postcode:	Phone:	Fax:	
	s22	s22	s22	
Mobile:	Email:			
	s22			
nitial Reporter Section - in the fina	I release this will connect to the	existing list of reporters in IRIS		
As Above?:	If No, fill out the following:	5	Initial Reporter Confidential:	
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		

Postcode:	Phone:	Fax:	Mobile:
Email:			
Device Information Section			
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:
No		126554	126554
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:
Medical Device	Included	Class III	36197

State:

Town/Suburb:

Address 2:

Form Details

Date Aware of Adverse Event:

GMDN Text:		Brand Name:		Document 15
Prosthesis, internal, mammary,	gel filled	McGhan Breast Implants		
Initial Device Description:				
McGhan Breast Implants, 220cc	, round, smooth			
Usage of Device:	Software Version:			
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
Unknown	Unknown	Unknown	Unknown	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
			s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Discarded				
Access Contact Phone:	Access Contact Fax:			
Manufacturer Information Section	L. C.			
Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22	Unknown	
Address 2:	Town/Suburb:	State/Province:	Country:	
		<>	Australia	

Fax:

Manufacturer Informed:

Contact Surname:

	p+1	20 I	6.4	-
Supp	lier in	torma	TION	Section
Jupp	11/24 . 211	LOCULUS IN	1.1.2.1.1	0.000001

Postcode:

Email:

Contact Title:

Supplier Name:			Address 2:	
Unknown				
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
			No	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

Phone:

Contact First Name:

12/07/2024,	11:50
-------------	-------

Statistics Checklist Section					
Date:	Assessed By:				
16/05/2012	s22				
Sample Received:	Sterile:	Reusable:	Single Use:		
No	Yes	No	Yes		
Potential Effect:	Actual Effect:	Injured Party:			
Serious Injury	Serious Injury	Patient			
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:	
Rarely	Serious	Occasionally	Routine		
DIRE Meeting Notes:					
More information required					
Sponsor Information Section					
Search Sponsors:	Name:		Client #:		
allergan	Allergan Australia Pty Ltd		17		
Attention To:	Address 1:	Address 2:	Town/Suburb:		
s22	Locked Bag 1514		PYMBLE		
State:	Postcode:	Phone:	Fax:		
NSW	2073	s22	(02) 9498 0299		
Email:					
allergan.com@allergan.com					
Investigation Information Section					
Device Analysis Results:					
Corrective/Preventative Actions:					
Details of Similar Events:					
Number of Similar Events: Rate of Similar Events:					
36 (Australia) 160 (WW) 0.74% (Aus) 0.15% (WW)					
Countries Similar Events Also Occu	urred:				
Agrentina, Belgium, Brazil, China, Sweden, UK, USA, Venezuela.	, Colombia, Denmark, Ecuador, Fra	nce, Germany, Ireland, Mexico, Netherla	nds, Peru, Philippines, Poland, Slovakia,	Spain,	
Additional Comments:					

Form Details

Document 15

Note: As in other places, on the production system the ARTG # text box will be replaced with a link to the register

Other Devices				
Search Device ARTG	Device ARTG No	Product Name	Serial #	

Related DIR Information - Click **New** to begin entering information.

Incident Details					
DIR #	Brand Name				

Samples Record - Click New to begin entering information.						
Sample Details	Sample Details					
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Details Date Response Sponsor's Response Investigator's Notes Correspondence Type Date Sent Date Received Expected Reporter Notification Letter 25/05/2012 02/05/2013 Extension to 03/05/2013 granted. Questionnaire Letter 18/04/2013 01/05/2013 Response from sponsor 06/05/2013 17/05/2013 Questionaire response RC letter 06/05/2013 17/05/2013 SC letter 06/05/2013 17/05/2013

List of Problem Type Codes - Click **New** to begin entering information.

Type Details				
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected		
Material	Material Separation			

Cause Details

Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Known Complication	Known Complication		

Outcome Details

Form Details

Outcome of Investigation	If Additional Outcome Detail Requested	Docun	nent 15
Not investigated			
Recall Number:			
Investigation Summary: Information received from the current sponsor of this device confirmed the reported rupture rate in Australia a complication of silicone breast implant surgery. No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern			

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To
FILE	w	DIR 26731 - questionnaire letter	93	Form	
FILE	×≣	s22 042213_final	19	Form	

Flow Details : DIR-REQ - Device Incident Request : 35795

Request Details

ID		Туре	Location	Status	Assigned By	Assigned To	Assigned On 🕜	Priority	Attach
357	795	DIR-REQ		Closed	s22	OPR Administration User	06/05/2013	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	06/05/2013 09:24:33	
Comment		

DIR: 6 - ID: 157241

Form Details

Document 16

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

23/05/2012 SIGNED

Released by Theta Technologies on 01/03/2012 12:04:11

Report Information Section				
Report #:	Records Management #:	Reporter's Reference #:	Report Type:	
26834	2012/012750		Final	
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:	
Closed		s22	15/05/2012	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:	
15/05/2012	23/05/2012	29/05/2012		
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:	
06/05/2013			No	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:		
Surgeon		For IRIS Meeting		
Clinical Event Information:				
Ruptured left breast implant. Pale yellow discolouration with rup	ture of implant and intracapsular silicon.			
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:	
1				
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:		
Patient Information				
Sex:	Weight:	Age:		
Female		s22		
Patient Focused Corrective Action T	aken:			
Patient History:				
Patient Outcome/Consequences:				
Other Devices Involved:				
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			

Form Details

0112021, 11.02				D	
s22	5369			Document 16	
Reporter Title:	First Name:	Surname:			
Dr	s22	s22			
Position:		Company/Institution:			
Plastic Surgeon					
Address 1:	Address 2:	Town/Suburb:	State:		
s22		s22	s22		
Country:	Postcode:	Phone:	Fax:		
Australia	s22	s22			
Mobile:	Email:				
	s22				
Initial Reporter Section - in the fina	al release this will connect to the existir	ig list of reporters in IRIS			
As Above?:	76 M 6 H 6 H 5		Initial Reporter Confidential:		
Yes	If No, fill out the following:				
Search Reporter By Surname:	Initial Reporter #:				
Title:	First Name:	t Name: Surname:			
Position:		Company/Institution:			
Address 1:	Address 2:	Town/Suburb:	State:		
Postcode:	Phone:	Fax:	Mobile:		
Email:					
Device Information Section					
Product Exempt:		Search Device ARTG:	Device ARTG #:		
	If No, fill out ARTG No:	128767	128767		
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN Code:		
Medical Device	Included	Class III	36197		
GMDN Text:					
Prosthesis, internal, mammary, g	el filled	McGhan Breast Implants			
Initial Device Description:					
McGhan Breast Implants					
Usage of Device:	Software Version:				

Form Details

Model #: Serial #: Batch #: Lot #: MHP 11562071 & 11550109 1119857 & 1117977 Purchase Date: Expiry Date: Date of Implant: Date of Explant:	Document To
Purchase Data: Data of Implant: Data of Explant:	
Fulctionse Date of Implant. Date of Implant.	
<u>s22</u>	
Reported Device Location: Access Contact Title: Access Contact First Name: Access Contact Surname:	
Place of use	
Access Contact Phone: Access Contact Fax:	

	Manu	facture	Inform	ation	Section
--	------	---------	--------	-------	---------

Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	
Postcode:	Phone:	Fax:		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
Contact Title:	Contact First Name:	Contact Surname:		

Supplier Information Section

Supplier Name:		Address 1:	Address 2:	
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
Contact Phone:	Contact Fax:			

Statistics Checklist Section				
Date:	Assessed By:			
23/05/2012	s22			
Sample Received:	Sterile:	Reusable:	Single Use:	

ileader.production.tga.gov.au/InformationLeaderAD/Forms/FormDetailPrint.aspx?sid=2008642495

Form Details

1//2024, 11.32			Form Details	Document 16
No	Yes	No	Yes	Document ro
Potential Effect:	Actual Effect:	Injured Party:		
Serious Injury	Serious Injury	Patient		
Risk Frequency:	Risk Severity:	Risk Detectability:	Classification:	Exclude report from DIRE:
Rarely	Serious	Occasionally	Routine	
DIRE Meeting Notes:				
ponsor Information Section				
Search Sponsors:	Name:		Client #:	
allergan	Allergan Australia Pty Ltd		17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
ACT	2073	s22		
Email:				
s22 @Allergan.com	1			
nvestigation Information Sect	ion			
Device Analysis Results:				
Corrective/Preventative Action	ns:			
Details of Similar Events:				
Number of Similar Events:		Rate of Similar Events:		
3 (Aus) 74 (WW)		2.63% (Aus) 0.14%(WW)		
Countries Similar Events Also				
	Ecuador, France, Israel, Italy, Mexico, I	lorway, Spain, & UK		
Additional Comments:				
lote: As in other places, on th	ne production system the ARTG $\#$ text b	ox will be replaced with a link to the reg	gister	
Other Devices				

Outer Devices							
Search Device ARTG	Device ARTG No	Product Name	Serial #				

Form Details

Related DIR Information - Click **New** to begin entering information.

Incident Details					
DIR #	Reporter First Name	Reporter Surname	Company/Institution		

Samples Record - Click **New** to begin entering information.

Sample Details							
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing		

Correspondence Details					
Correspondence Type	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes
asked for rupture stats	04/06/2012	15/06/2012			
RC letter	06/05/2013	17/05/2013			
SC letter	06/05/2013	17/05/2013			

List of Problem Type Codes - Click **New** to begin entering information.

Type Details				
Type of Problem (Level 1)	Type of Problem (Level 2)		If 'Other' Type Selected	
Material	Material Separation			
Cause Details				
Cause of Problem (Level 1)	Cause of Problem (Level 2)		If 'Other' Cause Selected	
Known Complication	Known Complication			
Outcome Details				
Outcome of Investigation		If A	dditional Outcome Detail Requested	
No further action				
Recall Number:				
Invoctigation Summany:				

Investigation Summary:

The implant was not returned to the manufacturer and as a result no physica device analysis was able to be undertaken. Rupture is a known complication of silicone breast implant surgery. No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern of occurrence and may re-open the file as appropriate.

Flow Details : DIR-REQ - Device Incident Request : 35935

Similar events - 3 (Aus) 74 (WW)

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 🛛	Priority	Attach
35935	DIR-REQ		Closed	s22	OPR Administration User	28/05/2013	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	06/05/2013 13:31:10	
Comment		

25/05/2012

SIGNED

17/2024, 11:53		Form Details	Document 1
Device Incid	ent Report : Medical Devices E	Branch - Device Vigilance and Mo	nitoring 2
	137403	Released by	on 25/06/2015 15:11:06
Report Information Section			
Report #:	Records Management #:	Reporter's Reference #:	Report Type:
26861	2012/012952	681173	Final
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed	Death / Serious Injury	s22	04/08/2011
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
06/06/2014	25/05/2012		27/05/2014
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
11/06/2014	Patient		No
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Sponsor		Trend data only	
Event Description for Website Publicat	ion:		
The healthcare professional informed	the Technical Consultant that the explant proc	edure is only a precaution and Anaplastic Lar	ge Cell Lymphoma (ALCL) has not been diag
Clinical Event Information:			
only. An explant date was not been of Anaplastic Large Cell Lymphoma (ALC	to an Allergan Technical Consultant that inforn onfirmed. The healthcare professional informed CL) has not been diagnosed. The patients origin serial numbers not known therefore Allergan A	d the Allergan Technical Consultant that the ex nal implants were implanted by another health	xplant procedure is only a precaution and heare professional on an unspecified date an
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:
1			
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:	
Patient Information			
Sex:	Weight:	Age:	
Female	NI	NI	

Patient Focused Corrective Action Taken:

NI

NI

Patient History:

12/07/2024,	11:53
-------------	-------

Patient Outcome/Consequences:			Document 17	
NI				
Other Devices Involved:				
NI				
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
s22	5166 - s22 - Regulatory	Affairs Officer - Allergan Australia		
Reporter Title:	First Name:	Surname:		
Miss	s22	s22		
Position:		Company/Institution:		
s22		Allergan Australia		
Address 1:	Address 2:	Town/Suburb:	State:	
Allergan Australia	Level 4/810 Pacific Hwy	Gordon	NSW	
Country:	Postcode:	Phone:	Fax:	
Australia	2072	1800 252 224	02 9498 0299	
Mobile:	Email:		Last External Submission By:	
	GO-Medical-Affairs@allergan.com			
nitial Reporter Section				
As Above?:			Initial Reporter Confidential:	
No	If No, fill out the following:		Yes	
Search Reporter By Surname:	Initial Reporter #:			
s22	5557 - <mark>s22</mark>			
Fitle:	First Name:	Surname:		
Dr	s22	s22		
Position:		Company/Institution:		
		s22		
Address 1:	Address 2:	Town/Suburb:	State:	
s22		s22	<mark>s22</mark>	
Postcode:	Phone:	Fax:	Mobile:	
s22	s22	s22		
Email:				
s22				

			Document 17
Device Information Section			
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:
No	In No, Im out Nicro No.	128763	128763
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN / UMDN Code:
Medical Device	Included	Class III	36197
GMDN / UMDN Text:		Brand Name:	
Prosthesis, internal, mammary, gel fil	led	Style 410 Cohesive Silicone Gel F	illed Breast Implant
Initial Device Description:			
Style 410 Cohesive Silicone Gel Filled	Breast Implant		
Usage of Device:	Software Version:		
Single Use	N/A		
Model #:	Serial #:	Batch #:	Lot #:
UNK (Full height/Full projection)	NI	N/A	NI
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:
Insitu			
Access Contact Phone:	Access Contact Fax:		
Ianufacturer Information Section			
Manufacturer Name:		Manufacturer Client Id:	Address 1:
Allergan		\$22	Marlow International Parkway
Address 2:	Town/Suburb:	State/Province:	Country:
	Marlow	Bucks	United Kingdom
Postcode:	Phone:	Fax:	
SL7 1YL	1800 252 224	02 9498 0299	
Email:		Manufacturer Informed:	Date Aware of Adverse Event:
GO-Medical-Affairs@allergan.com		Yes	27/07/2011
Contact Title:	Contact First Name:	Contact Surname:	

Miss

22

2/07/2024, 11:53		Form Details	
Supplier Name:		Address 1:	Address 2: Document 17
Town/Suburb:	State:	Postcode:	Phone:
Fax:	Email:		Supplier Informed:
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:
Contact Phone:	Contact Fax:		

Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:
11/06/2014	s22	Yes	Yes	
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:
No	Yes	No	Yes	Temporary Injury
Actual Effect:	Injured Party:			Risk Frequency:
Not Known	Patient			Unlikely
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:
Minor	Unlikely	Not Investigated		

Sponsor Information Section

Search Sponsors:	Name:		Client #:
Allergan	Allergan Australia Pty Ltd		17
Attention To:	Address 1:	Address 2:	Town/Suburb:
s22	Locked Bag 1514		PYMBLE
State:	Postcode:	Phone:	Fax:
NSW	2073	s22	(02) 9498 0299
Email:			
GO-Medical-Affairs@allergan.co	m		

Investigation Information Section	
Device Analysis Results:	
The reporting health professional stated that the device(s) would be explanted though this	was never confirmed. The device(s) has not returned to Allergan for analysis.
Corrective/Preventative Actions:	
The AE Term Code "No complaint against the device" has been assigned to this record in the	ne Company Safety Database. No corrective action is deemed necessary.
Details of Similar Events:	
N/A Allergan have assigned the AE Term Code "No complaint against the device".	
Number of Similar Events:	Rate of Similar Events:
Countries Similar Events Also Occurred:	
N/A	
Additional Comments:	
Repeated attempts to obtain further information about this patient have been made to the requested via email and telephone, by an Allergan Sales Representative and Allergan Medi	

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices							
Device ARTG No	Manufacturer Name	Sponsor/Supplier	Trade/Brand Name	Serial #	Model Number	GMDN / UMDN Text	
Related DIR Informa	ation - Click New to b	egin entering informati	on.				

Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Click **[N]** to begin entering information.

Form Details

Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Information Section. Note that the Correspondence Recipient will receive a notification if the Date Received is not filled in by the Date Expected.

Correspondence Det	ails						
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Request for final report		09/05/2013	22/05/2013			This was not recorded on my spreadsheet and Have sent another letter out.	
Request for final report		27/05/2014	10/06/2014				
Request for ARTG#		10/06/2014					

List of Problem Type Codes - Click **[N]** to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Other	Other	Explant as precaution	

Investigation Problem Causes

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Other	Other	Explant as precaution	

Investigation Outcomes

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
Reviewed, for Trending Purposes Only		

Form Details

Recall Number: Investigation Summary: No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern of occurrence and may re-open the file as appropriate.

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To	
FILE	ト	0039586_ Follow Up IRIS Report	114	Form		

Flow Details : DIR-REQ - Device Incident Request : 35968

Request Details

35968	DIR-REQ		Closed	s22	OPR Administration User	11/06/2014	Normal	0
ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	11/06/2014 09:59:43	
Comment		

Document 18

25/07/2012 SIGNED

DIR : 20 - ID : 1		Released by <mark>s</mark> 2	on 25/06/2015 15:11
Report Information Section			
Report #:	Records Management #:	Reporter's Reference #:	Report Type:
27494	2012/016549	0050980/AZ	Final
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed	Other	s22	29/05/2012
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
02/04/2013	25/07/2012	09/04/2013	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
05/06/2013	Patient		No
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Sponsor		For IRIS Meeting	
Event Description for Website Publicati	on:		
The patient had the LHS implant expla lymphoma.	anted and biopsies were taken and the histopa	thology report provided. Confirmed that there	e is no evidence of left breast involv
Clinical Event Information:			
The patient had the LHS implant explain involvement by lymphoma. No further information to report.	anted in <mark>\$22</mark> and biopsies were taken and	d the histopathology report provided. Confirm	ed that there is no evidence of left
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Na
가지 그 가 가 많은 것은 것은 것이 있다. 이 것은 것이 있다. 것은 것은 것은 것은 것은 것을 받았다.			

Patient Information

Sex:	Weight:	Age:	
Female		s22	
Patient Focused Corrective Action Taken:			
Define tilleter u			

Form Details

Right breast cancer in <mark>s22</mark> implants. *ALK negative anaplastic la <mark>s22</mark>	arger cell lymphoma involving capsule around	d implant of right breast diagnosed in <mark>SZ2</mark>	. * <mark>522</mark> bilateral breast augmentation with silicone * <mark>522</mark>
Patient Outcome/Consequences:			
On s22 further information w	vas received from Dr <mark>s22</mark> rooms	regarding this patient.	
On s22 the patient was revie s22 On s22 the patient was revie was unremarkable.		ogist (<mark>s22) who confirmed th</mark>	at the patient has been well and that clinical examination
Other Devices Involved:			
N/A.			
Submitting Reporter Section			
Search Reporter By Surname:	Reporter #:		
Allergan		Affairs Officer - Allergan Australia	
Reporter Title:	First Name:	Surname:	
Ms	s22	s22	
Position:		Company/Institution:	
Regulatory Affairs Officer		Allergan Australia	
Address 1:	Address 2:	Town/Suburb:	State:
Allergan Australia	Level 4/810 Pacific Hwy	Gordon	New South Wales
Country:	Postcode:	Phone:	Fax:
Australia	2072	s22	9498 0299
Mobile:	Email:		Last External Submission By:
	GO-Medical-Affairs@allergan.com		
Initial Reporter Section			
As Above?:	If No, fill out the following:		Initial Reporter Confidential:
No	In No, In out the following.		No
Search Reporter By Surname:	Initial Reporter #:		
Title:	First Name:	Surname:	
Dr	s22	s22	
Position:		Company/Institution:	

Form Details

Plastic and reconstruction Sur	geon		Document	10
Address 1:	Address 2:	Town/Suburb:	State:	
s22		s22	s22	
Postcode:	Phone:	Fax:	Mobile:	
s22	s22	s22		
Email:				

Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
		128764	128764	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN / UMDN Code:	
Medical Device	Included	Class III	36197	
GMDN / UMDN Text:		Brand Name:		
Prosthesis, internal, mammary, gel filled		Style 410 Cohesive Silicone Gel Filled Breast Implant		
Initial Device Description:				
Style 410 Cohesive Silicone Gel Fill	led Breast Implant			
Usage of Device:	Software Version:			
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
27-MM110-215	RC2012		185091	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
		s22	s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Access Contact Phone:	Access Contact Fax:			

Manufacturer Information Section

Manufacturer Name: Allergan		Manufacturer Client Id: s22	Address 1:	
Address 2:	Town/Suburb:	State/Province:	Country:	
Postcode:	Phone:	Fax:		

12/07/2024, 11:55

Form Details

			Document 18
Email:		Manufacturer Informed:	Date Aware of Adverse Event:
		Yes	21/05/2012
Contact Title:	Contact First Name:	Contact Surname:	
Supplier Information Section			
Supplier Name:		Address 1:	Address 2:
Town/Suburb:	State:	Postcode:	Phone:
Fax:	Email:		Supplier Informed:
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:
Contact Phone:	Contact Fax:		

Statistics Checklist Section

Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:
04/04/2013	s22	No		
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:
No	Yes	No	Yes	Serious Injury
Actual Effect:	Injured Party:		Risk Frequency:	
Serious Injury	Patient			Unlikely
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:
Minor	Occasionally	Routine		
DIRE Meeting Notes:				
Check to see if right implant repo				

Sponsor Information Section

Search Sponsors:

Client #:

12/07/2024, 11:55

Form Details

Allergan	Allergan Australia Pty Ltd		17 Document 18
Attention To:	Address 1:	Address 2:	Town/Suburb:
s22	Locked Bag 1514		PYMBLE
State:	Postcode:	Phone:	Fax:
NSW	2073	s22	02 9498 0299
Email:			
GO-Medical-Affairs@allergan.co	m		
Investigation Information Sectior	1		
Device Analysis Results:			
Devices were not returned for t	esting.		
Corrective/Preventative Actions:			
N/A.			
Details of Similar Events:			
Yes, for ARTG 128764 worldwid Event (Capsular contracture Lump/nodule 19 Lymphoma - ALCL 7 Cellulitis 4	Count: Event Rate:		
Sales: 309,007.			
Number of Similar Events:		Rate of Similar Events:	
Countries Similar Events Also Od	ccurred:		
	elgium, Brazil, Canada, Chile, China, Colombia and, Poland, Portugal, Russia, Slovenia, South		ce, Germany, Greece, Honduras, Hungary, Israel, Italy, e, United Kingdom, United States of America.

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices Manufacturer Sponsor/Supplier Trade/Brand Name Serial # Model Number GMDN / UMDN Name E

Related DIR Information - Click **New** to begin entering information.

	to begin entering	information.			
Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record -	Samples Record - Click [N] to begin entering information.							
Sample Details								
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing			

Correspondence Inf	ormation Section. No	te that the Corresp	ondence Recipient will	receive a notification	n if the Date Received is n	ot filled in by the Date Expected.	
Correspondence De	tails						
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Email requesting similar event info as it does not appear on final or previous reports		14/03/2013		19/04/2013			
Request for information		16/04/2013	29/04/2013				
41JA letter sent		06/05/2013	20/05/2013	08/05/2013			
Email to Sponsor		05/06/2013				R13/435284 Email with Sponsor Complete Letter	
Sponsor Complete Letter		05/06/2013				Attached	

List of Problem Type Codes - Click **[N]** to begin entering information.

Type Details

12/07/2024, 11:55

Form Details

Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	Document 18
Other	Other	Unknown	

Investigation Problem Causes

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Unable to confirm complaint	Investigation did not reveal a root cause		

Investigation Outcomes

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
Reviewed, No Further Action Required		

Recall Number:
Investigation Summary:
The TGA has investigated this complaint.
Advice received from the Sponsor and medical reports confirm that no Lymphoma was detected in the left breast. Lymphoma was detected around the right breast implant and the patient underwent treatment.
Both implants have been explanted. The reported rate for Lymphoma - ALCL is 0.0023%
No further investigation will occur at this time however TGA will continue to monitor the pattern and rate of occurrence and may re-open the file as appropriate.

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To
FILE	7	0050980 - Haemotology Report	53	Form	
FILE	w	IRIS - FORM - MDIR03 - 3rd followup	134	Form	

12/07/2024, 1	11:55	Form Details			Decument 19
FILE	7	0050980 redacted 23NOV12 - letter	62	Form	Document 18
FILE	7	0050980_FUP IRIS FORM_24DEC2012	53	Form	
FILE	7	MDM Discussion Summary	63	Form	
FILE	7	DIR 27494_Final IRIS report_14MAR2013	112	Form	
FILE	×	0050980_redacted Final from HCP_06MAR2013	112	Form	
FILE	x	s22 031313_ARTG_final	19	Form	
FILE	×	DIR 27494_FINAL IRIS Report_02APR2013	112	Form	
FILE	×	0050980_redacted fup_20MAR13	138	Form	
FILE	7	DIR 27494_follow up IRIS report_28MAR2013	113	Form	
FILE	7	_ DIR 27494 - 41JA letter [SEC=UNCLASSIFIED] A	184	Form	
FILE	7	0050980	54	Form	
FILE	7	DIR 27494 - Sponsor Complete Letter	262	Form	

Flow Details : DIR-REQ - Device Incident Request : 36805

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach
36805	DIR-REQ		Closed	s22	OPR Administration User	05/06/2013	Normal	0

Signature Details

Role		IRIS Investigator	
User		s22	
Signe	ed At	05/06/2013 09:29:36	

12/07/2024,	11	:55
-------------	----	-----

Comment

ileader.production.tga.gov.au/InformationLeaderAD/Forms/FormDetailPrint.aspx?sid=2	008642495

Document 19



Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

01/08/2012 SIGNED

DIR : 20 -	ID: 16202
------------	-----------

Released by	s22	on 25/06/2

25/06/2015 15:11:06

Report #:	Records Management #:	Reporter's Reference #:	Report Type:
27612	2012/017026	0052817/AZ	Final
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed	Other	s22	27/07/2012
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
09/06/2013	01/08/2012	18/06/2013	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
27/10/2014			No
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Sponsor		For IRIS Meeting	
Event Description for Website Publicati	ion:		
Report received reporting a patient wi	ith breast implants with a "possible suspicious	of s22 to Anaplastic Large Cel	l Lymphoma".
Clinical Event Information:			
Clinical Event Information: Initial report received to company on Cell Lymphoma", not confirmed by pa	s22 from HCP reporting a female patien thology.	t with BREAST implants with a "possible suspi	icious of <mark>\$22</mark> to Anaplastic Large
Initial report received to company on	s22 from HCP reporting a female patien thology. Contact:	t with BREAST implants with a "possible susp Alternative Person Title:	to Anaplastic Large Alternative Person First Name:
Initial report received to company on Cell Lymphoma", not confirmed by pa	thology.	-	
Initial report received to company on Cell Lymphoma", not confirmed by pa Number of Incidents in Report:	thology.	-	
Initial report received to company on Cell Lymphoma", not confirmed by pa Number of Incidents in Report: 1	thology. Contact:	Alternative Person Title:	
Initial report received to company on Cell Lymphoma", not confirmed by pa Number of Incidents in Report: 1 Alternative Person Surname:	thology. Contact:	Alternative Person Title:	
Initial report received to company on Cell Lymphoma", not confirmed by pa Number of Incidents in Report: 1 Alternative Person Surname:	thology. Contact:	Alternative Person Title:	
Initial report received to company on Cell Lymphoma", not confirmed by pa Number of Incidents in Report: 1 Alternative Person Surname: Patient Information	thology. Contact: Alternative Person Phone:	Alternative Person Title: Alternative Person Fax:	
Initial report received to company on Cell Lymphoma", not confirmed by pa Number of Incidents in Report: 1 Alternative Person Surname: Patient Information Sex:	thology. Contact: Alternative Person Phone: Weight:	Alternative Person Title: Alternative Person Fax: Age:	
Initial report received to company on Cell Lymphoma", not confirmed by pa Number of Incidents in Report: 1 Alternative Person Surname: Patient Information Sex: Female	thology. Contact: Alternative Person Phone: Weight:	Alternative Person Title: Alternative Person Fax: Age:	
Initial report received to company on Cell Lymphoma", not confirmed by pa Number of Incidents in Report: 1 Alternative Person Surname: Patient Information Sex: Female Patient Focused Corrective Action Take	thology. Contact: Alternative Person Phone: Weight:	Alternative Person Title: Alternative Person Fax: Age:	
Initial report received to company on Cell Lymphoma", not confirmed by pa Number of Incidents in Report: 1 Alternative Person Surname: Patient Information Sex: Female Patient Focused Corrective Action Take Explant surgery on \$22	thology. Contact: Alternative Person Phone: Weight:	Alternative Person Title: Alternative Person Fax: Age:	

5	~	. m	er	+ 4	
υ	υu		e	π.	19

Unknown.

Other Devices Involved:

N/A.

Submitting Reporter Section

Search Reporter By Surname:	Reporter #:		
<mark>s22</mark> Reporter Title:	First Name:	Surname:	
	s22	s22	
Position:		Company/Institution:	
		Allergan Australia	
Address 1:	Address 2:	Town/Suburb:	State:
Level 4	810 Pacific Highway	Gordon	NSW
Country:	Postcode:	Phone:	Fax:
Australia	2073	s22	02 9498 0299
Mobile:	Email:		Last External Submission By:
	allergan.com		
nitial Reporter Section As Above?: No	If No, fill out the following:		Initial Reporter Confidential:
Search Reporter By Surname:			
Search Reporter by Samane.	Initial Reporter #:		
	First Name:	Surname:	
		Surname:	
Title: Dr	First Name:		
Title:	First Name:	s22	
Title: Dr	First Name:	S22 Company/Institution:	State:
Title: Dr Position:	First Name:	s22 Company/Institution: s22	State:
Title: Dr Position:	First Name:	s22 Company/Institution: s22 Town/Suburb:	
Title: Dr Position: Address 1:	First Name:	s22 Company/Institution: s22 Town/Suburb: s22	s22

Device Information Section			Document 19
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:
No		128764	128764
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN / UMDN Code:
Medical Device	Included	Class III	36197
GMDN / UMDN Text:		Brand Name:	
Prosthesis, internal, mammary, gel	filled	Style 410 Cohesive Silicone Gel Fille	ed Breast Implant
Initial Device Description:			
Style 410 Cohesive Silicone Gel Fill	ed Breast Implant		
Usage of Device:	Software Version:		
Single Use			
Model #:	Serial #:	Batch #:	Lot #:
27-FF130-425	Right: II6794		Right: 253777
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:
		s22	s22
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:
Access Contact Phone:	Access Contact Fax:		
Anufacturer Information Section			
Manufacturer Name:		Manufacturer Client Id:	Address 1:
Allergan		\$22	
Address 2:	Town/Suburb:	State/Province:	Country:
Postcode:	Phone:	Fax:	
Email		Manufacturer Informed	Date Aware of Adverse Event

Email:		Manufacturer Informed:	Date Aware of Adverse Event:
Contact Title:	Contact First Name:	Contact Surname:	

Supplier Name:		Address 1:	Address 2: Document 19
Town/Suburb:	State:	Postcode:	Phone:
Fax:	Email:		Supplier Informed:
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:
Contact Phone:	Contact Fax:		

Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:
12/06/2013	s22	Yes	Yes	
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:
No	Yes	No	Yes	Death
Actual Effect:	Injured Party:			Risk Frequency:
Serious Injury	Patient			Unlikely
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:
Serious	Occasionally	Routine		

Sponsor Information Section	1
-----------------------------	---

Search Sponsors:	Name:	Name:		
Allergan	Allergan Australia Pty Ltd		17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073	1800 252224	02 9498 0299	
Email:				
GO-Medical-Affairs@allergan.co	om			

Investigation Information Section

Device Analysis Results:

Device analysis was not possible since the device was not returned to Allergan. Pathology results and results of inspection by the Pathologist were previously submitted to TGA on 27JUL2012.

Corrective/Preventative Actions:

Seroma is an expected event clearly documented in the product Directions for Use. Lymphoma - ALCL is not an expected event with Allergan Breast Implants and is not listed in product Directions for Use.

Allergan are committed to patient safety and perform regular signal detection on all adverse events reported to the Company. To date no new trend has been identified specific to the events in this report. In addition, Allergan conducts an annual review of Anaplastic Large Cell Lymphoma (ALCL) diagnosed in patients with breast implants - the last review was made available to TGA on 25JAN2013, sent via email.

Allergan will continue to gather, closely monitor and thoroughly investigate all sources of breast implant safety and performance data and act out of an abundance of caution to protect patients should adverse trends and/or events of significance can be identified.

Details of Similar Events:	
None reported for model # 27 FF130 425.	
Style 410 Breast Implant Cat# 27 FF130 425 Similar Incidents for PRID 894565* Received Worldwide through May 29, 2013	
Lymphoma - ALCL Aus Events: 1, Aus Rate: 0.74%, WW Events**: 1, WW Rate: 0.09%.	
Seroma Aus Events: 1, Aus Rate: 0.74%, WW Events**: 1, WW Rate: 0.09%.	
Sales: Aus***: 136. WW†: 1,160.	
*There are no other similar incidents to PR 894565. The above events do not include non **Worldwide events includes Australia. ***Australia sales are from January 1, 2007 through April 30, 2013. Country specific sale	
report. †Worldwide sales include Australia. The sales date range is form January 1, 2004 through available at the time of this report Report Date: 05/30/2013.	February 28, 2013. Sales prior to 2004 are not available. May 2013 sales are not
Number of Similar Events:	Rate of Similar Events:
Countries Similar Events Also Occurred:	
Additional Comments:	
Allergan have attempted to obtain the following information from the reporting health pro Patient history – previous cancers? Any chronic conditions? Surgery type Aug/Recon/Revision? And if applicable previous implant and expander histoplacement – sub muscular or sub glandular?	

. Should Allergan receive any additional information regarding this event this will be provided to TGA in a timely report.

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices							
Device ARTG No	Manufacturer Name	Sponsor/Supplier	Trade/Brand Name	Serial #	Model Number	GMDN / UMDN Text	

Related DIR Information - Click	lew to begin entering	information.			
Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Clic	k [N] to begin entering	information.				
Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Information Section. Note that the Correspondence Recipient will receive a notification if the Date Received is not filled in by the Date Expected.

Correspondence De	tails						
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	

Request for final report	20/05/2013	03/06/2013		C	Oocument 19
Questionnaire letter	18/07/2013	31/07/2013	24/07/2013		
Email requesting updated IFU	30/05/2014	10/06/2014		TRIM R14/745524	
Fololowup email re IFU update	22/07/2014	02/08/2014		TRIM R14/907187	
Email sponsor completion letter	27/10/2014	07/11/2014		TRIM R14/1123411	

List of Problem Type Codes Click [N] to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Incompatibility	Patient Device Incompatibility		

Investigation Problem Causes

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Known Complication	Known Complication		

Investigation Outcomes

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
Reviewed, No Further Action Required		

Recall Number:	Document 19
Investigation Summary: Review of the updated Instructions For Use (IFU), provided by the sponsor, shows the IFU has been updated accordingle include information regarding potential risk of contracting ALCL from breast implants. The sponsor advises that the updated IFU has not yet been implemented within the device packs being shipped to ANZ, this is scheduled for later in the year. further investigation will occur at this time; however the TGA will continue to monitor and may re-open the file as appropriate.	lated

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To
FILE	×≣	s22 053013_final	19	Form	
FILE	7	0052817_Final IRIS Report	116	Form	
FILE	×	0052817_AE incidence report	19	Form	
FILE	~	0052817_redacted laboratory results	227	Form	
FILE	w	DIR 27612 - questionnaire letter - Allergan Re	110	Form	
FILE	7	L3441 Natrelle rev 3 18.12.2013 DRAFT	483	Form	

Flow Details : DIR-REQ - Device Incident Request : 36954

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach
36954	DIR-REQ		Closed	s22	OPR Administration User	27/10/2014	Normal	1

Signature Details

Role	IRIS Investigator	

User	s22	Document 19
Signed At	27/10/2014 15:28:10	
Comment		

Document 20



Device Incident Report : Medical Devices Branch - Device Vigilance and Monitoring

14/08/2012 SIGNED

DIR : 20 -	- ID : 163040
------------	---------------

Released by s22

on 25/06/2015 15:11:06

Patient History:			
Patient Focused Corrective Action Tak	zen:		
Female	s22	s22	
Sex:	Weight:	Age:	
Patient Information			
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:	
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:
	de on the ruptured right side where the front a		
At surgery to upsize the implants on	e was found to be ruptured and the both were	found to be rotated and one was found to be f	flipped over.
Clinical Event Information:			
	ured and the both were found to be rotated an de on the ruptured right side where the front a		her through the ruptured gel.
Event Description for Website Publica			
Surgeon		For IRIS Meeting	
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
22/08/2012	Healthcare Professional		
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
08/08/2012	14/08/2012	21/08/2012	
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
Closed			08/08/2012
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
27916	2012/017870		Final
Report #:	Records Management #:	Reporter's Reference #:	Report Type:
Report Information Section			

			Document 20
Patient Outcome/Consequences:			
Other Devices Involved:			
Submitting Reporter Section			
Search Reporter By Surname:	Reporter #:		
s22 Reporter Title:	First Name:	Surname:	
Dr	s22	s22	
Position:		Company/Institution:	
Plastic Surgeon			
Address 1:	Address 2:	Town/Suburb:	State:
s22	s22	s22	<u></u>
Country:	Postcode:	Phone:	Fax:
Mobile:	Email:		Last External Submission By:
	s22		
Initial Reporter Section			
As Above?:	If No, fill out the following:		Initial Reporter Confidential:
Yes			
Search Reporter By Surname:	Initial Reporter #:		
Title:	First Name:	Surname:	
Position:		Company/Institution:	
Address 1:	Address 2:	Town/Suburb:	State:
Postcode:	Phone:	Fax:	Mobile:
Email:			

			Document 20	
Device Information Section				
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
No		175420	175420	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN / UMDN Code:	
Medical Device	Included	Class III	36197	
GMDN / UMDN Text:		Brand Name:		
Prosthesis, internal, mammary, gel	l filled	Allergan Breast Implant		
Initial Device Description:				
Breast Implants				
Usage of Device:	Software Version:			
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
410 FM	L: YM2070 & R: YR2031		L: 54915 & R: 58529	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
28/09/2000		s22	s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
Discarded				
Access Contact Phone:	Access Contact Fax:			

Manufacturer Information Section

Manufacturer Name:		Manufacturer Client Id:	Address 1:
Allergan		\$22	
Address 2:	Town/Suburb:	State/Province:	Country:
Postcode:	Phone:	Fax:	
Email:		Manufacturer Informed:	Date Aware of Adverse Event:
Contact Title:	Contact First Name:	Contact Surname:	

Document 20

Supplier Information Section

Supplier Name:		Address 1:	Address 2:
Town/Suburb:	State:	Postcode:	Phone:
Fax:	Email:		Supplier Informed:
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:
Contact Phone:	Contact Fax:		

Statistics Checklist Section

Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:
14/08/2012	s22	Yes	Yes	
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:
No	Yes	No	Yes	Serious Injury
Actual Effect:	Injured Party:			Risk Frequency:
Temporary Injury	Patient			Rarely
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:
Minor	Occasionally	Routine		
DIRE Meeting Notes:				
If sample available obtain. If not	close - No sample available			

Sponsor Information Section

Search Sponsors:	Name:		Client #:
allergan	Allergan Australia Pty Ltd		17
Attention To:	Address 1:	Address 2:	Town/Suburb:
s22	Locked Bag 1514		PYMBLE
State:	Postcode:	Phone:	Fax:
NSW	2073	s22	02 9498 0292

Email:	Document 20
@allergan.com	
Investigation Information Section	
Device Analysis Results:	
Corrective/Preventative Actions:	
Details of Similar Events:	
Number of Similar Events:	Rate of Similar Events:
Countries Similar Events Also Occurred:	
Additional Comments:	

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Device ARTG No	Manufacturer Name	Sponsor/Supplier	Trade/Brand Name	Serial #	Model Number	GMDN / UMDN Text	

Related DIR Informati	ion - Click New to begin enter	ring information.		
Incident Details				
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution

						Document 20
Samples Record - Clie	ck [N] to begin entering	g information.				
Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Information Section. Note that the Correspondence Recipient will receive a notification if the Date Received is not filled in by the Date Expected.

Correspondence Det	ails						
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Completion letter		22/08/2012					
Reporters Completion letter		22/08/2012					

List of Problem Type Codes - Click [N]	to begin entering information.		
Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Material	Burst		
Mechanical	Unintended Movement		

Investigation Problem Causes

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Not product related	Event related to patient condition or anatomy		
Not product related	User error caused or contributed to event		

Investigation Outcomes

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	

Not investigated		Document 20
Recall Number:		
Investigation Summary:		
No further investigation will occur at this time, however and may re-open the file as appropriate.	the TGA will continue to monitor the rate and pattern of occur	rrence

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To
FILE	7	SM578343	126	Form	

Flow Details : DIR-REQ - Device Incident Request : 37285

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach
37285	DIR-REQ		Closed	s22	OPR Administration User	22/08/2012	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	22/08/2012 11:26:47	
Comment		

Form Details

Document 21

Device Incident R
DIR : 20 - ID : 166597

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

28/09/2012 SIGNED

Released by s22

on 25/06/2015 15:11:06

Report Information Section						
Report #:	Records Management #:	Reporter's Reference #:	Report Type:			
28760	2012/024747	Allergan Ref # 919156	Final			
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:			
Closed		s22	28/09/2012			
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:			
28/09/2012	28/09/2012	09/10/2012				
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:			
24/01/2013			Yes			
Source of Report: If 'Other' Source Selected: Type of Initial Action:						
Nurse		For IRIS Meeting				
Event Description for Website Publication	ion:					
Left intracapsular implant rupture fou	nd at time of surgery.					
Clinical Event Information:						
Left intracapsular implant rupture fou	nd at time of surgery.					
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:			
1	Reporter					
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:				
Patient Information						
Sex:	Weight:	Age:				
	Teigne.	rige.				
Patient Focused Corrective Action Take	en:					
Patient History:						
N/A						
Patient Outcome/Consequences:						

12/07/2024, 11:	:49
-----------------	-----

Form Details

Other Devices Involved:			
ubmitting Reporter Section			
Search Reporter By Surname:	Reporter #:		
s22			
eporter Title:	First Name:	Surname:	
liss	s22	s22	
sition:		Company/Institution:	
Plastic & Cosmetic Nurse Consultar	nt (RN)	s22	
ddress 1:	Address 2:	Town/Suburb:	State:
22	s22	s22	s22
ountry:	Postcode:	Phone:	Fax:
	s22	s22	s22
obile:	Email:		Last External Submission By:
	s22		
tial Reporter Section			
s Above?:	If No, fill out the following:		Initial Reporter Confidential:
earch Reporter By Surname:	Initial Reporter #:		
itle:	First Name:	Surname:	
osition:		Company/Institution:	
	Address 2:	Town/Suburb:	State:
Address 1:	Address 2:		
Address 1: Postcode:	Address 2: Phone:	Fax:	Mobile:

07/2024, <mark>1</mark> 1:49		Form Details		
Device Information Section			Document 21	
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
	II NO, III OUL ARTG NO:	171512	171512	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN / UMDN Code:	
Medical Device	Included	Class III	36197	
GMDN / UMDN Text:		Brand Name:		
Prosthesis, internal, mammary, ge	el filled	INAMED Breast Implant		
Initial Device Description:				
INAMED Breast Implant				
Usage of Device:	Software Version:			
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
410 FX	12968071		1485420	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
20/11/2007		s22	s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
With Supplier				
Access Contact Phone:	Access Contact Fax:			
Manufacturer Information Section				
Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22	Level 4, 810 Pacific Highway	
Address 2:	Town/Suburb:	State/Province:	Country:	
	Gordon	NSW	Australia	
Postcode:	Phone:	Fax:		
2072	1800252224	02 94980184		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
Contact Title:	Contact First Name:	Contact Surname:		

Supplier Information Section

2/07/2024, 11:49		Form Details	
Supplier Name:		Address 1:	Address 2: Document 21
Same as above			
Town/Suburb:	State:	Postcode:	Phone:
Fax:	Email:		Supplier Informed:
			Yes
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:
27/09/2012	Mrs	s22	s22
Contact Phone:	Contact Fax:		
1800 252 224			

Statistics Checklist Section						
Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:		
02/10/2012	s22	Yes	Yes			
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:		
No	Yes	No	Yes	Serious Injury		
Actual Effect:	Injured Party:	Injured Party:				
Temporary Injury	Patient	Patient				
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:		
Serious	Occasionally	Routine				
DIRE Meeting Notes:						
Investigate s22						

Sponsor Information Section

Search Sponsors:	Name:		Client #:	
allergan	Allergan Australia Pty Ltd		17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073	s22	(02) 9498 0299	
Email:				
@allergan.com				

07/2024, 11:49	Form Details	Document 21
Investigation Information Section		Document 21
Device Analysis Results:		
Corrective/Preventative Actions:		
Details of Similar Events: 483 / 64930 units sold in Australia since 2004 (0.74%)		
Number of Similar Events:	Rate of Similar Events:	
483	0.74%	
Countries Similar Events Also Occurred:		
Additional Comments:		

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices							
Device ARTG No Manufacturer Sponsor/Supplier Trade/Brand Name Serial # Model Number GMDN / UN Text					GMDN / UMDN Text		

Related DIR Information - Click New to begin entering information.							
Incident Details							
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution			

Samples Record - Click [N] to begin entering information.

Sample Details	Document 21					
Sample #Sample RequestedSample Received# Samples from Reporter# Samples from SponsorOutcome of TGA's Testing						

Correspondence Information Section. Note that the Correspondence Recipient will receive a notification if the Date Received is not filled in by the Date Expected.

Correspondence Details								
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes		
Questionnaire sent		13/12/2012	02/01/2013	31/12/2012		See TRIM R13/30515.		
Report Notification Sent		13/12/2012						
SC letter		24/01/2013	04/02/2013					
RC letter		24/01/2013	04/02/2013					

List of Problem Type Codes - Click **[N]** to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Material	Burst		

Investigation Problem Causes

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Known Complication	Known Complication		

Investigation Outcomes

Outcome Details		
Outcome of Investigation		
Reviewed, for Trending Purposes Only		

Recall Number:

Investigation Summary:	
Rupture is a known complication of silicone filled breast implants.	
No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern of occurr and may re-open the file as appropriate.	ence
Similar events - 483 / 64930 units sold in Australia since 2004 (0.74%)	

Flow Details : DIR-REQ - Device Incident Request : 38336

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach
38336	DIR-REQ		Closed	s22	OPR Administration User	24/01/2013	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	24/01/2013 12:48:23	
Comment		

Document 22

28/09/2012



Report Information Section

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

SIGNED

DIR : 20 - ID : 166626

Released	by <mark>s22</mark>	
----------	---------------------	--

on 25/06/2015 15:11:06

Report #:	Records Management #:	Reporter's Reference #:	Report Type:
28766	2012/024748	Allergan Ref# 896502/900004	Final
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed		s22	28/09/2012
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
02/10/2012	02/10/2012	09/10/2012	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
24/01/2013			Yes
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Nurse		For IRIS Meeting	
Event Description for Website Publication	ion:		
Breast MRI confirmed intracapsular ru	pture of the right breast.		
Clinical Event Information:			
Breast MRI confirmed intracapsular ru	pture of the right breast.		
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:
1	Reporter		
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:	
Patient Information			
Sex:	Weight:	Age:	
Female		s22 rs	
Patient Focused Corrective Action Take	en:		
-			
Patient History:			
Patient Outcome/Consequences:			



: Pt had removal & replacement of bilateral implants. At surgery

Other Devices Involved:

Search Reporter By Surname:	Reporter #:			
s22 Reporter Title:	First Name:	Surname:		
Miss	s22	s22		
Position:		Company/Institution:		
Plastic & Cosmetic Nurse Consultant	(RN)	s22		
Address 1:	Address 2:	Town/Suburb:	State:	
s22	s22	s22	s22	
Country:	Postcode:	Phone:	Fax:	
	s22	s22	s22	
Nobile:	Email:		Last External Submission By:	
	s22			
nitial Reporter Section				
As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
As Above?: Search Reporter By Surname:	If No, fill out the following: Initial Reporter #:		Initial Reporter Confidential:	
		Surname:	Initial Reporter Confidential:	
Search Reporter By Surname:	Initial Reporter #:	Surname: Company/Institution:	Initial Reporter Confidential:	
Gearch Reporter By Surname: Fitle:	Initial Reporter #:		Initial Reporter Confidential:	
Gearch Reporter By Surname: Title: Position:	Initial Reporter #: First Name:	Company/Institution:		

Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:
		126554	126554
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN / UMDN Code:
Medical Device	Included	Class III	36197
GMDN / UMDN Text:		Brand Name:	
Prosthesis, internal, mammary, gel	filled	INAMED Breast Implant	
Initial Device Description:			
Breast Implant			
Usage of Device:	Software Version:		
Single Use			
Model #:	Serial #:	Batch #:	Lot #:
230 MLP	AHB 794		
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:
		s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:
With Supplier			

Manufacturer Information Section

	Manufacturer Client Id:	Address 1:
	s22	Level 4, 810 Pacific Highway
Town/Suburb:	State/Province:	Country:
Gordon	NSW	Australia
Phone:	Fax:	
1800 252224		
	Manufacturer Informed:	Date Aware of Adverse Event:
Contact First Name:	Contact Surname:	
	Gordon Phone: 1800 252224	Town/Suburb: State/Province: Gordon NSW Phone: Fax: 1800 252224 Manufacturer Informed:

Supplier Name:		Address 1:	Address 2: Document 22
Same as above			
Town/Suburb:	State:	Postcode:	Phone:
Fax:	Email:		Supplier Informed:
			Yes
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:
11/07/2012	Mrs	s22	s22
Contact Phone:	Contact Fax:		
94980111			

Statistics Checklist Section				
Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:
02/10/2012	s22	Yes	Yes	
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:
No	Yes	No	Yes	Serious Injury
Actual Effect:	Injured Party:			Risk Frequency:
Temporary Injury	Patient			Sometimes
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:
Serious	Likely	Routine		
DIRE Meeting Notes:				
Investigation s22				

Sponsor	Inform	ation	Section

Search Sponsors:	Name:		Client #:
allergan	Allergan Australia Pty Ltd		17
Attention To:	Address 1:	Address 2:	Town/Suburb:
s22	Locked Bag 1514		PYMBLE
State:	Postcode:	Phone:	Fax:
NSW	2073	s22	02 9498 0299
Email:			
s22 @allergan.com			

Document 22

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices							
Device ARTG No	Manufacturer Name	Sponsor/Supplier	Trade/Brand Name	Serial #	Model Number	GMDN / UMDN Text	

Related DIR Information - Click I	Related DIR Information - Click New to begin entering information.						
Incident Details	Incident Details						
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution			

Sample Details	Document 22					
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Details							
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Questionnaire sent		13/12/2012	02/01/2013	31/12/2012		See TRIM R13/30519.	
Report Notification Sent		13/12/2012					
SC		24/01/2013	04/02/2013				
RC		24/01/2013	04/02/2013				

List of Problem Type Codes - Click **[N]** to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Material	Burst		

Investigation Problem Causes

С	ause Details		
С	ause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected
K	nown Complication	Known Complication	

Investigation Outcomes

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
Reviewed, for Trending Purposes Only		

Recall Number:

Investigation Summary:
Rupture is a known complication of silicone filled breast implants.
No further investigation will occur at this time, however the TGA will continue to monitor the rate and pattern of occurrence and may re-open the file as appropriate.
Similar events - 483 / 64930 units sold in Australia since 2004 (0.74%)

Flow Details : DIR-REQ - Device Incident Request : 38345

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach
38345	DIR-REQ		Closed	s22	OPR Administration User	24/01/2013	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	24/01/2013 12:06:42	
Comment		

Form Details

Document 23

24/10/2012

SIGNED

-	
1	
-	

DIR: 20 - ID: 168251

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

on 25/06/2015 15:11:06

Report #:	Records Management #:	Reporter's Reference #:	Report Type:
29009	2012/023090		Final
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed			07/11/2012
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
07/11/2012	07/11/2012		
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
17/06/2014			No
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Surgeon		For IRIS Meeting	
Leakage - bilateral implants. Granuloma developed (extensive). Deformity of shape. Clinical Event Information:	ion:		
Leakage - bilateral implants. Granuloma developed (extensive). Deformity of shape. Clinical Event Information: Leakage - bilateral implants. Granuloma developed (extensive).	ion:		
Leakage - bilateral implants. Granuloma developed (extensive). Deformity of shape. Clinical Event Information: Leakage - bilateral implants. Granuloma developed (extensive). Deformity of shape. Number of Incidents in Report:	ion: Contact:	Alternative Person Title:	Alternative Person First Name:
Event Description for Website Publicati Leakage - bilateral implants. Granuloma developed (extensive). Deformity of shape. Clinical Event Information: Leakage - bilateral implants. Granuloma developed (extensive). Deformity of shape. Number of Incidents in Report: 1 Alternative Person Surname:		Alternative Person Title: Alternative Person Fax:	Alternative Person First Name:
Leakage - bilateral implants. Granuloma developed (extensive). Deformity of shape. Clinical Event Information: Leakage - bilateral implants. Granuloma developed (extensive). Deformity of shape. Number of Incidents in Report: 1 Alternative Person Surname:	Contact:		Alternative Person First Name:
Leakage - bilateral implants. Granuloma developed (extensive). Deformity of shape. Clinical Event Information: Leakage - bilateral implants. Granuloma developed (extensive). Deformity of shape. Number of Incidents in Report: 1	Contact:		Alternative Person First Name:

12/07/2024, 11:52

Patient History:			Document 23
Patient Outcome/Consequences:			
Other Devices Involved:			
Submitting Reporter Section			
Search Reporter By Surname:	Reporter #:		
s22	5352 - <mark>s22</mark> - P	astic Surgeon -	
Reporter Title:	First Name:	Surname:	
Mr	s22	s22	
Position:		Company/Institution:	
Plastic Surgeon			
Address 1:	Address 2:	Town/Suburb:	State:
s22		s22	s22
Country:	Postcode:	Phone:	Fax:
Australia	s22	s22	
Mobile:	Email:		Last External Submission By:
	s22		
Initial Reporter Section			
As Above?:			Initial Reporter Confidential:
No	If No, fill out the following:		No
Search Reporter By Surname:	Initial Reporter #:		
Title:	First Name:	Surname:	
Position:		Company/Institution:	
Address 1:	Address 2:	Town/Suburb:	State:
Postcode:	Phone:	Fax:	Mobile:

12	07/2024, 11:52	F	orm Details	Document 23
	Email:			Document 23

Device Information Section

Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:
No		128764	128764
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN / UMDN Code:
Medical Device	Included	Class III	36197
GMDN / UMDN Text:		Brand Name:	
Prosthesis, internal, mammary, gel	filled	Allergan Breast Implant	
Initial Device Description:			
Allergan Breast Implants			
Usage of Device:	Software Version:		
Single Use			
Model #:	Serial #:	Batch #:	Lot #:
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:
Reported Device Location:	Access Contact Title:	S22 Access Contact First Name:	Access Contact Surname:
Place of use			
Access Contact Phone:	Access Contact Fax:		

Manufacturer Information Section

Manufacturer Name:		Manufacturer Client Id:	Address 1:
Allergan		s22	
Address 2:	Town/Suburb:	State/Province:	Country:
Postcode:	Phone:	Fax:	
Email:		Manufacturer Informed:	Date Aware of Adverse Event:
Contact Title:	Contact First Name:	Contact Surname:	

12/07/2024,	11:52
-------------	-------

Supplier Information Section			
Supplier Name:		Address 1:	Address 2:
Town/Suburb:	State:	Postcode:	Phone:
Fax:	Email:		Supplier Informed: No
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:
Contact Phone:	Contact Fax:		

Statistics Checklist Section

Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:
08/11/2012	s22	Yes	Yes	
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:
No	Yes	No	Yes	Serious Injury
Actual Effect:	Injured Party:			Risk Frequency:
Temporary Injury	Patient			Sometimes
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:
Serious	Likely	Routine		
DIRE Meeting Notes:				

Sponsor Information Section

Search Sponsors:	Name:		Client #:
allergan	Allergan Australia Pty Ltd		17
Attention To:	Address 1: Address 2:		Town/Suburb:
s22	Locked Bag 1514		PYMBLE
State:	Postcode:	Phone:	Fax:
NSW	2073	s22	(02) 9498 0299

12/07/2024, 11:52

_				_
		mor	a + c	0
)ocu	innei	11 2	

Email:	Document 23
GO-Medical-Affairs@allergan.com	
Investigation Information Section	
Device Analysis Results:	
Corrective/Preventative Actions:	
Details of Similar Events:	
Number of Similar Events:	Rate of Similar Events:
Countries Similar Events Also Occurred:	
Additional Comments:	

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices							
Device ARTG No	Manufacturer Name	Sponsor/Supplier	Trade/Brand Name	Serial #	Model Number	GMDN / UMDN Text	

Related DIR Information - Click	New to begin entering	information.			
Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Click [N] to begin entering information.

Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Information Section. Note that the Correspondence Recipient will receive a notification if the Date Received is not filled in by the Date Expected.

Correspondence Details						
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes
Questionnaire letter sent		05/03/2013	18/03/2013	19/03/2013		
Followup request further question		09/08/2013	20/08/2013			R13/609601
Sponsor response				22/08/2013		TRIM R14/792515
Sponsor Completion Letter		17/06/2014				
Reporter completion letter		17/06/2014				

List of Problem Type Codes - Click **[N]** to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Material	Burst		

Investigation Problem Causes

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Known Complication	Known Complication		

Investigation Outcomes

12/07/2024, 11:52	Form Details	5
Outcome Details		Document 23
Outcome of Investigation	If Additional Outcome Detail Requested	
Reviewed, No Further Action Required		
Recall Number:		
Recall Number:		
Investigation Summary:		
0.0236%; and nodule/lump: 0.0101%. The adve The sponsor has advised that granuloma had not were unable to provide specific data and rates for	types of adverse events: rupture 0.4455%; post-operative deformatives events reported are known to occur with these types of devices. been an adverse event term captured in their database and hence to granuloma formation. However, the sponsor also advised that: "Prior at the need for such a code exists and it will added during the next of this specific code going forward."	hey or to
No further action is warranted at this stage. The	TGA will continue to monitor the adverse event rates.	

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To
FILE	x	DIR 29009 incident report	19	Form	
FILE	w	DIR 29009 - questionnaire letter completed	95	Form	

Flow Details : DIR-REQ - Device Incident Request : 38712

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach
38712	DIR-REQ		Closed	s22	OPR Administration User	17/06/2014	Normal	0

Role	IRIS Investigator	
User	s22	
Signed At	12/10/2015 09:23:40	
Comment		

Document 24



Device Incident Report : Medical Devices Branch - Device Vigilance and Monitoring

05/11/2012 SIGNED

DIR : 20 - I	D: 169016
--------------	-----------

Released by s22 on 25	Released	by <mark>s22</mark>	on 25
-----------------------	----------	---------------------	-------

25/06/2015 15:11:06

Report #:	Records Management #:	Reporter's Reference #:	Report Type:
29137	2012/022827	0054582/AZ	Final
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed	Death / Serious Injury	s22	13/09/2012
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
11/07/2013	05/11/2012	23/07/2013	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
12/08/2013	Patient		No
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Sponsor		For IRIS Meeting	
Event Description for Website Pul	blication:		
Patient had bilateral augmentation presented with RHS seroma and the RHS. The patient re-present another seroma - this was aspira	ature, an article entitled, "Breast Implant associate on. 522 later, she presented with RHS seroma had 2 revision surgeries. 522 year the patient ha ed again on several occasions with right breast sero ated (300mL), cytology workup on the fluid identifie replacement of implants. Left breast was negative f	a, resolving with conservative management se d bilateral replacement of implants and the do mas which were treated with multiple aspirat later, the patient had bilatera	everal weeks later. After another <u>\$22</u> she evice referenced in this report was implanted to ions. About <u>\$22</u> later, the patient presented with al explantation, bilateral capsulectomy, drainage of
Clinical Event Information:			
	the Global Literature, Allergan HQ identified an article was initially reported to Allergan by Dr on 27AUG2		wing confirmation that the involved implant was an

management **\$22** later. In **\$22** she presented with RHS seroma and had 2 revision surgeries. In **\$22** the patient had bilateral replacement of implants (Allergan Implants) and the device referenced in this report was implanted to the RHS. The patient re-presented again on several occasions with right breast seromas which were treated with multiple aspirations. On **\$22** the patient presented with another seroma - this was aspirated (300mL), cytology workup on the fluid identified ALCL (cytology report previously reported to TGA). On **\$22** the patient had bilateral explantation, bilateral capsulectomy, drainage of large serous fluid collection and replacement of implants (Allergan Implants), Left breast was negative for malignancy. RHS capsule showed evidence of ALCL (neoplastic cells), ALK1 was negative.

Additional information is received on 15/07/2014:

On 8th June 2014 Allergan received written correspondence from the patient that stated; "I can no longer work full time since radiation treatment which resulted in the diagnosis of psoriatic arthritis – a chronic and debilitating condition that I experience primarily in my spine and right side of my torso."

Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:
1			
Alternative Person Surname:	Alternative Person Phone:	Alternative Person Fax:	

			Document 24
atient Information			
Sex:	Weight:	Age:	
emale		s22	
tient Focused Corrective Action Take	en:		
xplant surgery on <mark>\$22</mark> with r	replacement of implant. 36Gy in 20 fractions	of <mark>s22</mark>	
itient History:			
lone reported.			
tient Outcome/Consequences:			
and follow other Devices Involved: See Section VII - device information i	hange of implants both breasts had healed of up is ongoing. is being requested from Dr <mark>\$220</mark> for the oth		d with an excellent aesthetic result. The patient finished ated with the recurrent seromas.
earch Reporter By Surname:	Reporter #:		
22.	5166 - s22 - Regulatory	Affairs Officer - Allergan Australia	
eporter Title:	First Name:	Surname:	
ls	s22	s22	
osition:		Company/Institution:	
legulatory Affairs Officer		Allergan Australia	
ddress 1:	Address 2:	Town/Suburb:	State:
llergan Australia	Level 4/810 Pacific Hwy	Gordon	New South Wales
ountry:	Postcode:	Phone:	Fax:
Australia	2072	s22	9498 0299
obile:	Email:		Last External Submission By:
	s22 allergan.com		
itial Reporter Section			
s Above?:	If No, fill out the following:		Initial Reporter Confidential:
lo	I No, III out the following.		No
earch Reporter By Surname:	Initial Reporter #:		
litle:	First Name:	Surname:	

Mr	s22	s22	Docume	nt 24
Position:		Company/Institution:		
		s22		
Address 1:	Address 2:	Town/Suburb:	State:	
s22	s22	s22	s2	
Postcode:	Phone:	Fax:	Mobile:	
s22	s22	s22		
Email:				

Device Information Section

f No, fill out ARTG No: Product Licence Category: Included	175422 Device Class:	175422 GMDN / UMDN Code:
		GMDN / UMDN Code:
Included		
	Class III	36197
	Brand Name:	
	Natrelle INSPIRA Truform 1 gel, Tex	xtured, Single Lumen Breast implants
gle Lumen Breast implants		
Software Version:		
Serial #:	Batch #:	Lot #:
16402266		2067491
Expiry Date:	Date of Implant:	Date of Explant:
	s22	s22
Access Contact Title:	Access Contact First Name:	Access Contact Surname:
Access Contact Fax:		
	Software Version: Serial #: 16402266 Expiry Date: Access Contact Title:	gle Lumen Breast implants Software Version: Serial #: 16402266 Expiry Date: Date of Implant: \$22 Access Contact Title: Access Contact Title:

Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	

			Document 24
Postcode:	Phone:	Fax:	
Email:		Manufacturer Informed:	Date Aware of Adverse Event:
		Yes	18/06/2013
Contact Title:	Contact First Name:	Contact Surname:	
Supplier Information Section			
Supplier Name:		Address 1:	Address 2:
Town/Suburb:	State:	Postcode:	Phone:
Fax:	Email:		Supplier Informed:
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:
Contact Phone:	Contact Fax:		

Statistics Checklist Section

Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:
15/07/2013	s22	No		
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:
No	No	No	Yes	Death
Actual Effect:	Injured Party:			Risk Frequency:
Serious Injury	Patient			Unlikely
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:
Serious	Unlikely	Routine		
DIRE Meeting Notes:				
investigate				

Document 24

Sponsor Information Section

Search Sponsors:	Name:		Client #:	
Allergan	Allergan Australia Pty Ltd		17	
Attention To:	Address 1:	Address 2:	Town/Suburb:	
s22	Locked Bag 1514		PYMBLE	
State:	Postcode:	Phone:	Fax:	
NSW	2073	1800 252 224	02 9498 0299	
Email:				
GO-Medical-Affairs@allergan.c	om			
Investigation Information Section	n			
Device Analysis Results:				
No analysis on this device was	possible as it was not returned to Allergan.			
Corrective/Preventative Actions	S:			
in this report with the associat is also continuing with Dr S22 Allergan conducts an annual re continue to gather, closely mo	and any additional information will be reported and any additional information will be reported eview of ALCL diagnosed in patients with breast	oma and ALCL with model # N-TRM275 will be ed to TGA. : implants - the last review was made availab	No new trend has been identified specific to the events e provided in a follow up and final IRIS report. Follow up le to TGA on 25JAN2013, sent via email. Allergan will and act out of an abundance of caution to protect patients	
Details of Similar Events:				
No, not for this specific model	#.			
Inspira Textured Silicone Brea	st Implant Cat# N-TRM275 Similar Incidents for	PRID 910509* Received Worldwide through	July 7, 2013:	
	Rate: 2.53%, WW Events**: 2, WW Rate: 0.04 ts: 1, AUS Rate: 1.27%, WW Events**: 1, WW 43.			
number outside of Australia. **Worldwide events includes / ***Australia sales are from da	Australia. Ite first distributed of October 1, 2010 to May 3	31, 2013. June and July 2013 sales are not a	nd 1 seroma event. There are no events for this catalog vailable at the time of this report. 1, 2013. June and July 2013 sales are not available at the	
Number of Similar Events:		Rate of Similar Events:		

Countries Similar Events Also Occurred:

Australia. There are no similar events for this device model # outside of Australia in our complaints database.

Additional Comments:

A request for follow up was sent to the health professional via email on 28JUN2013. No further information has been received to date. Section VII of this IRIS Report has been completed and this constitutes the final IRIS Report from Allergan Australia for this case.

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices							
Device ARTG No	Manufacturer Name	Sponsor/Supplier	Trade/Brand Name	Serial #	Model Number	GMDN / UMDN Text	

Related DIR Information - Click **New** to begin entering information.

Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Samples Record - Click [N] to begin entering information.									
Sample Details									
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing				

Correspondence Inf	Correspondence Information Section. Note that the Correspondence Recipient will receive a notification if the Date Received is not filled in by the Date Expected.							
Correspondence Details								
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes		

Completion letter	12/08/2013		D	ocument 24
thank you email	16/07/2014			

List of Problem Type Codes Click [N] to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Other	Other	patient factors	

Investigation Problem Causes

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Biological	Carcinogenicity		

Investigation Outcomes

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
Reviewed, No Further Action Required		

Recall Number:	
Investigation Summary:	
This report will be closed at this time however; the TGA will continue to monitor this type of issue.	

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To
FILE	7	0054582_article_18JUN2013	244	Form	
FILE	7	0054582 Follow up IRIS Report	119	Form	

FILE	7	0054582_Final IRIS Report	115 F		
FILE	x≣	0054582_AE incidence rate report_10JUL2013	19	Form	

Flow Details : DIR-REQ - Device Incident Request : 38888

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach
38888	DIR-REQ		Closed	s22	OPR Administration User	16/07/2014	Normal	2

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	16/07/2014 10:56:01	
Comment		

Form Details

Document 25

0	

DIR: 20 - ID: 169223

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

SIGNED

07/11/2012

Released by <mark>s22</mark>

on 25/06/2015 15:11:06

Demost #1	Descude Management #1	Deventerile Defense en #1	Dement Times
Report #:	Records Management #:	Reporter's Reference #:	Report Type:
29173	2012/022967		Final
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed			05/11/2012
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
05/11/2012	07/11/2012	13/11/2012	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
03/12/2012			Yes
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Other	Practice Manager	For IRIS Meeting	
Event Description for Website Public	ation:		
Event Description for Website Public Ultrasound suggests possible ruptur			
Ultrasound suggests possible ruptur		ateral partial capsulectomies.	
Ultrasound suggests possible ruptur The next day revised breast augme	e of right breast prosthesis.	ateral partial capsulectomies.	
Ultrasound suggests possible ruptur The next day revised breast augme Clinical Event Information:	e of right breast prosthesis.	ateral partial capsulectomies.	
Ultrasound suggests possible ruptur The next day revised breast augme Clinical Event Information: S22 Ultrasound suggests po	re of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bili pssible rupture of right breast prosthesis.		
Ultrasound suggests possible ruptur The next day revised breast augme Clinical Event Information: S22 Ultrasound suggests po S22 Revised breast augmer	re of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bili		Alternative Person First Name
The next day revised breast augme Clinical Event Information: s22 Ultrasound suggests po s22 Revised breast augmer Number of Incidents in Report:	re of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bili ossible rupture of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bila	teral partial capsulectomies.	Alternative Person First Name
Ultrasound suggests possible ruptur The next day revised breast augme Clinical Event Information: 522 Ultrasound suggests po 522 Revised breast augmer Number of Incidents in Report: 1	re of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bili ossible rupture of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bila	teral partial capsulectomies.	Alternative Person First Name
Ultrasound suggests possible ruptur The next day revised breast augme Clinical Event Information: 522 Ultrasound suggests po 522 Revised breast augmer Number of Incidents in Report: 1	re of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bili possible rupture of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bila Contact:	iteral partial capsulectomies. Alternative Person Title:	Alternative Person First Name
Ultrasound suggests possible ruptur The next day revised breast augme Clinical Event Information: S22 Ultrasound suggests po S22 Revised breast augmer Number of Incidents in Report: 1 Alternative Person Surname:	re of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bili possible rupture of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bila Contact:	iteral partial capsulectomies. Alternative Person Title:	Alternative Person First Name
Ultrasound suggests possible ruptur The next day revised breast augme Clinical Event Information: S22 Ultrasound suggests po S22 Revised breast augmer Number of Incidents in Report: 1 Alternative Person Surname:	re of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bili possible rupture of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bila Contact:	iteral partial capsulectomies. Alternative Person Title:	Alternative Person First Name
Ultrasound suggests possible ruptur The next day revised breast augme Clinical Event Information: S22 Ultrasound suggests possible S22 Revised breast augmen Number of Incidents in Report:	re of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bili possible rupture of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bila Contact:	iteral partial capsulectomies. Alternative Person Title:	Alternative Person First Name
Ultrasound suggests possible ruptur The next day revised breast augme Clinical Event Information: 22 Ultrasound suggests po 22 Revised breast augmer Number of Incidents in Report: 1 Alternative Person Surname: Patient Information	re of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bile possible rupture of right breast prosthesis. ntation. Right rupture. Left intact prosthesis. Bile Contact: Alternative Person Phone:	Alternative Person Title:	Alternative Person First Name

12/07/2024,	11:55
-------------	-------

			Document 25	
Patient Outcome/Consequences:				
Other Devices Involved:				
Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
s22	4991 - <mark>s22</mark> - Practic	e Manager - <mark>s22</mark>		
Reporter Title:	First Name: Surname:			
	<mark>s22</mark>	s22		
Position:		Company/Institution:		
Practice Manager		s22		
Address 1:	Address 2:	Town/Suburb:	State:	
s22		s22	s22	
Country:	Postcode:	Phone:	Fax:	
Australia	s22	s22	s22	
Mobile:	Email:		Last External Submission By:	
	s22			
Initial Reporter Section				
As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
No	i no, m cut the renormig.			
Search Reporter By Surname:	Initial Reporter #:			
s22	5344 - <mark>s22</mark> Surgeon -	s22		
Title:	First Name:			
Mr	s22	s22		
Position:		Company/Institution:	Company/Institution:	
Surgeon		s22		
Address 1:	Address 2:	Town/Suburb:	State:	
s22		s22	\$ <u>22</u>	
Postcode:	Phone:	Fax:	Mobile:	
s22	s22	s22		
Email:				

12/07/2024, 11:55

Form Details

Product Exempt:	If No. 611 and ADTO No.	Search Device ARTG:	Device ARTG #:	
No	If No, fill out ARTG No:	128764	128764	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN / UMDN Code:	
Medical Device	Included	Class III	36197	
GMDN / UMDN Text:		Brand Name:		
Prosthesis, internal, mammary, gel	filled	McGhan Breast Implant		
Initial Device Description:				
McGhan Breast Prosthesis				
Usage of Device:	Software Version:	Software Version:		
Model #:	Serial #:	Batch #:	Lot #:	
110-360	2V5057	27-110361	120248	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
		s22	s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
With Supplier				
Access Contact Phone:	Access Contact Fax:			

Manufacturer Information Section

Manufacturer Name:		Manufacturer Client Id:	Address 1:
Allergan		s22	
Address 2:	Town/Suburb:	State/Province:	Country:
Postcode:	Phone:	Fax:	
Email:		Manufacturer Informed:	Date Aware of Adverse Event:
Contact Title:	Contact First Name:	Contact Surname:	

12/07/2024, 1	1:55
---------------	------

Supplier Information Section					
Supplier Name:		Address 1:	Address 2:		
Town/Suburb:	State:	Postcode:	Phone:		
Fax:	Email:		Supplier Informed:		
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:		
Contact Phone:	Contact Fax:				

Statistics Checklist Section

Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:
08/11/2012	s22	Yes	Yes	
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:
No	Yes	No	Yes	Temporary Injury
Actual Effect:	Injured Party:			Risk Frequency:
Temporary Injury	Patient			Sometimes
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:
Serious	Likely	Routine		
DIRE Meeting Notes:				
Not investigated				

Sponsor Information Section

Search Sponsors:	Name:		Client #:
allergan	Allergan Australia Pty Ltd		17
Attention To:	Address 1:	Address 2:	Town/Suburb:
s22	Locked Bag 1514		PYMBLE
State:	Postcode:	Phone:	Fax:
NSW	2073	s22	(02) 9498 0292

12/07/2024, 11:55

Form Details

Email:	Document 25
\$22 @allergan.com	
Investigation Information Section	
Device Analysis Results:	
Corrective/Preventative Actions:	
Details of Similar Events:	
Number of Similar Events:	Rate of Similar Events:
Countries Similar Events Also Occurred:	
Additional Comments:	

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices	vices						
Device ARTG No	Manufacturer Name	Sponsor/Supplier	Trade/Brand Name	Serial #	Model Number	GMDN / UMDN Text	

Related DIR Information - Click New to begin entering information.							
Incident Details							
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution			

Samples Record - Click [N] to begin entering information.

Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Information Section. Note that the Correspondence Recipient will receive a notification if the Date Received is not filled in by the Date Expected.

Correspondence Details							
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Completion letter sents		03/12/2012					

List of Problem Type Codes - Click **[N]** to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Material	Burst		

Investigation Problem Causes

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Known Complication	Known Complication		

Investigation Outcomes

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
Reviewed, for Trending Purposes Only		

12	/07/2024, 11:55	Form Details	Day west of
	Investigation Summary:		Document 25
	No further investigation will occur at this time, however the TGA will continue to monitor the rand may re-open the file as appropriate.	rate and pattern of occurrence	

Flow Details : DIR-REQ - Device Incident Request : 38944

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach
38944	DIR-REQ		Closed	s22	OPR Administration User	03/12/2012	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	03/12/2012 13:22:02	
Comment		

Document 26

20/11/2012

SIGNED



Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

on 25/06/2015 15:11:06

Released by

Report Information Section

DIR : 20 - ID : 170266

Report #: Records Management #:		Reporter's Reference #:	Report Type:
29355	2013/001991		Final
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed		s22	20/11/2012
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
20/11/2012	21/11/2012	27/11/2012	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
23/04/2013			No
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Patient		For IRIS Meeting	
Event Description for Website Publicati	ion:		
Clinical Event Information: I have had a rupture in \$22			
I have had a rupture in <mark>\$22</mark> <mark>\$22</mark>	Contact:	Alternative Person Title	Alternative Person First Name
I have had a rupture in <mark>\$22 1</mark> \$22 \$22 Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:
I have had a rupture in <mark>\$22</mark> <mark>\$22</mark>	Contact: Reporter Alternative Person Phone:	Alternative Person Title: Alternative Person Fax:	Alternative Person First Name:
I have had a rupture in \$22 \$22 \$22 Number of Incidents in Report: 1	Reporter		Alternative Person First Name:
I have had a rupture in \$22 \$22 S22 Number of Incidents in Report: 1 Alternative Person Surname:	Reporter		Alternative Person First Name:
I have had a rupture in \$22 \$22 Number of Incidents in Report: 1 Alternative Person Surname: Patient Information	Reporter Alternative Person Phone:	Alternative Person Fax:	Alternative Person First Name:
I have had a rupture in \$22 \$22 Number of Incidents in Report: 1 Alternative Person Surname: Patient Information	Reporter Alternative Person Phone: Weight: \$22	Alternative Person Fax:	Alternative Person First Name:

\$22			Document 26	
Patient Outcome/Consequences:				
and I hope I have a hand in this.	coincidence. want this recorded as an issue on the re	gister as I will not stop trying to prove silicor	d for connective tissue disorders such as <mark>\$22</mark> and or ne is toxic I know I am right and one day it will be proven oval of gummy bear implant findings they just did not	
Other Devices Involved:				
L Submitting Reporter Section				
Search Reporter By Surname:	Reporter #:			
Reporter Title:	First Name:	Surname:		
Ms	s22	s22		
Position:	1. pa 12	Company/Institution:		
Public servant				
Address 1:	Address 2:	Town/Suburb:	State: \$22	
Country:	Postcode:	Phone:	Fax:	
Mobile:	Email:		Last External Submission By:	
Initial Reporter Section				
As Above?:	If No, fill out the following:		Initial Reporter Confidential:	
Search Reporter By Surname:	Initial Reporter #:			
Title:	First Name:	Surname:		
Position:		Company/Institution:		

Address 1:	Address 2:	Town/Suburb:	State: Document 26
Postcode:	Phone:	Fax:	Mobile:
Email:			
Device Information Section			
Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:
No		128764	128764
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN / UMDN Code:
1edical Device Included		Class III	36197
GMDN / UMDN Text:		Brand Name:	
Prosthesis, internal, mammary, gel	filled	McGhan Breast Implant	
Initial Device Description:			
Breast Implant Textured Gel			
Usage of Device:	Software Version:		
Single Use			
Model #:	Serial #:	Batch #:	Lot #:
Textured Gel	L#SNXG 6721; R# SNXZ 5240		
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:
01/01/1999		s22	s22
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:
Discarded			
	Access Contact Fax:		

Manufacturer Information Section

Manufacturer Name: Allergan		Manufacturer Client Id:	Address 1:	
		s22		
Address 2:	Town/Suburb:	State/Province:	Country:	
		<>	Australia	
Postcode:	Phone:	Fax:		

Email:			rer Informed: Da	ate Aware of Adverse Event:
Contact Title:	Contact First Nam	e: Contact Su	rname:	
Supplier Information Section				
Supplier Name:		Address 1:	Ac	ddress 2:
Mcghan Implants				
Town/Suburb:	State:	Postcode:	Ph	none:
Fax:	Email:		Su	upplier Informed:
			N	lo
Date of Supplier Contact:	Contact Title:	Contact Fire	st Name: Co	ontact Surname:
Contact Phone:	Contact Fax:			
Statistics Checklist Section				
Date:	Assessed By:	For website nublication:	Ready for Publication:	Exclude report from DIRE:

Date:	Assessed By: For website publication:		Ready for Publication:	Exclude report from DIRE:			
21/11/2012	s22	Yes	Yes				
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:			
No	Yes	No	Yes	Serious Injury			
Actual Effect:	Injured Party:	Injured Party:					
Serious Injury	Patient	Patient					
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:			
Serious	Likely	Routine					
DIRE Meeting Notes:							
Investigate							

 Sponsor Information Section
 Name:
 Client #:

 allergan
 Allergan Australia Pty Ltd
 17

Attention To:	Address 1:	Address 2:	Town/Suburb: Document 26
s22	Locked Bag 1514		PYMBLE
State:	Postcode:	Phone:	Fax:
NSW	2073	s22	(02) 9498 0299
Email:			
@allergan.com			
Investigation Information Section	n		
Device Analysis Results:			
Corrective/Preventative Actions	5:		
Details of Similar Events:			
Number of Similar Events:		Rate of Similar Events:	
Countries Similar Events Also (Dccurred:		
Additional Comments:			

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices							
Device ARTG No	Manufacturer Name	Sponsor/Supplier	Trade/Brand Name	Serial #	Model Number	GMDN / UMDN Text	

Related DIR Information - Click **New** to begin entering information.

Incident Details				
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution

Samples Record - Click [N] to begin entering information.

Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Information Section. Note that the Correspondence Recipient will receive a notification if the Date Received is not filled in by the Date Expected.

Correspondence Details							
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
Questionnaire letter sent		07/02/2013	20/02/2013	21/02/2013			
Reporter notification sent		07/02/2013					
Sponsor completion letter		23/04/2013				TRIM R13/339319	
Reporter completion letter		23/04/2013				TRIM R13/339462	

List of Problem Type Codes - Click [N] to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Material	Burst		
Other	Other	Mutliple systemic symptoms	

Investigation Problem Causes

Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	Document 26
Known Complication	Known Complication		

Investigation Outcomes

Outcome Details		
Outcome of Investigation	If Additional Outcome Detail Requested	
Reviewed, No Further Action Required		
Recall Number:		
Investigation Summary:		
information was requested from the sponsor. The device failure mode; the rate for similar incidents in Australia t	on was undertaken. As part of this investigation additional e incident described in the report was noted as a known pote between January 2004 to February 2013 was reported as 1.4 e clinical details of this adverse event and that their investiga	4%. The

Attachment(s) Details

Туре	Open	Name	Size	Attached Within	Attached To
FILE	w	DIR 29355 response letter	97	Form	
FILE	×≣	s22 020813_Final	19	Form	

Flow Details : DIR-REQ - Device Incident Request : 39162

Request Details

39162	DIR-REQ		Closed	s22	OPR Administration User	23/04/2013	Normal	0
ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach

Signature Details

Role	IRIS Investigator	IRIS Investigator	
User	s22	s22	
Signed At	27/06/2014 14:26:25	23/04/2013 15:11:42	
Comment			

Form Details

Document 27

0	N
1	V

Device Incident Report : Medical Devices Branch - Device Vigilance and Monitoring

21/12/2012 SIGNED

DIR : 20	- ID :	231854
----------	--------	--------

Released by s22

on 25/06/2015 15:11:06

Report #: 29691 Report Status: Closed Date of Final Report:	Records Management #: 2012/025151	Reporter's Reference #:	Report Type:
Report Status: Closed	2012/025151		
Closed			Final
	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Date of Final Report:			20/12/2012
	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
20/12/2012	21/12/2012	15/01/2013	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
25/02/2013			Yes
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Surgeon		For IRIS Meeting	
Left ruptured/Total Capsulectomy Bila	iteral.		
Right intact device. Left ruptured/Total Capsulectomy Bila Clinical Event Information: U/S - rupture. Rev Augment. Right intact device. Left runtured/Total Capsulectomy Bila			
Left ruptured/Total Capsulectomy Bila Clinical Event Information: U/S - rupture. Rev Augment. Right intact device. Left ruptured/Total Capsulectomy Bila		Alternative Person Title:	Alternative Person First Name:
Left ruptured/Total Capsulectomy Bila Clinical Event Information: U/S - rupture. Rev Augment. Right intact device.	ateral.	Alternative Person Title:	Alternative Person First Name:

12/07/2024	, 11:58
------------	---------

			Dobamont 21
Patient History:			
Patient Outcome/Consequences:			
Other Devices Involved:			
Submitting Reporter Section	1		
Search Reporter By Surname:	Reporter #:		
s22	4991 - <mark>s22</mark> - Prac	tice Manager - <mark>\$22</mark>	
Reporter Title:	First Name:	Surname:	
	s22	s22	
Position:		Company/Institution:	
Practice Manager		s22	
Address 1:	Address 2:	Town/Suburb:	State:
s22		s22	s22
Country:	Postcode:	Phone:	Fax:
Australia	s22	s22	s22
Mobile:	Email:		Last External Submission By:
	s22		
nitial Reporter Section			
As Above?:	If No, fill out the following:		Initial Reporter Confidential:
No			Yes
Search Reporter By Surname:	Initial Reporter #:		
s22	5344 - <mark>s22</mark> - Surgeo	on - <mark>s22</mark>	
Title:	First Name:	Surname:	
Mr	s22	s22	
Position:	di di seconda di second	Company/Institution:	
Surgeon		s22	
Address 1:	Address 2:	Town/Suburb:	State:
s22		s22	s22
Postcode:	Phone:	Fax:	Mobile:

12/07/2024,	11:58
-------------	-------

		Document 27
If No. fill out ARTG No:	Search Device ARTG:	Device ARTG #:
	128763	128763
Product Licence Category:	Device Class:	GMDN / UMDN Code:
Included	Class III	36197
	Brand Name:	
ed	INAMED Breast Implant	
Software Version:		
Serial #:	Batch #:	Lot #:
IH6152		249405
Expiry Date:	Date of Implant:	Date of Explant:
	s22	s22
Access Contact Title:	Access Contact First Name:	Access Contact Surname:
Access Contact Fax:		
	Manufacturer Client Id:	Address 1:
	s22	
Town/Suburb:	State/Province:	Country:
Phone:	Fax:	
	Manufacturer Informed:	Date Aware of Adverse Event:
Contact First Name:	Contact Surname:	
	Access Contact Title: Access Contact Fax: Phone:	If No, till out ARTG No: 128763 Product Licence Category: Device Class: Included Class III Brand Name: Brand Name: ed INAMED Breast Implant Software Version: Software Version: Serial #: Batch #: IH6152 Date of Implant: Expiry Date: Secontact Title: Access Contact Title: Access Contact First Name: Access Contact Fax: Manufacturer Client Id: Town/Suburb: State/Province: Phone: Fax: Manufacturer Informed: Manufacturer Informed:

12/07/2024,	11:58
-------------	-------

Form Details

D	oci	Jme	ent	27

Supplier Name:		Address 1:	Address 2:
Town/Suburb:	State:	Postcode:	Phone:
Fax:	Email:		Supplier Informed:
			No
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:
Contact Phone:	Contact Fax:		

Statistics Checklist Section

Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:	
24/12/2012	s22	Yes	Yes		
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:	
No	Yes	No	Yes	Serious Injury	
Actual Effect:	Risk Frequency:				
Temporary Injury	Patient	Patient			
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:	
Serious	Likely	Routine			
DIRE Meeting Notes:					
More information required					

Sponsor Information Section

Search Sponsors:	Name:		Client #:
allergan	Allergan Australia Pty Ltd		17
Attention To:	Address 1:	Address 2:	Town/Suburb:
s22	Locked Bag 1514		PYMBLE
State:	Postcode:	Phone:	Fax:

12/07/2024, 11:58

NSW 2073	s22 (02) 9498 0299 Document 27
Email:	
s22 @allergan.com	
Investigation Information Section	
Device Analysis Results:	
Corrective/Preventative Actions:	
Details of Similar Events:	
Australia 40 similar event from 7151 sales = 0.55%	
Number of Similar Events:	Rate of Similar Events:
40 (Aus)	0.55%
Countries Similar Events Also Occurred:	
Additional Comments:	

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices							
Device ARTG No	Manufacturer Name	Sponsor/Supplier	Trade/Brand Name	Serial #	Model Number	GMDN / UMDN Text	

Related DIR Information - Click New to begin entering information.					
Incident Details					
DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	

Form Details

Document 27

Samples Record - Click [N] to begin entering information.

Sample Details						
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing	

Correspondence Information Section. Note that the Correspondence Recipient will receive a notification if the Date Received is not filled in by the Date Expected.

Correspondence Details						
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes
RN		24/12/2012	04/01/2013			
Request for information		30/01/2013	10/02/2013			Requested ARTG #
Request for information		30/01/2013	10/02/2013			Requesting rates for rupture on ARTG 128763
RC letter		25/02/2013	08/03/2013			
SC letter		25/02/2013	08/03/2013			

List of Problem Type Codes - Click **[N]** to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Material	Burst		

Investigation Problem Causes

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Known Complication	Known Complication		

Investigation Outcomes

12/07/2024, 11:58	Form Details	Decument 07
Outcome Details		Document 27
Outcome of Investigation	If Additional Outcome Detail Requested	
Reviewed, for Trending Purposes Only		
Recall Number:		
Investigation Summary:		
the implant. Rupture is a known complication associa	the manufacturer was unable to undertake any physical analysi ed with silicone breast implants. No further investigation will oc ne rate and pattern of occurrence and may re-open the file as	

Similar events - 40 from 7151 sold in Australia = 0.55%

Flow Details : DIR-REQ - Device Incident Request : 39686

Request Details

ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 😿	Priority	Attach
39686	DIR-REQ		Closed	s22	OPR Administration User	25/02/2013	Normal	0

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	21/06/2013 16:10:07	
Comment		

Document 28

R

Device Incident Report: Medical Devices Branch - Device Vigilance and Monitoring

SIGNED

21/12/2012

DIR: 20 - ID: 2	31946
-----------------	-------

Released by s22 on 25/06/20	Released	by <mark>s22</mark>	on 25/06/20:
-----------------------------	----------	---------------------	--------------

25/06/2015 15:11:06

Report #:	Records Management #:	Reporter's Reference #:	Report Type:
29701	2012/025220		Final
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed			21/12/2012
Date of Final Report:	Date of Initial TGA Action:	Reviewed by DIRE:	Date Response Received:
21/12/2012	24/12/2012	15/01/2013	
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter Confidentiality:
15/01/2013			Yes
ource of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Nurse		For IRIS Meeting	
vent Description for Website Publicati Pt informed doctor that she gradually Patient had removal & replacement of	noticed the left breast was larger, no pain, wh	nich gradually subsided but remained bigger. ?	e leak, patient had an MRI. th the right implant intact. Supported by an MRI
vent Description for Website Publication Pt informed doctor that she gradually Patient had removal & replacement of which was performed. dinical Event Information: 22 Pt informed doctor that she 22 Patient had removal & repl	noticed the left breast was larger, no pain, wh bilateral breast implants. At surgery it was fo gradually noticed the left breast was larger, n acement of bilateral breast implants. At surge	nich gradually subsided but remained bigger. ? bund there was a left intracapsular rupture, wit no pain, which gradually subsided but remaine	th the right implant intact. Supported by an MRI
Event Description for Website Publication Pt informed doctor that she gradually Patient had removal & replacement of which was performed. Clinical Event Information: S22 Pt informed doctor that she S22 Pt informed doctor that she S22 Patient had removal & repl by an MRI which was performed on S2	noticed the left breast was larger, no pain, wh bilateral breast implants. At surgery it was fo gradually noticed the left breast was larger, n acement of bilateral breast implants. At surge	nich gradually subsided but remained bigger. ? bund there was a left intracapsular rupture, wit no pain, which gradually subsided but remaine	th the right implant intact. Supported by an MRI ed bigger. ? leak, patient had an MRI.
vent Description for Website Publicati Pt informed doctor that she gradually Patient had removal & replacement of which was performed. Clinical Event Information: 22 Pt informed doctor that she 22 Pt informed doctor that she 22 Patient had removal & repl by an MRI which was performed on so lumber of Incidents in Report:	noticed the left breast was larger, no pain, where bilateral breast implants. At surgery it was for a gradually noticed the left breast was larger, a acement of bilateral breast implants. At surge	nich gradually subsided but remained bigger. ? ound there was a left intracapsular rupture, wit no pain, which gradually subsided but remaine ry it was found there was a left intracapsular i	th the right implant intact. Supported by an MRI ed bigger. ? leak, patient had an MRI. rupture, with the right implant intact. Supported
vent Description for Website Publicati Pt informed doctor that she gradually Patient had removal & replacement of which was performed. Clinical Event Information: 22 Pt informed doctor that she 22 Patient had removal & repl py an MRI which was performed on alumber of Incidents in Report:	noticed the left breast was larger, no pain, wh f bilateral breast implants. At surgery it was fo e gradually noticed the left breast was larger, n acement of bilateral breast implants. At surge Contact:	nich gradually subsided but remained bigger. ? ound there was a left intracapsular rupture, wit no pain, which gradually subsided but remaine ry it was found there was a left intracapsular i	th the right implant intact. Supported by an MRI ed bigger. ? leak, patient had an MRI. rupture, with the right implant intact. Supported
Event Description for Website Publication Pt informed doctor that she gradually Patient had removal & replacement of which was performed. Clinical Event Information: S22 Pt informed doctor that she S22 Patient had removal & replacement by an MRI which was performed on S23 Jumber of Incidents in Report: 1 Iternative Person Surname:	noticed the left breast was larger, no pain, where bilateral breast implants. At surgery it was for the gradually noticed the left breast was larger, a acement of bilateral breast implants. At surge Contact:	nich gradually subsided but remained bigger. ? bund there was a left intracapsular rupture, with no pain, which gradually subsided but remained ry it was found there was a left intracapsular Alternative Person Title:	th the right implant intact. Supported by an MRI ed bigger. ? leak, patient had an MRI. rupture, with the right implant intact. Supported
Event Description for Website Publication Pt informed doctor that she gradually Patient had removal & replacement of which was performed. Clinical Event Information: S22 Pt informed doctor that she	noticed the left breast was larger, no pain, where bilateral breast implants. At surgery it was for the gradually noticed the left breast was larger, a acement of bilateral breast implants. At surge Contact:	nich gradually subsided but remained bigger. ? bund there was a left intracapsular rupture, with no pain, which gradually subsided but remained ry it was found there was a left intracapsular Alternative Person Title:	th the right implant intact. Supported by an MRI ed bigger. ? leak, patient had an MRI. rupture, with the right implant intact. Supported

Patien	tН	istor	y:
--------	----	-------	----

Dellast Out 10

Patient had removal & regleacement of bilateral breast implants. At surgery it was found there was a left intracapsular rupture, with the right implant intact. Supported Other Devices Involved: Submitting Reporter Section Search Reporter By Sumame: Reporter Title: First Name: Ostion: Postion:	Patient Outcome/Consequences:			
Other Devices Involved: Submitting Reporter Section Search Reporter By Surname: Reporter #: Reporter Title: First Name: Sufficient Reporter Title: First Name: Miss Surname: Miss Surname: Position: Company/Institution: Plactic & Cosmetic Nurse Consultant (RN) Surname: Address 1: Address 2: Town/Suburb: State: Address 1: Address 2: Town/Suburb: State: Country: Postode: Phone: State: Mobile: Email: Sufficient State: Mobile: Email: State: State: Initial Reporter Section Final: State: State: Subord: Email: State: State: Initial Reporter Section State: State: State: Search Reporter By Surname: Initial Reporter #: Initial Reporter #: Initial Reporter #: Search Reporter By Surname: Initial Reporter #: Surname: Initial Reporter #: Search Reporter By Surname: Initial Reporter #: Surn	s22 Patient had removal & rep by an MRI which was performed on s	lacement of bilateral breast implants. At	surgery it was found there was a left intraca	psular rupture, with the right implant intact. Supported
Search Reporter By Surname: Image:				
Search Reporter By Surname: Image:				
Search Reporter By Surname: Image:				
Image: Preside and Pres	Submitting Reporter Section			
Reporter Title: First Name: Sumame: Miss 22 22 Position: Company/Institution: State: Plastis & Cosmetic Nurse Consultant (RN) Size State: Address 1: Address 2: Formany/Suburb: State: Size State: State: State: Size Size Size State: State: Size	Search Reporter By Surname:	Reporter #:		
MissS2S2Position:Company/Institution:Plastic & Cossultant (RN)S2Address 1:Address 2:S2Town/Suburb:S2S2Country:Postcode:Postcode:Phone:S2S2Mobile:S2S2S2Mobile:S2S2S2Mobile:S2S2S2Mobile:S2S2S2Mobile:S2S2S2Mobile:S2S2S2Mobile:S2S2S2Mobile:Finall:S2S2Mobile:S2S2S2Mobile:Finall:S2S2Mobile:S2S2S2Mobile:Finall:S2S2S2S2Mobile:S2S2S2S2S2Mobile:Finall:S2S2S2S2S2S2S2S2S3S2S3S2S3S2S3S2S4S2S4	s22			
Position: Company/Institution: Plastic & Cosmetic Nurse Consultant (RN) See Address 1: Address 2: See Town/Suburb: State: See See See See See See See See See See See See See Country: Postcode: Postcode: Phone: See See Mobile: See See See Mobile: Email: See See Initial Reporter Section Initial Reporter for Section Search Reporter By Surname: Initial Reporter #: Search Reporter By Surname: Initial Reporter #: Initial Reporter #: Surname: Seconde: First Name: Source: Company/Institution:	Reporter Title:	First Name:	Surname:	
Plastic & Cosmetic Nurse Consultant (RN) \$2 Address 1: Address 2: Town/Suburb: State: \$2 \$2 \$2 \$2 Country: Postcode: Phone: Fax: Country: Postcode: Phone: \$2 Mobile: \$2 \$2 \$2 Mobile: Email: Last External Submission By: \$2 Initial Reporter Section \$2 Initial Reporter Confidential: \$2 Search Reporter By Surname: Initial Reporter #: Initial Reporter #: \$2 Title: First Name: Surname: \$2 \$2 Position: Company/Institution: Company/Institution: \$2	Miss	s22	s22	
Address 1: Address 2: Town/Suburb: State: S22 S22 S22 Country: Postcode: Phone: Fax: S22 S22 S22 Mobile: Email: S22 S22 Mobile: Email: Last External Submission By: S22 Initial Reporter Section S22 Initial Reporter Confidential: S22 Search Reporter By Sumame: Initial Reporter #: Initial Reporter #: Initial Reporter #: Title: First Name: Surname: Surname: Initial Reporter #: Position: First Name: Company/Institution: Company/Institution: Initial Reporter #:	Position:		Company/Institution:	
S22S23S24S24Country:Postode:Phone:Fax:Image: SectionS2S2Mobile:Email:Last External Submission By:Imitial Reporter SectionS2Imitial Reporter Confidential:As Above?:If No, fill out the following:Imitial Reporter Confidential:Search Reporter By Surname:Imitial Reporter #:Imitial Reporter #:Title:First Name:Surname:Imitial Reporter #:Imitial Reporter #:Sourd Action Act	Plastic & Cosmetic Nurse Consultant	(RN)	s22	
Country: Postcode: Phone: Fax: Image: Section Section: Sec	Address 1:	Address 2:	Town/Suburb:	State:
Country: Postcode: Phone: Fax: Image: Section Section: Sec	s22	s22	s22	s22
Mobile: Email: Last External Submission By: Initial Reporter Section Initial Reporter Section Initial Reporter Confidential: As Above?: Initial Reporter following: Initial Reporter Confidential: Search Reporter By Surname: Initial Reporter #: Initial Reporter #: Title: First Name: Surname: Position: Company/Institution:	Country:	Postcode:	Phone:	
search Reporter Section Search Reporter By Surname: Initial Reporter #:		s22	s22	s22
Initial Reporter Section As Above?: If No, fill out the following: Initial Reporter Confidential: Search Reporter By Sumame: Initial Reporter #: Initial Reporter #: I	Mobile:	Email:		Last External Submission By:
As Above?: If No, fill out the following: Search Reporter By Surname: Initial Reporter #: Initial Reporter #: <td></td> <td>s22</td> <td></td> <td></td>		s22		
As Above?: If No, fill out the following: Search Reporter By Surname: Initial Reporter #: Initial Reporter #: <td>Initial Reporter Section</td> <td></td> <td></td> <td></td>	Initial Reporter Section			
If No, fill out the following: Search Reporter By Surname: Initial Reporter #: Initial Reporter #: </td <td></td> <td></td> <td></td> <td>Initial Departur Confidential</td>				Initial Departur Confidential
Itel: First Name: Position: Company/Institution:	As Above?:	If No, fill out the following:		Initial Reporter Confidential:
Itel: First Name: Position: Company/Institution:	Count Boundary Da Community	To Well Describer #		
Position:	Search Reporter by Sumarie.	mittal Reporter #:		
Position:	Titler	First Name:	Surnama	
	nue.	Tilst Name.	Sumame.	
	Position:		Company/Institution:	
Address 1: Address 2: Town/Suburb: State:			company/institution.	
	Address 1:	Address 2:	Town/Suburb:	State:
Postcode: Phone: Fax: Mobile:	Postcode:	Phone:	Fax:	Mobile:

				Document 28
En	nail:			
1				

Device Information Section

Product Exempt:	If No, fill out ARTG No:	Search Device ARTG:	Device ARTG #:	
No		151739	151739	
Therapeutic Licence Type:	Product Licence Category:	Device Class:	GMDN / UMDN Code:	
Medical Device	Included	Class III	36197	
GMDN / UMDN Text:		Brand Name:		
Prosthesis, internal, mammary, gel	filled	Natrelle Inspira		
Initial Device Description:				
Textured, round, soft-touch breast	implant			
Usage of Device:	Software Version:			
Single Use				
Model #:	Serial #:	Batch #:	Lot #:	
TSF 415	14427984		1747248	
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:	
		s22	s22	
Reported Device Location:	Access Contact Title:	Access Contact First Name:	Access Contact Surname:	
With Supplier	Mrs	s22	s22	
Access Contact Phone:	Access Contact Fax:			
\$22				

Manufacturer Information Section

Manufacturer Name:		Manufacturer Client Id:	Address 1:	
Allergan		s22	Level 4, 810 Pacific Highway	
Address 2:	Town/Suburb:	State/Province:	Country:	
	Gordon	NSW	Australia	
Postcode:	Phone:	Fax:		
2072	s22	+ 61 2 9498 0184		
Email:		Manufacturer Informed:	Date Aware of Adverse Event:	
www.allergan.com.au				
Contact Title:	Contact First Name:	Contact Surname:		

			Docume	nt 28
Supplier Information Section				
Supplier Name:		Address 1:	Address 2:	
Same as above 'manufacturers'				
Town/Suburb:	State:	Postcode:	Phone:	
Fax:	Email:		Supplier Informed:	
			Yes	
Date of Supplier Contact:	Contact Title:	Contact First Name:	Contact Surname:	
20/11/2012	Mrs	s22	s22	
Contact Phone:	Contact Fax:			
s22				

Statistics Checklist Section

Date:	Assessed By:	For website publication:	Ready for Publication:	Exclude report from DIRE:
24/12/2012	s22	Yes	Yes	
Sample Received:	Sterile:	Reusable:	Single Use:	Potential Effect:
No	Yes	No	Yes	Serious Injury
Actual Effect:	Injured Party:			Risk Frequency:
Temporary Injury	Patient			Sometimes
Risk Severity:	Risk Detectability:	Classification:	Investigated:	Date of DIRE Meeting:
Serious	Occasionally	Routine		
DIRE Meeting Notes:				
More information required				

Sponsor Information Section

Search Sponsors:	Name:		Client #:
allergan	Allergan Australia Pty Ltd		17
Attention To:	Address 1:	Address 2:	Town/Suburb:
s22	Locked Bag 1514		PYMBLE
State:	Postcode:	Phone:	Fax:

NSW	2073	S	22		Document 28	
Email:						
@Allergan.com						
Investigation Information Section						
Device Analysis Results:	Device Analysis Results:					
Corrective/Preventative Actions:						
Details of Similar Events:						
Australia1611,6470.1379Worldwide29994,1380.3189	% %					
Number of Similar Events:		Ra	te of Similar Events:			
Aus (16) WW (299)		A	us 0.137% WW 0.318%			
Countries Similar Events Also Occur	rred:					
Additional Comments:						

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:
			2

Other Devices							
Device ARTG No	Manufacturer Name	Sponsor/Supplier	Trade/Brand Name	Serial #	Model Number	GMDN / UMDN Text	

Related DIR Information - Click **New** to begin entering information.

Incident Details

DIR #	Brand Name	Reporter First Name	Reporter Surname	Company/Institution	Document 28

Samples Record - Click [N] to begin entering inf	ormation.
--	-----------

Sample Details									
Sample #	Sample Requested	Sample Received	# Samples from Reporter	# Samples from Sponsor	Outcome of TGA's Testing				

Correspondence Information Section. Note that the Correspondence Recipient will receive a notification if the Date Received is not filled in by the Date Expected.

Correspondence Details							
Correspondence Type	Correspondence recipient (email)	Date Sent	Date Response Expected	Date Received	Sponsor's Response	Investigator's Notes	
RN letter		24/12/2012	04/01/2013				
Questionnaire		24/12/2012	04/01/2013				
RC		15/01/2013	26/01/2013				
SC		15/01/2013	26/01/2013				

List of Problem Type Codes - Click [N] to begin entering information.

Type Details			
Type of Problem (Level 1)	Type of Problem (Level 2)	If 'Other' Type Selected	
Material	Burst		

Investigation Problem Causes

Cause Details			
Cause of Problem (Level 1)	Cause of Problem (Level 2)	If 'Other' Cause Selected	
Known Complication	Known Complication		

Investigation Outcomes

Outcome of Investigation	If Additional Outcome Detail Requested		Document 28
Reviewed, No Further Action Required			
Recall Number:			
Investigation Summary:			
Rupture is a known complication of breast implant will continue to monitor the rate and pattern of occ	surgery. No further investigation will occur at this time, howev urrence and may re-open the file as appropriate.	/er the TGA	
Similar events - Aus (16/11,647 - 0.137%) WW (299/94,138 - 0.318%)		

Flow Details : DIR-REQ - Device Incident Request : 39702

Request Details

39702	DIR-REQ		Closed	s22	OPR Administration User	15/01/2013	Normal	2	
ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On	Priority	Attach	

Signature Details

Role	IRIS Investigator	
User	s22	
Signed At	15/01/2013 16:14:58	
Comment		

Form Details

/ DIR : 41 - ID : 511957			SIGNE
			Released by \$22 on 19/11/2020 14:40:19
Report #:	Records Management #:	Reporter's Reference #:	Report Type:
66372		2286679	Final
00372		2200079	Filla
ARTG: 220900	Document Container URL		
Report Information Section			
Report Status:	Sponsor's Reported Category:	Date of Adverse Event:	Date of Initial Report:
Closed	Death / Serious Injury		05/11/2020
Date of Final Report:	Date of Initial TGA Action:	Reviewed by Team:	Date Response Received:
15/12/2020	05/11/2020		
Date Completed:	Operator at Time of Event:	If 'Other' Operator Selected:	Reporter consents to contact by sponsor:
14/01/2021	Healthcare Professional		N/A
Source of Report:	If 'Other' Source Selected:	Type of Initial Action:	
Sponsor		Trend data only	
Event Description for Website Publication:			
Explant due to infection			
Clinical Event Information:			
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:
Number of Incidents in Report:	Contact:	Alternative Person Title:	Alternative Person First Name:
	Contact: Alternative Person Phone:	Alternative Person Title: Alternative Person Fax:	Alternative Person First Name: Alternative Person Email:
1 Alternative Person Surname:			
1 Alternative Person Surname:			
1 Alternative Person Surname: Recorded Problems Observed			
1 Alternative Person Surname: Recorded Problems Observed Recorded Problems Observed:			
1 Alternative Person Surname: Recorded Problems Observed Recorded Problems Observed: Appropriate Term/Code Not Available -> ->	Alternative Person Phone:		
1 Alternative Person Surname: Recorded Problems Observed Recorded Problems Observed: Appropriate Term/Code Not Available -> -> Clinical Signs, Symptoms and Conditions	Alternative Person Phone:		
1 Alternative Person Surname: Recorded Problems Observed Recorded Problems Observed: Appropriate Term/Code Not Available -> -> Clinical Signs, Symptoms and Conditions Recorded Clinical Signs, Symptoms and Conditions Immune System -> Autoimmune Disorder -> ; Infections -> Bacterial Infection ->	Alternative Person Phone:		
1 Alternative Person Surname: Recorded Problems Observed Recorded Problems Observed: Appropriate Term/Code Not Available -> -> Clinical Signs, Symptoms and Conditions Recorded Clinical Signs, Symptoms and Conditions Immune System -> Autoimmune Disorder -> ; Infections -> Bacterial Infection ->	Alternative Person Phone:		
1 Alternative Person Surname: Recorded Problems Observed Recorded Problems Observed: Appropriate Term/Code Not Available -> -> Clinical Signs, Symptoms and Conditions Recorded Clinical Signs, Symptoms and Conditions Immune System -> Autoimmune Disorder -> ; Infections -> Bacterial Infection ->	Alternative Person Phone:		
1 Alternative Person Surname: Alternative Person Surname: Recorded Problems Observed Recorded Problems Observed: Appropriate Term/Code Not Available -> -> Clinical Signs, Symptoms and Conditions Recorded Clinical Signs, Symptoms and Conditions Immune System -> Autoimmune Disorder -> ; Infections -> Bacterial Infection -> Health Impact Recorded Health Impacts: Surgical Intervention -> Device Explantation ->	Alternative Person Phone:		
1 Alternative Person Surname: Alternative Person Surname: Recorded Problems Observed Recorded Problems Observed: Appropriate Term/Code Not Available -> -> Clinical Signs, Symptoms and Conditions Recorded Clinical Signs, Symptoms and Conditions Immune System -> Autoimmune Disorder -> ; Infections -> Bacterial Infection -> Health Impact Recorded Health Impacts:	Alternative Person Phone:		

/07/2024, 13:53		Form Details	
Patient Focused Corrective Action Taken:		Patient History:	Document 29
Explant procedure and no replacement of the devices			
Patient Outcome/Consequences:		Additional Event Description:	
Describe any test (Lab, xray, etc.):	Injured - Extent of Injury:	Consequence:	Other medical devices currently using/implanted:
	Serious Injury	Required surgical intervention	
Medical Problem Device Used For:	Additional Patients Added:		
Submitting Reporter Section			
Search Reporter By Surname:	Reporter #:		Preferred Contact Method:
s22			
Reporter Title:	First Name:	Surname:	
Mrs	s22	s22	
Position:		Company/Institution:	
Product Surveillance Manager APAC		Allergan	
Address 1:	Address 2:	Town/Suburb:	State:
Level 4, 810 Pacific Highway		Gordon	NSW
Country:	Postcode:	Phone:	Fax:
Australia	2072	s22	
Mobile:	Email:	Last External Submission By:	
	@allergan.com	101076_17 - 15/12/2020 09:48	
As Above?: Search Reporter By Surname:	If No, fill out the following: Initial Reporter #:		Initial Reporter Confidential: Preferred Contact Method:
s72			
Title:	First Name:	Surname:	
Dr	<u>\$72</u>	\$22	
Position:		Company/Institution:	
Explanting surgeon			
Address 1:	Address 2:	Town/Suburb:	State:
Postcode:	Country:	Phone:	Fax:
Mobile:	Email:	Allow the device company to contact you about the incident:	
Device Information Section			
Product Exempt (Note: If not exempt, enter ARTG No):	Search Device ARTG:	Device ARTG #:	Therapeutic Licence Type:
No	220900	220900	Medical Device
Product Licence Category:	Device Class:	GMDN / UMDN Code:	GMDN / UMDN Text:
Included	Class III	36197	Prosthesis, internal, mammary, gel filled
Brand Name:	Initial Device Description:	Usage of Device:	Software Version:
BRST Round Textured Cohesive gel filled - Prosthesis, internal, mammary, gel filled	BRST Round Textured Cohesive gel filled - Prosthesis, internal, mammary, gel filled	Single Use	na

BRST Round Textured mammary, gel filled	Cohesive gel	filled - Pros	thesis, internal,	
Model #:				

e beachpiton.	badge of Device.
d Textured Cohesive gel filled - Prosthesis,	Single Use
ammary, gel filled	
	Batch #:

L	ot	#	:	

ileader.production.tga.gov.au/InformationLeaderAD/Forms/FormDetailPrint.aspx?sid=-286828871

Serial #:

Form Details

CHP-345	23423939		3239454 Document 29
Purchase Date:	Expiry Date:	Date of Implant:	Date of Explant:
		s22	\$22
Date of Inital Procedure:	Place of Implantation:	Reported Device Location:	Access Contact Title:
	breasts	Discarded	
Access Contact First Name:	Access Contact Surname:	Access Contact Phone:	Access Contact Fax:
Access Contact Email:	Licence Status:	Status Effective Date:	Additional Devices Added:
	A	07/03/2014	0

Manufacturer Information Section

Manufacturer Name: Manufacturer Client Id: Address 1: 22 Allergan Address 2: Town/Suburb: State/Province: Country: Postcode: Phone: Fax: Email: Manufacturer Informed: Date Aware of Adverse Event: Contact Title: Contact First Name: Yes 27/10/2020 Contact Surname:

Supplier Information Section

	Address 1:	Address 2:
State:	Country:	Postcode:
Fax:	Email:	Website:
Date of Supplier Contact:	Contact Title:	Contact First Name:
Contact Phone:	Contact Fax:	Contact Email:
	Fax: Date of Supplier Contact:	State: Fax: Date of Supplier Contact: Country: Contact: Conta

Report Status						
For website publication:	Ready for Publication:	Investigated:	Investigation Reason:	Team Assignment:	Team Priority:	
Yes	Yes	No	Known complication	Unassigned	Not Investigated	
Team Review						
Reviewed by Team:	Reason Sent To Meeting:	Outcome from team meeting:				
Notes for Team meeting:						
Outcomes from Team Meeting:						
DPRC Review						
Reviewed by DPRC:	DPRC Reason Sent To Meeting:	Outcome from DPRC Meeting:				

Form Details

Meeting Notes:					
Meeting Notes.					
Initial Risk Analysis					
Background Information	Risk Assessment - Section A	Risk Assessment - Section B	Risk Assessment - Section C	Risk Assessment - Section D	ŝ.
Date:	Severity:	Incidents in the last 12 months:	Manufacturer analysis:	Assessor:	Manufacturer documentation:
05/11/2020	6 - Ongoing minor impairment			s22	
Incidents in last 24 months:	Manufacturer action:	ESTIMATED LEVEL OF INVESTIGATION:	FINAL LEVEL OF INVESTIGATION:	Injured Party:	Device Recalls:
		Screening only	Screening only	Patient	
Incidents in last 36 months:	IVD status:	EXCEPTION TO INVESTIGATION LEVEL:		Found Prior To Use:	Is AE covered by current recall:
		Similar events based on lymphadenopath	у	No	
Incidents Worldwide:	Number of potential contributing factors:			Reusable:	Similar events (past 6 months):
	No			No	0 incidents
Products supplied the last 12 months:	Specific factors identified:	ESTIMATED LEVEL OF PRIORITY:	FINAL LEVEL OF PRIORITY:		3 or more events - batch/model:
		Routine	Routine		
Products supplied last 24 months:	Number of potential sensitivities:	EXCEPTION TO PRIORITY LEVEL:			3 or more events - health district:
	Yes - some potential sensitivities (up to 3)				
Products supplied last 36 months:	Specific sensitivities identified:				3 or more events - organisation:
	Device is difficult to substitute				
Products supplied Worldwide:	Consultations during risk assessment:	Final Risk Assessment:			
	I did none of the above incidents	No			

Additional Risk Analysis

Click 'N' to start a new risk analysis

Analysis Details	Statistics Checklist Section						
Ipdate Device Details?:	Background Information	Risk Assessment - Section A	Risk Assessment - Section B	Risk Assessment - Section C	Risk Assessment - Section D		
les	Date:	Severity:	Incidents in the last 12 months:	Manufacturer analysis:			
Copy Data From:	14/01/2021	6 - Ongoing minor impairment		Yes			
nitial	Assessor:	Manufacturer documentation:	Incidents in last 24 months:	Manufacturer action:	ESTIMATED LEVEL OF INVESTIGATION:	FINAL LEVEL OF INVESTIGATION	
	s22	Unknown - updated information from the manufacturer is required		Unable to take action (device was not returned for analysis)	Level 2 Investigation (for a single DIR)	Screening only	
Injured Pa	Injured Party:	Device Recalls:	Incidents in last 36 months:	IVD status:	EXCEPTION TO INVESTIGATION LEVEL:		
	Patient	2. Recalls for similar incidents in Australia have occurred more than 12 months up to 3 years ago			Known complication		
	Found Prior To Use:	Is AE covered by current recall:	Incidents Worldwide:	Number of potential contributing factors:			
	No	Yes		Yes - some potential factors (up to 3)			
	Reusable:	Similar events (past 6 months):	Products supplied the last 12 months:	Specific factors identified:	ESTIMATED LEVEL OF PRIORITY:	FINAL LEVEL OF PRIORITY:	
	No	0 incidents		Compatibility of device - patient characteristics, Use of device - fit for purpose	Routine	Routine	
		3 or more events - batch/model:	Products supplied last 24 months:	Number of potential sensitivities:	EXCEPTION TO PRIORITY LEVEL:		
				Yes - some potential sensitivities (up to 3)			
		3 or more events - health district:	Products supplied last 36 months:	Specific sensitivities identified:			

Form Details

			Device is difficult to substitute, Investigations/actions by other regulator	rs.		Document 29
	3 or more events - organisation:	Products supplied Worldwide:		Final Risk A	ssessment:	
			I discussed issues with one of the team	Yes		
			leaders			
Sponsor/Manufacturer Information Section						
Search Sponsors:	Name:				Client #:	
17 Attention To:	Allergan Australia Pty Ltd Address 1:		Address 2:		17 Town/Suburb:	
			Address 2:			
State:	Locked Bag 1004 Postcode:		Phone:		Gordon Fax:	
NSW	2072					
Email:						
@allergan.com						
Investigation Information Section - Submitted by Sponsor	Manufaduwar					
	Manufacturer		Corrective/Preventative Actions:			
Device Analysis Results:	1-15122					
Primary cause assessment: Not possible as the device w Lab analysis was not possible as the device was not retu			None. The event is not a new or novel event, an Additional actions will be taken if an outlying tre	nd based on the s end is noticed as	part of the aggregate tre	occurrence, no CAPA required at this time. ending based on severity and frequency
DHR						
The review of the documentation associated to the manu released in accordance with Allergan Medical's procedure event.						
Details of Similar Events:			Additional Details (use for tables):			
Period: Nov 2017 to Oct 2020 DEPRESSION: Australia: 2 similar events, out of 4962 devices distribu Worldwide: 0 similar events, out of 10964 devices distr LYMPHADENOPHATY Australia: 1 similar events, out of 4962 devices distribu Worldwide: 0 similar events, out of 10964 devices distr INFECTION (unknown onset)-NDR	ributed= NIL uted= 0.020%			1	4	
Australia: 2 similar events, out of 4962 devices distribu Worldwide: 0 similar events, out of 10964 devices distri						
CAPA# Reference:						
Risk Assessment						
Frequency:	Severity:					
Rating:			Type Cause and Outcome:		Number of Similar E	vents:
Expected Rate:	Actual Rate:					
Countries Similar Events Also Occurred:						
DEPRESSION: Australia LYMPHADENOPHATY: Australia II	NFECTION (unknown onset)-NDR: Australia					
Completed Actions:			Planned Actions and Proposed Timelines:			
Additional Comments:						
Report closed 14 January 2021						

Reason for Level 1 Investigation

1	2/07/2024, 13:53	Form Details	_
	Details of Reasons		Document 29
	Reason for Level 1 Investigation		

Focus of Level 2 Investigation

Details of Focus

Essential Principles	If 'Other' Selected

Sources of Evidence for Level 2

Details of Source

Sources of Evidence	If 'Others' please specify here	Expected Sourcing Date	Date of Evidence Received

Evidence

Investigation Questions (Level 1 and Level 2):

	Risks	

Delays in response by product manufacturers:	Delays in response by incident reporters:	Delays in analysis within the TGA:	Delays in reporting by other sources (e.g. clinical registries):
Other Risks (which need to be specified):			
Next Steps for Level 1 & Level 2 Investigations			
Next Steps for Level 1 Investigation:		Next Steps for Level 2 Investigation:	

Click [N] to begin a new Correspondence entry. Note that the Email address specified here will receive a notification if the Date Received is not filled in by the Date Expected.

Correspondence and Chronology Details										
Include?	Heading	Type L1	Type L2	Email	Sent	Expected	Received	Response	Notes	

List of Problem Observed Codes - Click [N] to begin entering information.						
Problem Observed Details						
Problem Observed (Level 1)	Problem Observed (Level 2)	Problem Observed (Level 3)	If 'Other' Selected			
Appropriate Term/Code Not Available			Lymphadenopathy			

Clinical signs symptoms and conditions

Details			
Level 1	Level 2	Level 3	
Infections	Bacterial Infection		

ileader.production.tga.gov.au/InformationLeaderAD/Forms/FormDetailPrint.aspx?sid=-286828871

Form Details

		Document 29
Immune System	Autoimmune Disorder	Document 29

Lla	- 14 h	1.000.00	
пе	aith	Imp	act

Details			
Level 1	Level 2	Level 3	
Surgical Intervention	Device Explantation		

Investigation Findings

Finding Details

· · · · · · · · · · · · · · · · · · ·				
Investigation Findings (Level 1)	Investigation Findings (Level 2)	Investigation Findings (Level 3)	If 'Other' Selected	
No Findings Available				

Investigation Conclusion

Conclusion Details			
Investigation Conclusion (L1)	Investigation Conclusion (L2)	If Additional Conclusion Detail Requested	
Cause Not Established			

Investigation Outcomes

Outcome Details

Outcome of Investigation (L1)	Outcome of Investigation (L2)	If Additional Conclusion Detail Requested	
Reviewed, for Trending Purposes Only			

Investigation Summary

Latest Investigation (DII) where this DIR is the Primary DIR:	Latest Investigation (DII) where this DIR is a Related DIR:	Investigator:	Peer Review:	
			No	
Investigator's Notes:		Summary Findings:		Recall Number:
		No further investigation will occur at this time and pattern of occurrence and may re-open th		RC-2020-RN-00186-1

Note: Letter generation buttons disabled if report not ready for website publication or risk analysis not completed.

Device Lookup

This section is used to match information provided via UDIR forms to ARTG information. You can select a Brand/Name from information provided in the 'Other Devices Involved' table below or enter information manually.

Other Device (Entered):	Brand Name:	Manufacturer Name:	Device ARTG #:

Other Devices					
Device ARTG No:	Manufacturer Name:	Sponsor/Supplier:	GMDN / UMDN Text:	Trade/Brand Name:	Serial #:
Model Number:	Batch #:	Lot #:	Expiry Date:		

12/07/2024,	13:53
-------------	-------

Form Details

ated DIR Information	- Click New to	beain enterina	information.

Rec No	
1	

Samples Record - Click [N] to begin entering information. Note: Sample # Generated on Save.

Rec No	Details	Sample Details			Additional Details				
1	Date Entered:	LIMS #:	Sample Requested:	Sample Received:	Manufacturer:	GMDN:	Device Description:	Brand Name:	Serial Number:
	Reason for Testing:	# Samples from Reporter:	# Samples from Sponsor:	Outcome of TGA's Testing:	Lot Number:	Batch Number:	Model Number:	Version Number:	
1									
					Who sent the device to the TGA?:			Why does the TGA have the sample?:	

Additional Patients

lick	[N]	to	begin	entering	information.	
------	-----	----	-------	----------	--------------	--

Patient Details						
Sex: Weight: A		Age:				
Patient Focused Corrective Action Taken:		Patient History:				
Injured - Extent of Injury:	Was device directly linked to death?:	Was device directly linked to permanent disabiltiy?:	Consequence:			
Other Consequence:	Describe any test (Lab, xray, etc.):	Additional Event Description:	Medical Problem Device Used For:			

Additional Device Information

Where did you get this device from?:

How reliant is the affected person on correct/safe operation of this device?:

Any other relevant information to aid assessing/investigating the incident?:

Similar Events

Similar events - how many times?:	Date of Recent Report:	Event Reported To:	Reporter Reference Number:
Device Access - Alternate Device Contact Information Prov	vided		
Title:	First Name:	Last Name:	Phone:
Fax:	Email:		

Incident Location Details

Form Details

Document 29

Occurred in Australia: Organisation: Address Line 1: Address Line 2: Town/Suburb: State: Postcode: Attachment(s) Details Туре Open Name Size Attached Within Attached To 7 FILE TGA Recall Notice & Hazard Alert - RC-2020-RN-... 277 Form Flow Details : DIR-REQ - Device Incident Request : 285815 **Request Details**

285815	DIR-REQ		Closed	s22	OPR Administration User	14/01/2021	Normal	0
ID	Туре	Location	Status	Assigned By	Assigned To	Assigned On 😿	Priority	Attach

Signature Details

Role	IRIS Investigator	
User	\$22	
Signed At	14/01/2021 10:50:29	
Comment		



Australian Government

Department of Health Therapeutic Goods Administration

URGENT PRODUCT DEFECT CORRECTION; AND IMPLANT HAZARD ALERT*

LEVEL: Hospital

CLASS: Class II

REFERENCE: RC-2020-RN-00186-1

DATE AGREED: 28/02/2020

PRODUCT: Allergan Breast Implants

BRST Round Microcell Textured Cohesive gel filled ARTG 220900

BRST Round Microcell Textured Responsive gel filled ARTG 218869

BRST Round Smooth Responsive gel filled ARTG 220696

NATRELLE INSPIRA Truform 2 gel, Smooth, Single Lumen ARTG 175426

NATRELLE INSPIRA, Truform 1 gel, Smooth, Single Lumen ARTG 175421

NATRELLE Truform1 Gel, Smooth Single Lumen ARTG 171393

- **SPONSOR:** Allergan Australia Pty Ltd
- PHONE: 02 9498 0290 Allergan Customer Service
- **REASON:** As an outcome of the TGA post market review of breast implants and breast tissue expanders supplied in Australia, Allergan Australia are required to update their Instructions For Use (IFU) and issue a hazard alert pertaining to the risk of Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL).

PROPOSEDHazard Alert Instructions:CUSTOMERImplanting surgeons are alerted to this issue and requested to review the
relevant literature in the context of their particular patients on a case-by-
case basis.

Product Defect Correction Instructions: Allergan is advising customers that a boxed warning regarding BIA-ALCL will be placed on the product packaging.



The sponsor is expected to dispatch letters to all affected customers within two working days of the agreed date. <u>Please do not contact the sponsor for further information unless you</u> <u>believe that you have the goods under recall and have not received a recall letter.</u>

Product Distribution: 177 surgeons nationally

Product export status: Unknown

This issue was first identified by the Sponsor

*For further details about Recall Actions, please refer to <u>http://tga.gov.au/safety/recalls-about.htm</u>



Australian Government

Department of Health Therapeutic Goods Administration

Recall Action Notification

Macro Textured Breast Implants & Tissue Expanders

© Commonwealth of Australia 2024.

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <tga.copyright@tga.gov.au>.

Important information on the System for Australian Recall Actions

The TGA publishes information about therapeutic goods supplied in the Australian market that have been subject to a recall action in a publicly searchable database.

Recall action means action taken by the responsible entity (being the person who is responsible for taking the recall action) to resolve a problem with therapeutic goods supplied in the Australian market that have, or may potentially have, deficiencies relating to safety, quality, efficacy (performance) or presentation.

- Recall actions include: the permanent removal of therapeutic goods from supply in the market, the taking of corrective action in relation to therapeutic goods (such as repair, modification, adjustment or relabelling) and, in the case of medical devices that have been implanted into patients, the issuing of a hazard alert containing information for health practitioners on how to manage patients.
- More information about Australian recall actions is available at <<u>http://tga.gov.au/safety/recalls-about.htm</u>>
- If you are taking a medicine, using a medical device or have had a medical device implanted into you, that is the subject to a recall action, and you have any concerns you should seek advice from a health professional. <<u>http://www.healthdirect.org.au/</u>>

About the release of this information

While reasonable care is taken to ensure that the information is an accurate record of recall actions that responsible entities have reported to the TGA or of which the TGA has become aware, the TGA does not guarantee or warrant the accuracy, reliability, completeness or currency of the information or its usefulness in achieving any purpose. To the fullest extent permitted by law, including but not limited to section 61A of the Therapeutic Goods Act 1989, the TGA will not be liable for any loss, damage, cost or expense incurred in or arising by reason of any person relying on this information.

The information contained in the SARA database is released under s 61(5C) of the Therapeutic Goods Act 1989. Copyright restrictions apply to the System of Australian Recall actions (SARA) <<u>http://tga.gov.au/about/website-copyright.htm</u>>.

Recall detail

Type of Product ⁱ	Medical Device
TGA Recall Reference ⁱⁱ	RC-2019-RN-01116-1
Product Name/Description ⁱⁱⁱ	Macro Textured Breast Implants & Tissue Expanders
	Natrelle Products: INSPIRA Truform 1 gel, Textured, Single Lumen INSPIRA Truform 2 gel, Textured Single Lumen Truform 1 gel, Textured, Single Lumen Truform 3 gel, Textured Single Lumen Soft Touch, Truform 2 gel, Textured, Single Lumen Truform Dual gel, Textured Single Lumen Saline-filled, Textured Double Lumen Gel/Saline Tissue Expanders - Skin expander
Recall Action Level ^{iv}	ARTGs: 175422, 175425, 175420, 171512, 171475, 171387, 171388, 169956, 175797 Hospital
Recall Action Classification ^v	Class I
Recall Action Commencement Date ^{vi}	30/07/2019
Responsible Entity ^{vii}	Allergan Australia Pty Ltd
Reason / Issue ^{viii}	Allergan is taking this action as a precautionary measure, following notification of recently updated global safety information concerning the uncommon incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Recent evaluation suggests there is an increased risk of BIA-ALCL in individuals with highly textured (macro-textured) implants in comparison with those having less textured (micro-textured) or smooth implants. BIA-ALCL is a type of non-Hodgkin lymphoma that may develop many months or years after a breast implant procedure. It is not a cancer of the breast tissue. BIA-ALCL usually presents as an accumulation of fluid (known as seroma fluid) between the implant and the surrounding tissue. Whilst the specific mechanism is unknown, possible risk factors for the disease include the high surface area
	of the macro-textured implants, genetic factors, and long-term inflammation around the implant, possibly triggered by factors such as bacterial infection.
Recall Action ^{ix}	Hazard Alert

The TGA publishes Australian recall actions in a searchable database to ensure the public has access to information about therapeutic products that have been recalled from the Australian market. If you are concerned about your health or if you have experienced an adverse event please seek advice from a health professional as soon as possible. Please read all the important information at the beginning of this report.

System for Australian Recall Actions

Recall Action Instructions [×]	Hazard Alert Instructions: Implanting surgeons are alerted to this issue and requested to review the relevant literature in the context of their particular patients on a case-by-case basis. The TGA does not provide clinical advice as part of its mandate under the Therapeutic Goods Act 1989, however the TGA website does contain information for health professionals and consumers regarding this matter. Furthermore, the TGA has been advised that removal or replacement of macro-textured breast implants or tissue expanders in asymptomatic patients is not recommended.
	Recall Instructions: Customers are requested to inspect all breast implant stock and quarantine any affected inventory. Following receipt of a completed Customer Acknowledgement Form (provided with the Customer Letter), the distributor, Device Technologies, will arrange collection of affected product. This action has been closed out on 09/02/2021.
Contact Information ^{xi}	02 9975 5755 - Device Technologies (distributor)

Footnotes

ⁱ Type of Product: Medicine, Medical Device, or Biological

ⁱⁱ TGA Recall Reference: Unique number given by the TGA

ⁱⁱⁱ Product Name/Description: Brand name (including active ingredient for medicines) and may include generic reference for the kind of medical devices. Includes all necessary information such as affected: catalogue / model and / or batch / serial numbers.

^{iv} Recall Action Level: The level to which the recall action is to be undertaken. This is based on the significance of the risk and the channels through which the goods have been distributed. The recall action levels are / Wholesale / Hospital / Retail / Consumer.

- Wholesale includes wholesalers and state purchasing authorities.
- **Hospital** includes nursing homes and institutions, hospital pharmacists, ambulance services, blood and tissue banks and laboratories as well as wholesale as appropriate.
- **Retail** includes retail pharmacists, medical, dental and other health care professionals as well as wholesale and hospital as appropriate.
- Consumer includes patients and consumers, as well as wholesale, hospital and retail levels as appropriate.

v Recall Action Classification**: Recall actions of therapeutic goods are classified based on the potential risk the deficiency poses to patients / consumers. They are classified as Class I, Class II or Class III.

- **Class I** A situation in which there is a reasonable probability that the use of, or exposure to, the deficient therapeutic good(s) will cause serious adverse health consequences or death.
- **Class II** A situation in which use of, or exposure to, the deficient therapeutic good(s) may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
- **Class III-** A situation in which use of, or exposure to, the deficient therapeutic good(s) is not likely to cause adverse health consequences.

^{vi} Recall Action Commencement Date: The date the recall strategy and communication was agreed by the TGA.

vii Responsible Entity: Sponsor / Supplier / Importer responsible for the recall actions.

Report generated 11/07/2024 11:42:30 AM

Page 4 of 5

The TGA publishes Australian recall actions in a searchable database to ensure the public has access to information about therapeutic products that have been recalled from the Australian market. If you are concerned about your health or if you have experienced an adverse event please seek advice from a health professional as soon as possible. Please read all the important information at the beginning of this report.

System for Australian Recall Actions

viii Reason / Issue: Reason for the recall action.

^{ix} Recall Action**: Recall action is an action taken to resolve a problem with a therapeutic good already supplied in the market for which there are issues or deficiencies in relation to safety, quality, efficacy (performance) or presentation. There are four distinct recall actions – recall, product defect correction, hazard alert and product defect alert.

Recall - The permanent removal of an affected therapeutic good from supply or use in the market.

- **Product defect correction** Repair, modification, adjustment or re-labelling of a therapeutic good. The corrective action may take place at the user's premises or any other agreed location.
- **Hazard alert** Information issued to healthcare professionals about issues or deficiencies relating to an implanted medical device or biological product and advice about the ongoing management of patients.
- **Product defect alert** Information issued to raise awareness about issues or deficiencies for a therapeutic good where a recall action will result in interruption of patient treatment or a medicine shortage, including advice to reduce potential risks of using affected goods.

^x Recall Action Instructions: What customers with affected goods should do.

^{xi} Contact Information: Who the customer should contact for additional information and clarification regarding the recall action.

** These definitions are applicable to the 2017 URPTG (Implemented from Jan 15 2018). Recall Action types and Recall Action Classifications prior to 15 Jan 2018 can be found at: https://www.tga.gov.au/sites/default/files/recalls-urptg-170412.pdf

The TGA publishes Australian recall actions in a searchable database to ensure the public has access to information about therapeutic products that have been recalled from the Australian market. If you are concerned about your health or if you have experienced an adverse event please seek advice from a health professional as soon as possible. Please read all the important information at the beginning of this report.